0000917520-24-000108.txt : 20241104 0000917520-24-000108.hdr.sgml : 20241104 20241104160939 ACCESSION NUMBER: 0000917520-24-000108 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 97 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241104 DATE AS OF CHANGE: 20241104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRA LIFESCIENCES HOLDINGS CORP CENTRAL INDEX KEY: 0000917520 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 510317849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26224 FILM NUMBER: 241423578 BUSINESS ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6092750500 MAIL ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRA LIFESCIENCES CORP DATE OF NAME CHANGE: 19950614 10-Q 1 iart-20240930.htm 10-Q iart-20240930
false2024Q30000917520December 310.0135739P6Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:CHFiso4217:EURiart:renewalOptioniart:Segmentiart:productiart:liabilityiart:payment00009175202024-01-012024-09-3000009175202024-11-0100009175202024-07-012024-09-3000009175202023-07-012023-09-3000009175202023-01-012023-09-3000009175202024-09-3000009175202023-12-3100009175202022-12-3100009175202023-09-300000917520us-gaap:CommonStockMember2023-12-310000917520us-gaap:TreasuryStockCommonMember2023-12-310000917520us-gaap:AdditionalPaidInCapitalMember2023-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000917520us-gaap:RetainedEarningsMember2023-12-310000917520us-gaap:RetainedEarningsMember2024-01-012024-03-3100009175202024-01-012024-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000917520us-gaap:CommonStockMember2024-01-012024-03-310000917520us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000917520us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000917520us-gaap:CommonStockMember2024-03-310000917520us-gaap:TreasuryStockCommonMember2024-03-310000917520us-gaap:AdditionalPaidInCapitalMember2024-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000917520us-gaap:RetainedEarningsMember2024-03-3100009175202024-03-310000917520us-gaap:RetainedEarningsMember2024-04-012024-06-3000009175202024-04-012024-06-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000917520us-gaap:CommonStockMember2024-04-012024-06-300000917520us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000917520us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000917520us-gaap:CommonStockMember2024-06-300000917520us-gaap:TreasuryStockCommonMember2024-06-300000917520us-gaap:AdditionalPaidInCapitalMember2024-06-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000917520us-gaap:RetainedEarningsMember2024-06-3000009175202024-06-300000917520us-gaap:RetainedEarningsMember2024-07-012024-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000917520us-gaap:CommonStockMember2024-07-012024-09-300000917520us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000917520us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000917520us-gaap:CommonStockMember2024-09-300000917520us-gaap:TreasuryStockCommonMember2024-09-300000917520us-gaap:AdditionalPaidInCapitalMember2024-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000917520us-gaap:RetainedEarningsMember2024-09-300000917520us-gaap:CommonStockMember2022-12-310000917520us-gaap:TreasuryStockCommonMember2022-12-310000917520us-gaap:AdditionalPaidInCapitalMember2022-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000917520us-gaap:RetainedEarningsMember2022-12-310000917520us-gaap:RetainedEarningsMember2023-01-012023-03-3100009175202023-01-012023-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000917520us-gaap:CommonStockMember2023-01-012023-03-310000917520us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000917520us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000917520us-gaap:CommonStockMember2023-03-310000917520us-gaap:TreasuryStockCommonMember2023-03-310000917520us-gaap:AdditionalPaidInCapitalMember2023-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000917520us-gaap:RetainedEarningsMember2023-03-3100009175202023-03-310000917520us-gaap:RetainedEarningsMember2023-04-012023-06-3000009175202023-04-012023-06-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000917520us-gaap:CommonStockMember2023-04-012023-06-300000917520us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000917520us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000917520us-gaap:CommonStockMember2023-06-300000917520us-gaap:TreasuryStockCommonMember2023-06-300000917520us-gaap:AdditionalPaidInCapitalMember2023-06-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000917520us-gaap:RetainedEarningsMember2023-06-3000009175202023-06-300000917520us-gaap:RetainedEarningsMember2023-07-012023-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000917520us-gaap:CommonStockMember2023-07-012023-09-300000917520us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000917520us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000917520us-gaap:CommonStockMember2023-09-300000917520us-gaap:TreasuryStockCommonMember2023-09-300000917520us-gaap:AdditionalPaidInCapitalMember2023-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000917520us-gaap:RetainedEarningsMember2023-09-300000917520iart:AcclarentInc.Member2024-04-012024-04-010000917520iart:AcclarentInc.Member2024-09-012024-09-300000917520iart:AcclarentInc.Member2024-01-012024-09-300000917520iart:AcclarentInc.Member2024-04-010000917520iart:AcclarentInc.Memberiart:CompletedTechnologyMember2024-04-010000917520iart:AcclarentInc.Memberiart:CompletedTechnologyMember2024-04-012024-04-010000917520iart:AcclarentInc.Memberus-gaap:TrademarksAndTradeNamesMember2024-04-010000917520iart:AcclarentInc.Memberus-gaap:TrademarksAndTradeNamesMember2024-04-012024-04-010000917520iart:AcclarentInc.Memberus-gaap:OtherIntangibleAssetsMember2024-04-010000917520iart:AcclarentInc.Memberus-gaap:OtherIntangibleAssetsMember2024-04-012024-04-010000917520us-gaap:SubsequentEventMemberiart:DurepairRegenerationMatrixMember2024-10-022024-10-020000917520srt:ScenarioForecastMemberiart:DurepairRegenerationMatrixMember2025-10-022025-10-020000917520srt:ScenarioForecastMemberiart:DurepairRegenerationMatrixMember2026-10-022026-10-0200009175202024-10-012024-09-300000917520iart:NeurosurgeryMemberiart:CodmanSpecialtySurgicalMember2024-07-012024-09-300000917520iart:NeurosurgeryMemberiart:CodmanSpecialtySurgicalMember2023-07-012023-09-300000917520iart:NeurosurgeryMemberiart:CodmanSpecialtySurgicalMember2024-01-012024-09-300000917520iart:NeurosurgeryMemberiart:CodmanSpecialtySurgicalMember2023-01-012023-09-300000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2024-07-012024-09-300000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2023-07-012023-09-300000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2024-01-012024-09-300000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2023-01-012023-09-300000917520iart:ENTMemberiart:CodmanSpecialtySurgicalMember2024-07-012024-09-300000917520iart:ENTMemberiart:CodmanSpecialtySurgicalMember2023-07-012023-09-300000917520iart:ENTMemberiart:CodmanSpecialtySurgicalMember2024-01-012024-09-300000917520iart:ENTMemberiart:CodmanSpecialtySurgicalMember2023-01-012023-09-300000917520iart:CodmanSpecialtySurgicalMember2024-07-012024-09-300000917520iart:CodmanSpecialtySurgicalMember2023-07-012023-09-300000917520iart:CodmanSpecialtySurgicalMember2024-01-012024-09-300000917520iart:CodmanSpecialtySurgicalMember2023-01-012023-09-300000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2024-07-012024-09-300000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2023-07-012023-09-300000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2024-01-012024-09-300000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2023-01-012023-09-300000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2024-07-012024-09-300000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2023-07-012023-09-300000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2024-01-012024-09-300000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2023-01-012023-09-300000917520iart:TissueTechnologiesMember2024-07-012024-09-300000917520iart:TissueTechnologiesMember2023-07-012023-09-300000917520iart:TissueTechnologiesMember2024-01-012024-09-300000917520iart:TissueTechnologiesMember2023-01-012023-09-300000917520iart:CodmanSpecialtySurgicalMember2023-12-310000917520iart:TissueTechnologiesMember2023-12-310000917520iart:AcclarentInc.Memberiart:CodmanSpecialtySurgicalMember2024-01-012024-09-300000917520iart:AcclarentInc.Memberiart:TissueTechnologiesMember2024-01-012024-09-300000917520iart:CodmanSpecialtySurgicalMember2024-09-300000917520iart:TissueTechnologiesMember2024-09-300000917520us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberiart:TissueTechnologiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520us-gaap:MeasurementInputDiscountRateMemberiart:TissueTechnologiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520iart:TissueTechnologiesMember2024-09-300000917520us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberiart:NeurosurgeryMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520us-gaap:MeasurementInputDiscountRateMemberiart:NeurosurgeryMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520iart:NeurosurgeryMember2024-09-300000917520us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberiart:InstrumentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520us-gaap:MeasurementInputDiscountRateMemberiart:InstrumentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520iart:InstrumentsMember2024-09-300000917520iart:NeurosurgeryMember2024-01-012024-09-300000917520iart:InstrumentsMember2024-01-012024-09-300000917520us-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-07-012024-09-300000917520iart:TissueTechnologiesMember2024-07-012024-09-300000917520iart:NeurosurgeryMember2024-07-012024-09-300000917520iart:InstrumentsMember2024-07-012024-09-300000917520us-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:TradeNamesMember2024-01-012024-03-310000917520us-gaap:TradeNamesMember2024-01-012024-09-300000917520iart:CompletedTechnologyMember2024-09-300000917520us-gaap:CustomerRelationshipsMember2024-09-300000917520iart:TrademarksBrandNamesMember2024-09-300000917520us-gaap:TradeNamesMember2024-09-300000917520iart:SupplierRelationShipsMember2024-09-300000917520iart:AllOtherMember2024-09-300000917520iart:CompletedTechnologyMember2023-12-310000917520us-gaap:CustomerRelationshipsMember2023-12-310000917520iart:TrademarksBrandNamesMember2023-12-310000917520us-gaap:TradeNamesMember2023-12-310000917520iart:SupplierRelationShipsMember2023-12-310000917520iart:AllOtherMember2023-12-310000917520iart:CompletedTechnologyMember2024-07-012024-09-300000917520iart:CompletedTechnologyMember2024-01-012024-09-300000917520us-gaap:CustomerRelationshipsMember2024-01-012024-09-300000917520iart:CompletedTechnologyMember2023-07-012023-09-300000917520iart:CompletedTechnologyMember2023-01-012023-09-300000917520us-gaap:CustomerRelationshipsMember2024-01-012024-03-310000917520iart:CompletedTechnologyMemberiart:CompletedTechnologySurgiMendMember2024-09-300000917520iart:CompletedTechnologyMemberiart:CompletedTechnologyPriMatrixMember2024-09-300000917520iart:SeniorCreditFacilityMember2023-03-240000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2023-03-240000917520us-gaap:RevolvingCreditFacilityMember2023-03-240000917520us-gaap:StandbyLettersOfCreditMember2023-03-240000917520iart:SwinglineLoanMember2023-03-240000917520iart:DebtCovenantPeriod2Memberiart:SeniorCreditFacilityMember2023-03-240000917520iart:DebtCovenantPeriod1Memberiart:SeniorCreditFacilityMember2023-03-240000917520iart:DebtCovenantPeriod3Memberiart:SeniorCreditFacilityMember2023-03-240000917520iart:DebtCovenantPeriod4Memberiart:SeniorCreditFacilityMember2023-03-240000917520iart:SeniorCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-09-300000917520iart:SeniorCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-01-012024-09-300000917520iart:SeniorCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2024-01-012024-09-300000917520iart:SeniorCreditFacilityMemberus-gaap:FederalFundsEffectiveSwapRateMember2024-01-012024-09-300000917520iart:SeniorCreditFacilityMembersrt:MinimumMember2024-01-012024-09-300000917520iart:SeniorCreditFacilityMembersrt:MaximumMember2024-01-012024-09-300000917520us-gaap:RevolvingCreditFacilityMember2024-09-300000917520us-gaap:RevolvingCreditFacilityMember2023-01-012023-03-310000917520us-gaap:RevolvingCreditFacilityMember2023-12-310000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2024-09-300000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2023-12-310000917520us-gaap:FairValueInputsLevel2Memberiart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2024-09-300000917520us-gaap:FairValueInputsLevel2Memberiart:SeniorCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000917520iart:SeniorCreditFacilityMemberus-gaap:StandbyLettersOfCreditMember2023-12-310000917520iart:SeniorCreditFacilityMemberus-gaap:StandbyLettersOfCreditMember2024-09-300000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-02-070000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-02-072020-02-070000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-12-090000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-02-042020-02-040000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMemberus-gaap:CallOptionMember2020-02-042020-02-040000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-02-040000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMemberus-gaap:ConvertibleDebtMember2024-09-3000009175202023-12-150000917520us-gaap:FairValueInputsLevel2Member2024-09-300000917520iart:InterestRateSwapDesignatedDecember132017Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedDecember132017Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedDecember132017Tranche3Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedDecember132017Tranche3Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche1Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedOctober102018Tranche1Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedOctober102018Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche3Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedOctober102018Tranche3Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedDecember182018Tranche1Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedDecember182018Tranche1Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedDecember182018Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedDecember182018Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedDecember152020Tranche1Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedDecember152020Tranche1Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedDecember152020Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedDecember152020Tranche2Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedMarch312023Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:InterestRateSwapDesignatedMarch312023Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300000917520us-gaap:InterestRateSwapMember2024-09-300000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-220000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ShortMember2023-09-220000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMember2024-09-230000917520us-gaap:CrossCurrencyInterestRateContractMember2020-12-210000917520us-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractOneMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractOneMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractOneMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractOneMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-07-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-01-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-07-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMember2024-07-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMember2024-09-300000917520us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-05-020000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractThreeMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractThreeMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractThreeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractThreeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractThreeMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractThreeMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2024-07-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2024-01-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2023-07-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2023-01-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2024-07-012024-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2024-01-012024-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SubsequentEventMember2024-10-160000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2023-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2024-06-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2024-07-012024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-06-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2024-06-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2024-06-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2024-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000917520us-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2023-06-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2023-07-012023-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-06-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-09-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-06-300000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2023-06-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2023-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000917520us-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2023-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2024-01-012024-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-12-310000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2023-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2022-12-310000917520us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2023-01-012023-09-300000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-12-310000917520us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2022-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2022-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300000917520us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2021-06-300000917520us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2024-09-300000917520us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2023-12-310000917520us-gaap:CurrencySwapMember2024-07-012024-09-300000917520us-gaap:CurrencySwapMember2023-07-012023-09-300000917520us-gaap:CurrencySwapMember2024-01-012024-09-300000917520us-gaap:CurrencySwapMember2023-01-012023-09-300000917520us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-300000917520us-gaap:EmployeeStockOptionMembersrt:DirectorMember2024-01-012024-09-300000917520us-gaap:EmployeeStockOptionMemberiart:EmployeeMember2024-01-012024-09-300000917520us-gaap:EmployeeStockOptionMemberiart:DirectorsandCertainExecutiveOfficersMembersrt:MinimumMember2024-01-012024-09-300000917520us-gaap:EmployeeStockOptionMemberiart:DirectorsandCertainExecutiveOfficersMembersrt:MaximumMember2024-01-012024-09-300000917520us-gaap:RestrictedStockMember2024-01-012024-09-300000917520us-gaap:EmployeeStockOptionMember2024-09-300000917520us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000917520iart:PerformanceStockAndRestrictedStockAwardsMember2024-01-012024-09-300000917520us-gaap:RestrictedStockMember2024-09-300000917520us-gaap:PerformanceSharesMember2024-01-012024-09-300000917520srt:ChiefExecutiveOfficerMember2024-01-012024-09-300000917520srt:ChiefExecutiveOfficerMembersrt:ScenarioForecastMember2024-01-012024-12-310000917520us-gaap:RelatedPartyMember2023-01-012023-09-300000917520us-gaap:RelatedPartyMember2024-01-012024-09-300000917520us-gaap:BuildingMember2024-09-300000917520us-gaap:BuildingMember2023-12-310000917520us-gaap:VehiclesMember2024-09-300000917520us-gaap:VehiclesMember2023-12-310000917520iart:RelatedPartiesMember2024-09-300000917520iart:ThirdPartiesMember2024-09-300000917520iart:FiveYearOptionLeasePeriodOneMemberus-gaap:RelatedPartyMember2024-09-300000917520iart:FiveYearOptionLeasePeriodOneMemberus-gaap:RelatedPartyMember2024-01-012024-09-300000917520iart:FiveYearOptionLeasePeriodTwoMemberus-gaap:RelatedPartyMember2024-09-300000917520iart:FiveYearOptionLeasePeriodTwoMemberus-gaap:RelatedPartyMember2024-01-012024-09-3000009175202023-01-012023-12-3100009175202024-05-1600009175202024-07-3100009175202023-08-1500009175202023-10-1800009175202023-01-260000917520iart:A2023ShareRepurchaseProgramMemberus-gaap:SubsequentEventMember2024-10-012024-10-310000917520iart:A2023ShareRepurchaseProgramMember2023-07-180000917520iart:A2023ShareRepurchaseProgramMember2024-09-3000009175202024-09-302024-09-3000009175202023-09-302023-09-300000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000917520us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000917520us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000917520us-gaap:OtherIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300000917520us-gaap:InterestIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2024-07-012024-09-300000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2023-07-012023-09-300000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2024-01-012024-09-300000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2023-01-012023-09-300000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2024-07-012024-09-300000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2023-07-012023-09-300000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2024-01-012024-09-300000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2023-01-012023-09-300000917520us-gaap:OperatingSegmentsMember2024-07-012024-09-300000917520us-gaap:OperatingSegmentsMember2023-07-012023-09-300000917520us-gaap:OperatingSegmentsMember2024-01-012024-09-300000917520us-gaap:OperatingSegmentsMember2023-01-012023-09-300000917520us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000917520us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000917520us-gaap:CorporateNonSegmentMember2024-01-012024-09-300000917520us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000917520country:US2024-07-012024-09-300000917520country:US2023-07-012023-09-300000917520country:US2024-01-012024-09-300000917520country:US2023-01-012023-09-300000917520srt:EuropeMember2024-07-012024-09-300000917520srt:EuropeMember2023-07-012023-09-300000917520srt:EuropeMember2024-01-012024-09-300000917520srt:EuropeMember2023-01-012023-09-300000917520srt:AsiaPacificMember2024-07-012024-09-300000917520srt:AsiaPacificMember2023-07-012023-09-300000917520srt:AsiaPacificMember2024-01-012024-09-300000917520srt:AsiaPacificMember2023-01-012023-09-300000917520iart:RestOfWorldMember2024-07-012024-09-300000917520iart:RestOfWorldMember2023-07-012023-09-300000917520iart:RestOfWorldMember2024-01-012024-09-300000917520iart:RestOfWorldMember2023-01-012023-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-12-310000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-12-310000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-12-310000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-12-310000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-01-012024-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-01-012024-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-01-012024-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-01-012024-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2024-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2024-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2024-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2024-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2024-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2022-12-310000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2022-12-310000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2022-12-310000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2022-12-310000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-01-012023-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-01-012023-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-01-012023-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-01-012023-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMember2023-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300000917520iart:ArkisBioSciencesInc.Memberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000917520iart:ACellMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000917520iart:SurgicalInnovationAssociatesIncMemberus-gaap:FairValueInputsLevel3Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000917520iart:ArkisBioSciencesInc.Member2019-07-290000917520iart:ArkisBioSciencesInc.Memberiart:MilestonePaymentOneMember2019-07-290000917520iart:ArkisBioSciencesInc.Memberiart:MilestonePaymentTwoMember2019-07-290000917520iart:DermaSciencesMemberiart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember2024-01-012024-09-300000917520iart:DermaSciencesMember2024-09-300000917520iart:ACellIncMember2021-01-200000917520iart:ACellIncMember2024-09-300000917520iart:SurgicalInnovationAssociatesIncMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMember2022-12-062022-12-060000917520iart:SurgicalInnovationAssociatesIncMemberiart:RevenueBasedPerformanceMilestonesMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMemberiart:FDAApprovalOfPremarketApprovalMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMemberiart:RevenueBasedPerformanceMilestonesMember2024-04-012024-06-300000917520iart:PlainsboroNewJerseyManufacturingFacilityMembersrt:ScenarioForecastMember2025-01-012025-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             
COMMISSION FILE NUMBER 000-26224
 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
Delaware 51-0317849
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)		 (I.R.S. EMPLOYER
IDENTIFICATION NO.)
1100 Campus Road 08540
Princeton,New Jersey(ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) 
Registrant's Telephone Number, Including Area Code: (609) 275-0500
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report:
Securities registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASSTRADING SYMBOLNAME OF EACH EXCHANGE ON WHICH REGISTERED
Common Stock, Par Value $.01 Per ShareIARTNasdaq Global Select Market
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.




Large accelerated filer☒Accelerated filer☐
Non-accelerated filer
☐  
Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
The number of shares of the registrant’s Common Stock, $0.01 par value, outstanding as of November 1, 2024 was 77,163,524.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
INDEX

 
 Page
Number



PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
(UNAUDITED)
(Dollars in thousands, except per share amounts)
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Total revenue, net$380,834 $382,421 $1,167,881 $1,144,534 
Costs and expenses:
Cost of goods sold180,596 164,076 534,892 486,292 
Research and development27,435 26,596 84,167 79,908 
Selling, general and administrative177,193 161,948 538,463 493,513 
Intangible asset amortization3,760 3,208 17,575 9,342 
Total costs and expenses388,984 355,828 1,175,097 1,069,055 
Operating (loss) income(8,150)26,593 (7,216)75,479 
Interest income5,049 4,607 15,147 12,653 
Interest expense(19,373)(13,062)(51,648)(37,626)
Other income, net2,112 471 2,939 1,705 
(Loss) income before income taxes(20,362)18,609 (40,778)52,211 
(Benefit) provision for income taxes(9,667)(888)(14,399)4,304 
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Net (loss) income per share
Basic$(0.14)$0.24 $(0.34)$0.59 
Diluted$(0.14)$0.24 $(0.34)$0.59 
Weighted average common shares outstanding (See Note 13):
Basic76,448 79,690 77,196 80,842 
Diluted76,448 79,811 77,196 81,112 
Comprehensive income (See Note 14)
(16,823)16,412 (36,126)$39,387 

The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
3
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Dollars in thousands, except per share amounts)
September 30, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$215,157 $276,402 
Short-term investments62,441 32,694 
Trade accounts receivable, net of allowances of $7,423 and $4,879
248,298 259,327 
Inventories, net436,930 389,608 
Prepaid Expenses86,326 67,362 
Other Current Assets50,370 32,643 
Total current assets1,099,522 1,058,036 
Property, plant and equipment, net390,906 340,199 
Right of use asset - operating leases146,342 156,184 
Intangible assets, net1,209,548 1,067,833 
Goodwill1,116,535 1,055,462 
Deferred tax assets, net48,936 46,080 
Other assets54,014 58,194 
Total assets$4,065,803 $3,781,988 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of borrowings under senior credit facility$29,063 $14,531 
Current portion of lease liability - operating leases15,039 15,284 
Convertible securities572,442 — 
Accounts payable, trade77,666 92,326 
Contract liabilities9,990 8,540 
Accrued compensation76,424 75,455 
Accrued expenses and other current liabilities131,939 100,844 
Total current liabilities912,563 306,980 
Long-term borrowings under senior credit facility1,132,292 825,563 
Long-term borrowings under securitization facility72,800 89,200 
Long-term convertible securities— 570,255 
Lease liability - operating leases167,808 166,849 
Deferred tax liabilities68,945 35,317 
Other liabilities189,808 199,940 
Total liabilities2,544,216 2,194,104 
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding
— — 
Common stock; $0.01 par value; 240,000 authorized shares; 91,588 and 90,920 issued at September 30, 2024 and December 31, 2023, respectively
916 909 
Additional paid-in capital1,316,854 1,302,484 
Treasury stock, at cost; 14,454 shares and 12,751 shares at September 30, 2024 and December 31, 2023, respectively
(691,810)(647,262)
Accumulated other comprehensive loss(24,854)(15,106)
Retained earnings920,481 946,859 
Total stockholders’ equity1,521,587 1,587,884 
Total liabilities and stockholders’ equity$4,065,803 $3,781,988 
The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
4

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(Dollars in thousands)
 Nine Months Ended September 30,
 20242023
OPERATING ACTIVITIES:
Net (Loss) Income$(26,379)$47,907 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization103,304 92,527 
Non-cash impairment charges12,173 — 
Deferred income tax (benefit) provision(13,743)2,963 
Share-based compensation17,225 14,350 
Amortization of debt issuance costs and expenses associated with debt refinancing4,193 4,731 
Non-cash lease expense(129)2,120 
Loss (gain) on disposal of property and equipment1,337 (4)
Change in fair value of contingent consideration and others(319)8,278 
Changes in assets and liabilities:
Accounts receivable38,861 5,050 
Inventories(27,579)(43,350)
Prepaid expenses and other current assets(34,401)(21,700)
Other non-current assets(1,745)(8,774)
Accounts payable, accrued expenses and other current liabilities2,686 (22,141)
Contract liabilities1,822 141 
Other non-current liabilities1,336 (893)
Net cash provided by operating activities78,642 81,205 
INVESTING ACTIVITIES:
Purchases of property and equipment(74,818)(42,330)
Cash (paid) for business acquisitions, net of cash acquired(281,994)— 
Purchases of short term investments(48,997)— 
Proceeds from maturities of short term investments19,250 — 
Net proceeds from swaps designated as net investment hedges— 5,381 
Net cash used in investing activities(386,559)(36,949)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness451,100 146,900 
Payments on debt(147,188)(85,900)
Payment of debt issuance costs— (7,578)
Purchases of treasury stock(50,000)(275,000)
Payments for Contingent Consideration (11,923)— 
Proceeds from exercised stock options6,398 4,092 
Cash taxes paid in net equity settlement(3,374)(5,549)
Net cash provided by (used in) financing activities245,013 (223,035)
Effect of exchange rate changes on cash and cash equivalents1,659 (4,150)
Net decrease in cash and cash equivalents(61,245)(182,929)
Cash and cash equivalents at beginning of period276,402 456,661 
Cash and cash equivalents at end of period$215,157 $273,732 
The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
5
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(UNAUDITED)
(Dollars in thousands)
Nine Months Ended September 30, 2024
Common StockTreasury StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossRetained EarningsTotal Equity
SharesAmountSharesAmount
Balance, January 1, 202490,920 $909 (12,751)$(647,262)$1,302,484 $(15,106)$946,859 $1,587,884 
Net loss— — — — — — (3,281)(3,281)
Other comprehensive income (loss), net of tax— — — — — 4,460 — 4,460 
Issuance of common stock through employee stock purchase plan23 — — — 965 — — 965 
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures541 2 16 840 1,470 — — 2,312 
Share-based compensation— 4 — — 5,608 — — 5,612 
Accelerated shares repurchased— $— — — — $— — — 
Balance, March 31, 202491,484 $915 (12,735)$(646,422)$1,310,527 $(10,646)$943,578 $1,597,952 
Net loss— — — — — — (12,402)(12,402)
Other comprehensive loss, net of tax— — — — — (8,080)— (8,080)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures107 1 — 20 (101)— — (80)
Share-based compensation— — — — 7,305 — — 7,305 
Accelerated shares repurchased— $— (1,273)(34,351)(16,149)$— $— (50,500)
Balance, June 30, 202491,591 $916 (14,008)$(680,753)$1,301,582 $(18,726)$931,176 $1,534,195 
Net loss— — — — — — (10,695)(10,695)
Other comprehensive income, net of tax— — — — — (6,128)— (6,128)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures(3)— — 10 (181)— — (171)
Share-based compensation— — — — 4,386 — — 4,386 
Accelerated shares repurchased— — (446)(11,067)11,067 — — — 
Balance, September 30, 202491,588 $916 (14,454)$(691,810)$1,316,854 $(24,854)$920,481 $1,521,587 
6
Nine Months Ended September 30, 2023
Common StockTreasury StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossRetained EarningsTotal Equity
SharesAmountSharesAmount
Balance, January 1, 2023
90,476 $905 (6,823)$(362,862)$1,276,977 $10,265 $879,118 $1,804,403 
Net income— — — — — — 24,226 24,226 
Other comprehensive income, net of tax— — — — — (3,198)— (3,198)
Issuance of common stock through employee stock purchase plan21 — — — 1,107 — — 1,107 
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures316 1 16 846 (4,858)— — (4,011)
Share-based compensation— 2 — — 3,609 — — 3,611 
Accelerated shares repurchased— — (2,111)(119,662)(31,538)— — (151,200)
Balance, March 31, 2023
90,813 $908 (8,918)$(481,678)$1,245,297 $7,067 $903,344 $1,674,938 
Net income— — — — — — 4,184 4,184 
Other comprehensive income (loss), net of tax— — — — — (2,237)— (2,237)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures68 1 — 21 985 — — 1,007 
Share-based compensation— — — — 5,268 — — 5,268 
Accelerated shares repurchased— — (609)(32,125)32,125 — — — 
Balance, June 30, 2023
90,881 909 (9,527)(513,782)1,283,675 4,830 907,528 1,683,160 
Net income— — — — — — 19,497 19,497 
Other comprehensive income, net of tax— — — — — (3,085)— (3,085)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures54 — — 17 424 — — 441 
Share-based compensation— — — — 5,457 — — 5,457 
Accelerated shares repurchased— — (2,296)(99,012)(27,237)— — (126,249)
Balance, September 30, 2023
90,935 909 (11,823)(612,777)1,262,319 1,745 927,025 1,579,221 
The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
7
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the September 30, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2024 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and, in January 2021, subsequently amended the initial guidance in: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to a SOFR-indexed rate. (See Note 6. Debt). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR. The Company has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR.
8
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.
Cash and cash equivalents
The Company had cash and cash equivalents, primarily consisting of cash on-hand as well as time deposits with original maturities of three months or less and money market funds which are highly liquid and readily convertible to cash, totaling approximately $215.2 million and $276.4 million at September 30, 2024 and December 31, 2023 respectively. Time deposits with original maturities of three months or less and money market funds are valued based on Level 1 measurements in the fair value hierarchy established within FASB Topic 820, Fair Value Measurement (“ASC 820”). Level 1 inputs represent quoted prices in active markets for identical assets or liabilities.
Short-term investments
The Company had short term investments, primarily consisting of time deposits with original maturities between three months and one year, which are valued based on Level 1 measurements in the fair value hierarchy, totaling approximately $62.4 million at September 30, 2024 compared to $32.7 million at December 31, 2023.
2. ACQUISITIONS AND DIVESTITURES
Acquisition of Acclarent, Inc.
On April 1, 2024, the Company completed the acquisition of all of the outstanding capital stock of Acclarent, Inc. (“Acclarent”), a developer and marketer of medical devices used in ear, nose, throat (“ENT”) procedures, from Ethicon, Inc., a subsidiary of Johnson & Johnson, for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. In September 2024, the Company finalized the working capital adjustment in the amount of $4.2 million, which resulted in a reduction to goodwill. This adjustment will be settled during the three months ending December 31, 2024. The addition of Acclarent’s ENT product portfolio, including sinus balloon dilation, eustachian tube balloon dilation, and surgical navigation systems technologies, and dedicated salesforce will enhance the Company’s position in the ENT specialty device market.
Acclarent’s results of operations have been reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition. The Company recorded revenue from Acclarent of approximately $62.3 million, in the consolidated statements of operations and comprehensive income for the nine months ended September 30, 2024. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company’s operations.
Assets Acquired and Liabilities Assumed at Fair Value
The Acclarent acquisition has been accounted for using the acquisition method of accounting in accordance with FASB Topic ASC 805, Business Combinations (“ASC 805”). This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date. The Company estimated fair values at the date of acquisition for the preliminary allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed. The Company has not completed its analysis regarding the assets acquired and liabilities assumed. Therefore, the allocation to intangible assets, goodwill, and income taxes are preliminary and subject to finalization. During the measurement period ending no later than one year after the acquisition date, the Company will continue to obtain information to assist in finalizing the fair values of the net assets acquired, which may differ materially from these preliminary estimates. If any measurement period adjustment is material, the Company will record such adjustment, including any related impact on net income, in the reporting period in which the adjustment is determined.
9
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date:
Dollars in thousandsEstimated Fair ValueEstimated Useful Life
Current assets:
Cash$— 
Trade accounts receivable, net 23,716 
Inventories, net20,294 
Prepaid expenses273 
Other current assets476 
Total current assets$44,759 
Property, plant and equipment, net7,716 
Right of use asset - operating leases989 
Intangible assets, net
Completed technology202,000 12 years
Trademarks/brand names3,000 5 years
All other17,000 4 years
Goodwill61,396 
Deferred tax assets6,863 
Total assets acquired$343,723 
Current liabilities:
Accounts payable, trade3,989 
Contract liabilities3,984 
Accrued compensation1,037 
Accrued expenses and other current liabilities2,278 
Current portion of lease liability - operating leases365 
Total current liabilities$11,653 
Lease liability - operating leases624 
Deferred tax liabilities53,635 
Total liabilities assumed65,912 
Net assets acquired$277,811 
The carrying value of trade accounts receivable, prepaid expenses, other current assets, accounts payable, contract liabilities, accrued compensation, accrued expenses and other current liabilities, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.
Intangible Assets
The estimated fair value of the intangible assets acquired was determined using the multi-period, excess earnings method of the income approach, which estimates value based on the present value of future economic benefits attributable to the intangible assets. The significant assumptions used in developing the valuation included the estimated annual net cash flows including application of forecasted revenue, the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. Preliminary assumptions may change and may result in significant changes to the final valuation. The intangible assets acquired have a weighted average useful life of 11 years.
The Company used a discount rate of 12.2% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.
10
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Goodwill
Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill has been allocated to the Codman Specialty Surgical segment, as shown in Note 5. Goodwill and Other Intangible Assets. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.
Deferred Tax Liabilities
Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.
Acquisition of Durepair®
On October 2, 2024, the Company completed the acquisition of the product rights for Durepair® Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $45.0 million. The Company made a cash payment of $10.0 million upon the closing of the acquisition and will make additional cash payments of $15.0 million upon the first anniversary of the acquisition and $20.0 million upon the second anniversary of the acquisition.
The Company will account for the acquisition of the product rights for Durepair, which consist of certain patents and trademarks, regulatory approvals, and other records, as an asset acquisition in accordance with ASC 805 because the acquisition does not include an assembled workforce and substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset and, thus, the assets are not considered a business.
3. REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Estimates
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.
11
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset$(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period$7,828 
Contract asset, September 30, 2024
$7,828 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability$(6,616)
Contract liability, acquired with Acclarent$3,984 
Contract liability, net of revenue recognized on contracts during the period$4,447 
Foreign currency translation$21 
Contract liability, September 30, 2024
$18,088 
At September 30, 2024, the short-term portion of the contract liability of $10.0 million and the long-term portion of $8.1 million are included in current liabilities and other liabilities, respectively, in the consolidated balance sheets.
As of September 30, 2024, the Company is expected to recognize revenue of approximately 55% of unsatisfied (or partially unsatisfied) performance obligations as revenue within 12 months, with the remaining balance to be recognized thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
12
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Neurosurgery$175,956 $209,229 $583,726 $607,902 
Instruments54,238 49,920 153,148 152,523 
ENT(1)
40,588 9,056 92,103 26,946 
Total Codman Specialty Surgical270,782 268,205 828,977 787,371 
Wound Reconstruction and Care80,460 88,071 249,032 280,129 
Private Label29,592 26,145 89,872 77,034 
Total Tissue Technologies110,052 114,216 338,904 357,163 
Total revenue$380,834 $382,421 $1,167,881 $1,144,534 
(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.
See Note 15. Segment and Geographic Information, for details of revenues based on the location of the customer.
4. INVENTORIES
Inventories, net consisted of the following:
Dollars in thousandsSeptember 30, 2024December 31, 2023
Finished goods$219,347 $196,402 
Work in process85,493 74,035 
Raw materials132,090 119,171 
Total inventories, net$436,930 $389,608 
5. GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2024 were as follows:
Dollars in thousandsCodman Specialty
Surgical		Tissue TechnologiesTotal
Goodwill at December 31, 2023$666,937 $388,525 $1,055,462 
Acclarent Acquisition 61,396 — 61,396 
Foreign currency translation(210)(113)(323)
Goodwill at September 30, 2024
$728,123 $388,412 $1,116,535 
The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with FASB ASC Topic 350, Intangibles—Goodwill and Other (“ASC 350”). Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.
The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test uses a combination of both an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and EBITDA
13
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
multiples. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins, and a discount rate for each reporting unit. Discount rates are determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and slight changes in these assumptions could have a significant impact on the concluded value. The estimates and assumptions applied represent a Level 3 measurement in the fair value hierarchy. Level 3 inputs are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
For goodwill, during the third quarter of 2024, the Company elected to bypass the qualitative evaluations of its Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units and perform quantitative tests. The quantitative test for the Tissue Technologies reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was not less than its carrying amount, with 21.2% headroom. The quantitative test for the Neurosurgery reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.0% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was not less than its carrying amount, with 11.7% headroom. The quantitative test for the Instruments and ENT reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 11.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Instruments and ENT reporting unit was not less than its carrying amount, with 22.1% headroom. Based on the results of these quantitative tests, the Company recorded no impairment of goodwill for Tissue Technologies, Neurosurgery, or Instruments and ENT reporting units.
The Company performed a hypothetical sensitivity analysis of the fair value for each reporting unit by increasing the discount rate by 50 basis points, decreasing the terminal growth rate by 50 basis points, and holding all other assumptions constant, which resulted in a decrease to the estimated fair value of the Tissue Technology reporting unit by 4.5%, a decrease to the estimated fair value of the Neurosurgery reporting unit by 3.8%, and a decrease to the estimated fair value of the Instruments and ENT reporting unit by 3.5%. Based on the results of the hypothetical sensitivity analyses, the Company would still not have recorded an impairment of goodwill for Tissue Technologies, Neurosurgery, or Instruments and ENT reporting units.
For intangible assets with indefinite lives, the Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test during the third quarter 2024. In performing this test, the Company utilized a discount rate of 13.0%. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.
14
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Other Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 September 30, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology17 years$1,427,186 $(509,825)$917,361 
Customer relationships12 years168,396 (138,022)30,374 
Trademarks/brand names27 years101,896 (41,833)60,063 
Codman tradenameIndefinite174,118 — 174,118 
Supplier relationships30 years30,211 (18,882)11,329 
All other6 years23,154 (6,851)16,303 
$1,924,961 $(715,413)$1,209,548 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
Total amortization of intangible assets for the three and nine months ended September 30, 2024 was $25.6 million and $78.7 million, respectively. Of these amounts, $21.8 million and $61.1 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.
Total amortization of intangible assets for the three and nine months ended September 30, 2023 was $20.9 million and $62.1 million, respectively. Of these amounts, $17.7 million and $52.8 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold, with the remainder included in intangible amortization in the statement of operations.
Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $25.6 million for the remainder of 2024, $102.4 million in 2025, $102.2 million in 2026, $101.2 million in 2027, $97.6 million in 2028, $92.4 million in 2029 and $511.8 million thereafter.
The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
In the first quarter of 2024, due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform quantitative impairment testing on certain definite-lived intangible assets including completed technology and customer relationships in accordance with FASB ASC Topic 360, Property, Plant and Equipment. The Company recorded an impairment charge related to the definite-lived intangible asset associated with the customer relationships of $7.1 million in intangible asset amortization in the consolidated statement of operations. With respect to the definite-lived intangible assets associated with the completed technology of SurgiMend® and PriMatrix®, the Company determined that the carrying amount of these definite-lived intangible assets were recoverable and, therefore, the intangible assets were not deemed to be impaired. In the second quarter of 2024, the Company approved a plan to transition the commercial distribution of SurgiMend® and PriMatrix® from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts (the “Braintree facility”). The Company considered the impact to the update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility on the assumptions used in the quantitative assessment of the definite-lived intangible assets completed in the first quarter of 2024, which did not require further evaluation for impairment. The carrying values of SurgiMend® and PriMatrix® are $34.6 million and $25.5 million, respectively, as of September 30, 2024.
15
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
6. DEBT
Amendment to the Seventh Amended and Restated Senior Credit Agreement
On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of the Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The March 2023 Amendment extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775.0 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans. The terms of the Senior Credit Facility limit the amount of dividends we may pay.
The Company’s maximum Consolidated Total Leverage Ratio (as defined in the March 2023 Amendment) in the financial covenants is outlined below. Concurrent with the Durepair acquisition (see Note 2. Acquisitions and Divestitures), in accordance with the terms of the March 2023 Amendment, the Company elected to increase the maximum Consolidated Total Leverage Ratio to 5.00 from the fiscal quarter ending December 31, 2024 through the fiscal quarter ending September 30, 2025.
Fiscal Quarter EndingMaximum Consolidated Total Leverage Ratio
March 31, 2023 through September 30, 2024
4.50 to 1.00
December 31, 2024 through September 30, 2025
5.00 to 1.00
December 31, 2025 through June 30, 2026
4.25 to 1.00
September 30, 2026 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%), or
ii.The highest of:
1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%;
2.the prime lending rate of Bank of America, N.A.; or
3.the one-month Term SOFR plus 1.00%.
The applicable rates are based on the Company’s Consolidated Total Leverage Ratio (defined, as of any date of determination, as the ratio of (a) Consolidated Funded Indebtedness as of such date (as defined in the Credit Agreement) less cash that is not subject to any restriction on the use or investment thereof to (b) Consolidated EBITDA (as defined by the Seventh Amended and Restated Credit Agreement (the “Credit Agreement”)), for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility component of the Senior Credit Facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2024, the Company was in compliance with all such covenants. The Company capitalized $7.6 million in deferred financing costs in connection with the modification of the Senior Credit Facility and wrote off $0.2 million of previously capitalized financing costs during the first quarter of 2023.
At September 30, 2024 and December 31, 2023 there was $400.0 million and $70.0 million, respectively, outstanding under the revolving credit facility component of the Senior Credit Facility. At September 30, 2024 and December 31, 2023, there was $765.3 million and $775.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.4% and 6.8%, respectively. As of September 30, 2024 and December 31, 2023 there was $29.1 million and $14.5 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.
16
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The fair value of the term loan and revolving portion of the Senior Credit Facility at September 30, 2024 was $756.3 million, and $395.3 million, respectively. The fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
Letters of credit outstanding as of September 30, 2024 and December 31, 2023 totaled $1.7 million. There were no amounts drawn under the letters of credit outstanding as of September 30, 2024.
Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:
As of September 30, 2024
Principal Repayment
Dollars in thousands
Remainder of 2024
$4,844 
2025
33,906 
2026
38,750 
2027
53,281 
2028634,531 
$765,312 
Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $12.3 million for the remainder of 2024, $48.1 million in 2025, $45.6 million in 2026, $42.6 million in 2027, and $9.4 million in 2028. Interest is calculated on the term loan portion of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Credit Agreement. As the revolving credit facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.
Any outstanding borrowings on the revolving credit facility component of the Senior Credit Facility are due on March 24, 2028.
Convertible Senior Notes
On February 7, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”) pursuant to an indenture, dated as of February 7, 2020 (the “Original Indenture”), between the Company and Citibank, N.A., as trustee. The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. In connection with this offering, the Company capitalized $13.2 million of financing fees.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on an initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company’s common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period specified in the Original Indenture; (3) if the Company calls the notes for optional redemption as described in the Original Indenture; or (4) if specified corporate transactions occur. As of September 30, 2024, none of these conditions existed and the 2025 Notes are classified as current convertible securities on the consolidated balance sheet, as they are due within one year.
On December 9, 2020, the Company entered into the first supplemental indenture to the Original Indenture (the “First Supplemental Indenture” and, together with Original Indenture, the “Indenture”), pursuant to which the Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement (as defined in the First Supplemental Indenture) for a conversion of the 2025 Notes, the Specified Dollar Amount (as defined in the First Supplemental Indenture) that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.
Holders of the 2025 Notes will have the right to require the Company to repurchase for cash all or a portion of their 2025 Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the Indenture). The Company will also be required to increase the conversion rate for holders who convert their 2025 Notes in connection with certain Fundamental Changes (as defined in the Original Indenture) occurring prior to the maturity date or following delivery by the Company of a notice of redemption.
17
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
At September 30, 2024, the carrying amount of the liability of the 2025 Notes was $575.0 million. The fair value of the 2025 Notes at September 30, 2024 was $547.7 million. Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quotes. The 2025 Notes are valued based on Level 1 measurements in the fair value hierarchy. Level 1 inputs represent quoted prices in active markets for identical assets or liabilities.
Securitization Facility
In 2018, the Company entered into an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2024, the Company was in compliance with the covenants and none of the termination events had occurred.
On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December 2023 Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, three years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.
At September 30, 2024 and December 31, 2023, the Company had $72.8 million and $89.2 million, respectively, of outstanding borrowings under its Securitization Facility at an interest rate of 5.9% and 6.4%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2024 was $71.2 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
18
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
7. DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR.
The Company held the following interest rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month Term SOFR Loan— 150,000 December 13, 2017July 1, 2019June 28, 20242.423 %— 2,105 
1-month Term SOFR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %1,246 4,978 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %525 1,349 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %515 1,312 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %501 1,346 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %1,425 3,015 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %1,616 3,052 
1-month Term SOFR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %22,809 22,965 
1-month Term SOFR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,159 5,263 
Basis Swap (1)
—— March 31, 2023March 24, 2023December 31, 2027N/A(1,949)0(1,829)
$1,325,000 $1,475,000 $31,847 $43,556 
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time
The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three and nine months ended September 30, 2024, the Company recorded a loss of $17.1 million and a gain of $2.7 million, respectively, in AOCI related to the change in fair value of the interest rate swaps. For the three and nine months ended September 30, 2023 the Company recorded a gain of $15.3 million and $23.5 million, respectively, in AOCI related to the change in fair value of the interest rate swaps.
For the three and nine months ended September 30, 2024, the Company recorded gains of $4.1 million and $14.4 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. For the three and nine months ended September 30, 2023 the Company recorded gains of $5.0 million and $12.9 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2024 within the next twelve months is $7.1 million.
The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.
19
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Foreign Currency Hedging
From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.
On September 22, 2023, the Company amended the CHF denominated intercompany loan to partially settle CHF 20.0 million and extend the termination date to September 2024 and as a result, the Company terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $48.5 million. Simultaneously, the Company entered into a cross-currency swap agreement to hedge a notional amount of CHF 28.5 million equivalent to $31.5 million of this amended intercompany loan into U.S. dollars. On September 23, 2024, the Company settled this cross-currency swap designated as a cash flow hedge of an intercompany loan. Based on the closing exchange rates, the loss upon settlement was approximately $2.3 million which was offset by the gain on the settlement of the intercompany loan.
On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.
The Company held the following cross-currency rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay CHFDecember 21, 2020December 22, 20253.00%CHF333,887 351,137 (30,892)(38,324)
Receive U.S.$3.98%$374,817 394,183 
Pay CHFSeptember 22, 2023September 23, 20242.40%CHF— 28,500 — (2,348)
Receive U.S.$6.27%$— 31,457 
Total$(30,892)$(40,672)
20
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The cross-currency swaps designated as cash flow hedges are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2024, the Company recorded a loss of $16.6 million and a gain of $13.5 million, respectively, in AOCI related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded gains of $13.8 million and $3.1 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2024 the Company recorded a loss of $23.2 million and a gain of $5.4 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans. For the three and nine months ended September 30, 2023, the Company recorded a gain of $15.3 million and $3.3 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.
For the three and nine months ended September 30, 2024, the Company recorded a gain of $1.1 million and $3.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded a gain of $1.5 million and $4.4 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of September 30, 2024 within the next twelve months is $0.7 million. As of September 30, 2024, the Company does not expect any gains or losses will be reclassified into earnings because the original forecasted transactions will not occur.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business.
On May 2, 2024, the Company entered into a cross-currency swap agreement with a notional amount of CHF 68.5 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.
On October 1, 2018, May 24, 2022, and November 21, 2023, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2024 and December 31, 2023, respectively (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 2,106 2,475 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,211 288,210 (48,153)(48,047)
Receive U.S.$1.94%$300,000 300,000 
Pay CHFNovember 17, 2023December 17, 2029—%CHF66,525 66,525 (5,248)(4,037)
Receive U.S.$2.54%$75,000 75,000 
Pay CHFMay 6, 2024December 18, 2030—%CHF68,483 — (6,071)— 
Receive U.S.$2.74%$75,000 — 
Total(57,366)(49,609)
21
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2024, the Company recorded a loss of $21.1 million and $0.4 million, respectively, in AOCI related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded a gain of $6.1 million and a loss of $4.1 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2024, the Company recorded a gain of $2.7 million and $7.4 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded gains of $1.8 million and $6.0 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2024 within the next twelve months is $9.6 million.
Foreign Currency Forward Contracts
The Company has entered into a hedge for forecasted intercompany purchases denominated in foreign currencies through the use of forward contracts designated as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in accumulated comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs.
In the first and third quarter of 2024, the Company entered into foreign currency forwards to mitigate the exchange rate risk of CHF denominated intercompany purchases. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2024 the notional amount of foreign currency forward contracts was 10.4 million CHF.
For the three and nine months ended September 30, 2024 the Company recorded a gain of $0.5 million and a loss of $0.2 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts and a loss of $0.1 million and $0.3 million, respectively, in cost of goods sold included in the consolidated statements of operations.
For the three and nine months ended September 30, 2023 the Company recorded a gain of $0.1 million and $0.3 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts and a gain of $0.1 million and $0.4 million, respectively, in cost of goods sold included in the consolidated statements of operations.
On October 16, 2024, the Company entered into forward currency forwards with a notional amount of 5.2 million CHF to mitigate the exchange rate risk of Swiss franc denominated intercompany purchases. These contracts settle at various dates within twelve months of execution.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.
22
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:
Fair Value as of
Location on Balance Sheet (1):
September 30, 2024December 31, 2023
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap
$7,335 $14,675 
Cross-currency swap708 537 
Foreign currency forward contracts292 — 
Net Investment Hedges
Cross-currency swap5,764 2,938 
Other assets
Cash Flow Hedges
Interest rate swap26,461 30,710 
Net Investment Hedges
Cross-currency swap— 1,470 
Total derivatives designated as hedges — Assets$40,560 $50,330 
Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap$265 $579 
Cross-currency swap— 4,813 
Foreign currency forward contracts— — 
Net Investment Hedges
Cross-currency swap2,120 2,903 
Other liabilities
Cash Flow Hedges
Interest rate swap1,684 1,250 
Cross-currency swap31,600 36,396 
Net Investment Hedges
Cross-currency swap61,010 51,114 
Total derivatives designated as hedges — Liabilities$96,679 $97,055 
(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.

23
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2024 and 2023:
Dollars in thousandsBalance in AOCI
Beginning of
Quarter		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Three Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap$53,116 $(17,133)$4,135 $31,848 Interest expense
Cross-currency swap(16,867)(16,625)(22,089)(11,403)Other income, net
Foreign Currency Forward Contract(430)474 (119)163 Cost of Sales
Net Investment Hedges
Cross-currency swap(29,466)(21,051)2,739 (53,256)Interest income
$6,353 $(54,335)$(15,334)$(32,648)
Three Months Ended September 30, 2023
Cash Flow Hedges
Interest rate swap$56,901 $15,317 $4,964 $67,254 Interest expense
Cross-currency swap(18,925)13,796 15,347 (20,476)Other income, net
Foreign Currency Forward Contract$(123)$98 $87 $(112)
Net Investment Hedges
Cross-currency swap(21,239)6,051 1,772 (16,960)Interest income
$16,614 $35,262 $22,170 $29,706 
Dollars in thousandsBalance in AOCI
Beginning of
Year		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Nine Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap$43,556 $2,678 $14,386 $31,848 Interest expense
Cross-currency swap(15,763)13,505 9,145 (11,403)Other income (expense), net
Foreign currency forward contract— (159)(322)163 Cost of sales
Net Investment Hedges
Cross-currency swap(45,498)(364)7,394 (53,256)Interest income
$(17,705)$15,660 $30,603 $(32,648)
Nine Months Ended September 30, 2023
Cash Flow Hedges
Interest rate swap$56,712 $23,477 $12,935 $67,254 Interest expense
Cross-currency swap(20,271)3,114 3,319 (20,476)Other income (expense), net
Foreign currency forward contract— $333 $445 (112)
Net Investment Hedges
Cross-currency swap(6,914)(4,066)5,980 (16,960)Interest income
$29,527 $22,858 $22,679 $29,706 
24
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Derivative Instruments not Designated Hedges:
During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $4.6 million as of September 30, 2024.
The fair value of the foreign currency swaps not designated as hedges was $1.1 million and $1.2 million as of September 30, 2024 and December 31, 2023, respectively. The following table summarizes the gains on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsThree Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Foreign currency swaps10 135 385 778 
Total$10 $135 $385 $778 
8. STOCK-BASED COMPENSATION
As of September 30, 2024, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).
Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.
Stock Options
As of September 30, 2024, there were approximately $3.5 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 243,964 stock options granted during the nine months ended September 30, 2024. For the nine months ended September 30, 2024, the weighted average grant date fair value for stock options granted was $15.68 per option.
Awards of Restricted Stock and Performance Stock
Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2024, there was approximately $35.4 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 737,623 restricted stock awards and 263,350 performance stock awards during the nine months ended September 30, 2024. For the nine months ended September 30, 2024, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $34.45 and $36.22 per award, respectively.
The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.
25
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
CEO Separation
On February 27, 2024, the Company announced that Mr. De Witte would retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process and entered into a letter agreement with Mr. De Witte to modify his current employment agreement and put forth the form of a post-employment consulting agreement. The Company applied modification accounting to the outstanding equity-based awards granted to Mr. De Witte as of that date, which revalued and accelerated stock-based compensation associated with equity-based awards granted to him over his expected service period to the Company. Pursuant to this letter agreement, Mr. De Witte’s unvested equity-based awards will continue to vest during his continued service period to the Company and vested stock options were modified such that they will remain exercisable until the lesser of (a) the stated term of the stock options and (b) six months following his cessation of continued service to the Company. As a result of the modifications, the Company recorded incremental stock-based compensation expense of $1.4 million during the nine months ended September 30, 2024. The Company will record a total of $1.9 million in accelerated stock-based compensation expenses for the twelve months ended December 31, 2024 that would not have been recognized if Mr. De Witte had not announced his retirement from Integra.
9. RETIREMENT PLANS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany, India and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2024 were $0.4 million and $1.3 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.8 million and $2.4 million for the three and nine months ended September 30, 2024, respectively, are included in other income, net in the consolidated statements of operations.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2023 were $0.3 million and $0.9 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.5 million and $1.6 million for the three and nine months ended September 30, 2023, respectively, are included in other income, net in the consolidated statements of operations.
The estimated fair values of plan assets were $43.4 million and $45.7 million as of September 30, 2024 and December 31, 2023, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2024 and December 31, 2023. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.
Deferred Compensation Plan
The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $6.5 million and $6.1 million as of September 30, 2024 and December 31, 2023, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.
10. LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2024. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
26
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Total operating lease expense for the nine months ended September 30, 2024 and September 30, 2023 was $18.8 million and $17.9 million, respectively, which includes $0.2 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases were as follows:
Dollars in thousands, except lease term and discount rateSeptember 30, 2024
December 31, 2023
ROU assets$146,342 $156,184 
Current lease liabilities15,039 15,284 
Non-current lease liabilities167,808 166,849 
Total lease liabilities$182,847 $182,133 
Weighted average remaining lease term (in years):
Leased facilities16.2 years16.3 years
Leased vehicles2.2 years1.9 years
Weighted average discount rate:
Leased facilities5.6 %5.9 %
Leased vehicles2.6 %2.7 %
Supplemental cash flow information related to leases for the nine months ended September 30, 2024 and 2023 were as follows:
Dollars in thousandsSeptember 30, 2024
September 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$18,255 $14,778 
ROU assets obtained in exchange for lease liabilities, net of modifications:
Operating leases$1,575 $19,540 
Future minimum lease payments under operating leases at September 30, 2024 were as follows:
Dollars in thousandsRelated PartiesThird PartiesTotal
Remainder of 2024
$74 $6,057 $6,131 
2025296 23,016 23,312 
2026296 21,317 21,613 
2027296 19,425 19,721 
2028296 17,163 17,459 
2029246 16,306 16,552 
Thereafter— 165,343 165,343 
Total minimum lease payments$1,504 $268,627 $270,131 
Less: Imputed interest87,284 
Total lease liabilities182,847 
Less: Current lease liabilities15,039 
Long-term lease liabilities167,808 
27
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
There were no future minimum lease payments under finance leases at September 30, 2024.
Related Party Leases
The Company leases one of its manufacturing facilities in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
Lease Impairment Charge
The Company approved a plan to transition the commercial distribution of PriMatrix® and SurgiMend® from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts and permanently cease use of the Boston facility. As a result, in the second quarter of 2024, the Company recorded a $4.6 million impairment charge, as the carrying amounts of the operating lease right-of-use asset and fixed assets related to the Boston facility exceeded their fair values based on the Company’s estimates of future discounted cash flows through the end of the lease term and the end of their remaining useful lives, respectively. The $4.6 million impairment charge was comprised of a $1.7 million impairment of an operating lease right-of-use asset and a $2.9 million write-off of fixed assets, which was recorded as a component of cost of goods sold in the condensed consolidated statements of operations.
11. TREASURY STOCK
As of September 30, 2024 and December 31, 2023, there were 14.5 million and 12.8 million shares of treasury stock outstanding with a cost of $691.8 million and $647.3 million, at a weighted average cost per share of $47.86 and $50.76, respectively.
On May 16, 2024, the Company entered into a $50 million accelerated share repurchase (“May 2024 ASR”) and received 1.3 million shares of common stock at inception of the May 2024 ASR, which represented approximately 70% of the expected total shares under the May 2024 ASR. On July 31, 2024, the early exercise provision was exercised by the May 2024 ASR counterparty. The Company received an additional 0.4 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the May 2024 ASR.
On August 15, 2023, the Company entered into a $125 million accelerated share repurchase (“August 2023 ASR”) and received 2.3 million shares of common stock at inception of the August 2023 ASR, which represented approximately 80% of the expected total shares under the August 2023 ASR. On October 18, 2023 the early exercise provision was exercised by the August 2023 ASR counterparty. The Company received an additional 0.9 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the August 2023 ASR.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase (“January 2023 ASR”) and received 2.1 million shares of common stock at inception of the January 2023 ASR, which represented approximately 80% of the expected total shares under the January 2023 ASR. The settlement of the January 2023 ASR agreement was completed in the second quarter of 2023, where the Company received 0.6 million shares, determined using the volume-weighted average price of the Company’s common stock during the term of the January 2023 ASR.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “Inflation Act”) was signed into law. The Inflation Act implements a new excise tax of 1% on the net share repurchases made by the Company effective for share repurchases performed January 1, 2023, or after. In October 2024, the Company made an excise tax payment of $2.5 million related to the January 2023 ASR and the August 2023 ASR.
On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program. As of September 30, 2024, $50 million remained authorized. The program, which was authorized in July 2023 and expires on December 31, 2025, allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.
28
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
12. INCOME TAXES
The following table provides a summary of the Company’s effective tax rate:
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Reported tax rate47.5 %(4.8)%35.3 %8.2 %
The Company’s effective income tax rates for the three months ended September 30, 2024 and 2023 were 47.5% and (4.8)%, respectively. For the three months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income realized during the third quarter. For the three months ended September 30, 2023,the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.3 million benefit related to the filing of prior year tax returns.
The Company’s effective income tax rates for the nine months ended September 30, 2024 and 2023 were 35.3% and 8.2%, respectively. For the nine months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income and a $1.9 million shortfall from stock-based compensation, as compared to the prior year. For the nine months ended September 30, 2023, the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.8 million benefit related to the filing of prior year tax returns.
Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Act was signed into law. The Company did not experience a material impact on the Company’s effective tax rate under the Inflation Act. Further, legislation in foreign jurisdictions may be enacted, in continued response to the base erosion and profit-sharing (“BEPS”) project begun by the Organization for Economic Cooperation and Development (“OECD”).
The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). Several of the jurisdictions that the Company operates in have already adopted some form of the model rules, which could impact the amount of taxes that the Company pays after 2023. However, the rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. At this time, the Company is projecting an immaterial amount related to Pillar 2 tax liability for the year ending December 31, 2024. Related changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
29
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
13. NET INCOME PER SHARE
Basic and diluted net income per share was as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 Dollars in thousands, except per share amounts2024202320242023
Basic net (loss) income per share:
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Weighted average common shares outstanding76,448 79,690 77,196 80,842 
Basic net (loss) income per common share$(0.14)$0.24 $(0.34)$0.59 
Diluted net (loss) income per share:
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Weighted average common shares outstanding — Basic76,448 79,690 77,196 80,842 
Effect of dilutive securities:
Stock options and restricted stock— 121 — 270 
Weighted average common shares for diluted earnings per share76,448 79,811 77,196 81,112 
Diluted net (loss) income per common share$(0.14)$0.24 $(0.34)$0.59 
Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Common stock of approximately 1.3 million and 0.6 million shares at September 30, 2024, and 2023, respectively, were not included in the computation of diluted net (loss) income per share because their effect would have been anti-dilutive.
14. ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME
Comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Foreign currency translation adjustment5,386 (9,541)(2,558)(16,378)
Change in unrealized loss/(gain) on derivatives, net of tax(11,044)6,790 (6,714)7,858 
Pension liability adjustment, net of tax(470)(334)(475)— 
Comprehensive (loss) income, net$(16,823)$16,412 $(36,126)$39,387 
30
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Changes in accumulated other comprehensive (loss) income by component between December 31, 2023 and September 30, 2024 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at January 1, 2024
$21,489 $2,712 $(39,307)$(15,106)
Other comprehensive gain (loss)11,632 (475)3,129 14,286 
Less: Amounts reclassified from accumulated other comprehensive income, net18,346 — 5,688 24,034 
Net current-period other comprehensive gain (loss)(6,714)(475)(2,559)(9,748)
Balance at September 30, 2024
$14,775 $2,237 $(41,866)$(24,854)
For the nine months ended September 30, 2024, the Company reclassified a gain of $7.3 million and $16.8 million from accumulated other comprehensive income to other income, net and interest income, respectively.
15. SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices; and (iii) the ENT business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.
•The Tissue Technologies segment consists of the Wound Reconstruction and Care business, which includes offerings such as skin and wound repair products, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The Tissue Technologies segment includes the Company’s private label business.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2024 and 2023 are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Segment Net Sales
Codman Specialty Surgical$270,782 $268,205 $828,977 $787,371 
Tissue Technologies
110,052 114,216 338,904 357,163 
Total revenues$380,834 $382,421 $1,167,881 $1,144,534 
Segment Profit
Codman Specialty Surgical$100,538 $105,170 $368,171 $332,444 
Tissue Technologies
28,482 31,789 96,33592,132 
Segment profit129,020 136,959 464,506 424,576 
Amortization(3,760)(3,208)(17,575)(9,342)
Corporate and other(133,410)(107,158)(454,147)(339,755)
Operating income$(8,150)$26,593 $(7,216)$75,479 
31
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
United States$290,192 $269,838 $856,646 $817,622 
Europe34,368 41,524 116,653 120,040 
Asia Pacific37,052 48,777 132,548 146,956 
Rest of World19,222 22,282 62,034 59,916 
Total Revenues$380,834 $382,421 $1,167,881 $1,144,534 
16. COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded and actual results may differ from these estimates. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.
On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra Life Sciences claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer to the contingent consideration section of this footnote for additional information on the ACell contingent considerations. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.
On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to defend the matter vigorously.
On March 17, 2021, a complaint was filed against the Company in the Court of Common Pleas of Philadelphia County in Pennsylvania asserting product liability claims relating to a surgical procedure in which the Company’s CUSA® Clarity allegedly was used. The plaintiff seeks damages against the Company based upon plaintiff’s claim that the CUSA® Clarity did not function as intended. The plaintiff also asserts separate claims against the surgeon and the hospital. In the third quarter of 2024, a settlement was reached, which has since been paid by the Company’s insurance carriers.
32
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Contingent Consideration
The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2024 and September 30, 2023 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2024 and September 30, 2023 is as follows (in thousands):
Nine Months Ended September 30, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Payment(12,400)
Change in fair value of contingent consideration liabilities (3,019)Research and development137 — 3,100 Selling, general and administrative
Balance as of September 30, 202412,736 2,694 300 59,400 
Short-Term $8,320 $— $— $19,600 Accrued expenses and other current liabilities
Long-Term4,416 2,694 300 39,800 Other liabilities
Total12,736 2,694 300 59,400 
Nine Months Ended September 30, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,600 
Change in fair value of contingent consideration liabilities1,991 Research and development1,887 (2,200)6,600 Selling, general and administrative
Balance as of September 30, 2023
$14,886 $2,117 $1,500 $64,200 
Short-Term $4,373 $— $503 $13,000 Accrued expenses and other current liabilities
Long-Term10,513 2,117 997 51,200 Other liabilities
Total14,886 2,117 1,500 64,200 
Arkis BioSciences Inc.
As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date.
Derma Sciences, Inc.
The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains, which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million.
33
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
ACell, Inc.
As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date.
Surgical Innovations Associates, Inc.
As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on (1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as (2) the approval by the FDA of the pre-market approval ("PMA") application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). In the second quarter of 2024, the Company paid out $12.4 million related to the 2023 performance year. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date.
Other Commitments
In October 2024, the Company entered into a definitive agreement to acquire a manufacturing facility in Plainsboro, New Jersey for $10 million in cash at closing. The manufacturing facility is currently leased by the Company. The transaction is expected to close in the first quarter of 2025.
34
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.
We have made statements in this Quarterly Report that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements other than statements of historical fact contained in this Quarterly Report, including, but not limited to, statements regarding our business strategy and plans, growth and growth strategies, developments in the markets for our products and services, financial results, development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, objectives of management for future operations and current expectations or forecasts of future results, our expectations regarding the Boston facility and plans to operationalize the Company's Braintree facility, transition the manufacture of SurgiMend® and PriMatrix® to the Braintree facility, and to obtain pre-market approval of SurgiMend® PRS in implant-based breast reconstruction; our expectations regarding CMP (as defined below) implementation and engagement; restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, governmental proceedings and investigations, mergers and acquisitions, divestitures, market acceptance of our products and services, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts, are forward-looking statements. In some cases, these forward-looking statements may be identified by forward-looking words such as “believe,” “may,” “might,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” or the negative version of these words or other similar words and expressions in this Quarterly Report.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions about the Company and other matters that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We believe these risks include but are not limited to those described under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in our Annual Report on Form 10-K for the year ended December 31, 2023 and in this Quarterly Report, as such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at https://www.sec.gov. Such risks and uncertainties include, but are not limited, to the following: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, other economic disruptions and U.S. and global recession concerns, on the Company’s customers and on the Company’s business, financial condition, results of operations and cash flows; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion; the Company’s ability to manufacture and ship sufficient quantities of its products to meet its customers’ demands; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions, including the war in Ukraine and the conflict in Israel and Gaza; the Company’s ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company’s ability to access and maintain relationships with customers of acquired entities and businesses; physicians’ willingness to adopt and third-party payors’ willingness to provide or maintain reimbursement for the Company’s recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company’s ability to remediate quality systems violations; difficulties or delays in obtaining and maintaining required regulatory approvals related to the transition of the manufacturing to the Braintree facility and obtain pre-market approval of SurgiMend® PRS in implant-based breast reconstruction; the possibility that costs or difficulties related to building and the operationalization of the Braintree facility or the transition of manufacturing activities from the Company’s Boston facility to the Braintree facility will be greater than expected; fluctuations in hospitals’ spending for capital equipment; the Company’s ability to comply with regulations regarding products of human origin and products containing materials derived from animal source; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company’s ability to leverage its existing selling organizations and administrative infrastructure; the Company’s ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Devices Regulation; the scope, duration and effect of additional U.S. and international
35
governmental, regulatory, fiscal, monetary and public health responses to public health crises; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; potential negative impacts resulting from environmental, social and governance matters; and the potential impact of our compliance with governmental regulations and accounting guidance.
We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, financial condition, and/or cash flows. These forward-looking statements speak only as of the date of this Quarterly Report and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law. You should carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties.
GENERAL
We are a leading global medical technology company innovating treatment pathways in surgical, neurologic and regenerative care to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. Founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue, our common stock trades on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “IART.” We have developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. We have expanded our base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of our customers and enhance patient care.
Our products are sold in more than 120 countries through a direct sales force as well as distributors and wholesalers. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care and otolaryngology. We are the world leader in neurosurgery and one of the top three providers in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about one-third of our overall revenue and focuses on three main areas: complex wound surgery, surgical reconstruction, and peripheral nerve repair.
We have key manufacturing and research facilities located in California, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland. We source most of our handheld surgical instruments and dural sealant products through specialized third-party vendors.
Our strategies are focused around five pillars. Of these five pillars, we have identified three core growth drivers: (1) innovating for outcomes, (2) growing internationally, and (3) broadening our impact on care pathways. Our execution of the core growth drivers is enabled by two key levers: (4) driving operational and customer excellence and (5) cultivating a high-performance culture. As outlined in greater detail below, we believe these five pillars will enable us to realize and advance our integrated growth strategy.
To this end, our executive leadership team has established the following key priorities aligned to the following five pillars:
Innovating for Outcomes. An important part of Integra’s growth strategy is introducing new products to strengthen and expand our portfolio through clinical evidence to support regulatory approval and strong reimbursement of our product portfolio around the world, including new indications for existing technologies. For example, in 2021, we filed a pre-market approval (“PMA”) application for a specific indication for Surgimend® in the use of post-mastectomy breast reconstruction. We cannot predict an approval date because of the timeline of restarting manufacturing at the Braintree, Massachusetts facility (the "Braintree facility"), where Surgimend® will be manufactured. We are also pursuing a PMA for DuraSorb for use in implant-based breast reconstruction (“IBBR”). We completed enrollment for the DuraSorb U.S. investigational device exemption clinical study for two-stage breast reconstruction in June 2023 and are conducting the primary follow-up one year after device implantation. We hope to secure approval for DuraSorb in 2025.
In addition, in March 2024, we expanded our urinary bladder matrix platform with the U.S. launch of MicroMatrix® Flex, a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas.
We also continued to advance the development of pioneering neurosurgical technologies with the expansion of our product offerings. In 2023, we launched additional CUSA® Clarity tips for use in surgical procedures requiring the controlled fragmentation, emulsification and aspiration of bone as well as in laparoscopic liver surgery.
36
Growing Internationally: Over the years, we have been significantly expanding our global footprint through investments in our commercial and manufacturing organizations, the expansion and development of international markets and new product introductions. As part of our In-China-For-China strategy, we continue the build out of our assembly capabilities in our new facility in Suzhou, China. Several new products were introduced in select international markets in 2023 and 2024, including MicroMatrix® and Certas Plus® Programmable Valve, which were launched in Europe, and CUSA Clarity laparoscopic tip, which was launched in Australia, New Zealand, Japan, Canada, South Africa and Israel. In addition, DuraGen® Secure, received approval in Japan, while DuraGen Plus, an absorbable and sutureless collagen onlay indicated as a dura substitute for the repair of dura mater, and Certas Plus were approved in China. We also continued to strengthen our presence in South Asia, Southeast Asia and South Korea with key leadership appointments.
Broadening Impact on Care Pathways. We seek ways to develop and acquire products and technologies that impact the lives of patients, starting with the journey that a patient takes from diagnosis and treatment planning to surgery and postoperative care. We are well-established in acute care in the hospital setting and continue to leverage that strong position to grow in this segment and shape treatment pathways into preoperative care and additional sites of care. On April 1, 2024, the Company successfully completed the acquisition of Acclarent from Ethicon, Inc., a subsidiary of Johnson & Johnson. Acclarent is an innovator and market leader in ear, nose and throat (“ENT”) procedures and the acquisition of Acclarent has positioned Integra as one of the leading providers of ENT products and technologies. Furthermore, we believe that, owing to the ENT business being an anatomical adjacency to neurosurgery, the acquisition will allow Integra to deliver future innovation both within the ENT business and across our other CSS technology platforms.
Driving Operations and Customer Excellence. We have been making investments to build more responsive and scalable processes, enhance the reliability of our quality systems and supply chain, and drive productivity initiatives to further supply and lower costs. We continue to invest in technologies, systems and processes to enhance the customer experience. We also continue to invest in our capacity expansion. This includes ongoing projects of transferring our Boston manufacturing to a new location in Braintree, Massachusetts, validating manufacturing processes in our manufacturing facility in Plainsboro, New Jersey and increasing capacity in our Memphis, Tennessee location.
Cultivating a High-Performance Culture. In seeking to sustain a culture of excellence and accountability, we have focused on employee empowerment and agility and building a diverse and inclusive workplace. These efforts resulted in our being named in several best workplace lists globally in 2023 and 2024. Additionally, we have been making further strides in advancing our environmental, social and governance (“ESG”) agenda to drive sustainability across the organization and recently published our third annual ESG report in the third quarter of 2024. For more information on our ESG strategy, goals, performance, and achievements, please visit “Our Company—ESG Report” at https://www.integralife.com/esg-report. Information on our website is not incorporated by reference herein and is not part of this Quarterly Report.
New Product Introductions and Research and Development Updates
We continue to invest in collecting clinical evidence to support our existing products and new product launches, and to ensure that we obtain market access for broader and more cost-effective solutions.
Neurosurgical Solutions and Surgical Instruments. The CSS business consists of a broad portfolio of market-leading brands, such as Codman®, DuraGen®, DuraSeal®, CUSA®, Mayfield®, Bactiseal®, and Certas® Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The growth in this business in recent years has been fueled by geographic expansion and new product registrations in markets, such as China, Japan, and Europe, which we expect to continue in the near-to-long term. Because our electromechanical products and instruments address significant needs in surgical procedures and limit uncertainty for surgeons, we continue to invest in registrations, clearances, and approvals for new indications and next generation improvements to our market-leading products. We have several active programs focused on life cycle management and innovation for capital and disposable products in our portfolio. Our product development efforts are focused on core clinical applications in cerebrospinal fluid (“CSF”) management, neuro-critical care monitoring, minimally invasive instruments and electrosurgery and ultrasonic medical technologies, as well as our ambition to transform the standard of care in neurosurgery with product advancements in minimally invasive surgery (“MIS”) and the surgical management of intracerebral hemorrhage (“ICH”). Our lighting franchise is among the most dynamic in the industry.
We are focused on the development of core clinical applications in our electromechanical technologies portfolio. We continue to update our CUSA® Clarity platform by incorporating new ultrasonic handpiece and integrated electrosurgical capabilities. We have made several enhancements to our CUSA® Clarity Tissue Ablation System. The extended laparoscopic tip was launched in the U.S. to enhance laparoscopic liver procedures. In addition, a single-sided bone tip received 510(k) clearance from the FDA. Commercial launch was completed successfully in early 2023. In August 2023, we launched a modified 23 kHz CUSA® Electrosurgery Module (“CEM”) for Clarity handpieces that can be used with additional electrosurgery generators. We continue to work with several instrument partners to bring new surgical instrument platforms to the market.
37
We also continued to advance the early-stage technology platforms we acquired in 2019. Through the acquisition of Arkis Biosciences, Inc. (“Arkis”) we added a platform technology, CerebroFlo® external ventricular drainage (“EVD”), a catheter with Endexo® technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation. The CerebroFlo EVD catheter has demonstrated an average of 99% less thrombus accumulation onto its surface, in vitro, compared to a market leading EVD catheter. Our work to combine our Bactiseal® antimicrobial technology with the Endexo anti-occlusive technology continues to progress for both a silicone-based hydrocephalus and EVD project.
We also continued to advance our innovation from the Rebound Therapeutics Corporation (“Rebound Therapeutics”), which was acquired in 2019. Rebound Therapeutics specializes in a single-use medical device, known as the Aurora Surgiscope, which is the only tubular retractor system designed for cranial surgery with an integrated access channel, camera and lighting. The 9mm Surgiscope received 510(k) clearance from the FDA in the fourth quarter of 2023.
Regenerative Technologies. We were the first company to receive an FDA claim for regeneration of dermal tissue and are a world leader in regenerative technology. Our regenerative technology development program applies our expertise in bioengineering to a range of biomaterials including natural materials such as purified collagen, intact human or animal tissues, honey as well as resorbable synthetic polymers with our DuraSorb and DuraSeal® product lines. These unique product designs are used for neurosurgical and reconstructive surgical applications, as well as dermal regeneration, including the healing of chronic and acute wounds, tendon and nerve repair. Our regenerative technology platform includes our legacy Integra® Dermal Regeneration Template (“IDRT”) products and complementary technologies that we have acquired. Our collagen manufacturing capability, combined with our history of innovation, including our launch of NeuraGen 3D, provides us with strong platform technologies for multiple indications.
In the third quarter of 2021, we filed a PMA application for a specific indication for Surgimend® in the use of post-mastectomy breast reconstruction and in July 2024 received approvable pending GMP status from FDA, which approved and closed out the clinical portion of this PMA application. In 2022, we acquired SIA, which has also submitted a PMA application for DuraSorb with IBBR, and in June 2023 we completed enrollment in the DuraSorb U.S. investigational device exemption clinical study for two-stage breast reconstruction; the primary follow-up period is one year after device implantation. By offering two distinct product solutions, we believe we have the opportunity to build a leading position in the IBBR market. We hope to secure approval for DuraSorb in 2025. For SurgiMend®, we cannot predict an approval date because of the timeline of restarting manufacturing at the Braintree facility.
Additionally, in 2022, we launched NeuraGen 3D Nerve Guide Matrix, a resorbable implant for repair of peripheral nerve discontinuities and engineered to create an optimized environment for nerve regeneration. Following the completion of design control activities in 2022, we launched both Cytal and MicroMatrix in Europe in 2023. In 2023, the Company received 510(k) clearance from the FDA for MicroMatrix® Flex, which is now commercially available in the U.S. as of March 2024.
European Union Medical Device Regulation Updates
As part of our ongoing efforts to remain compliant, the Company continues to work towards European Union Medical Device Regulation (“EU MDR”) certifications. In 2023, the Company received EU MDR certification in the CSS segment for Hakim Programmable Valves, Certas Plus without Bactiseal catheters, and DuraSeal Dural, as well as IDRT and BioPatch for the TT segment. In 2024, the Company also received EU MDR certification for DuraGen Suturable for the CSS segment and MicroMatrix, as well as Cytal for the TT segment.
38
FDA Matters
On March 7, 2019, TEI Biosciences, Inc. (“TEI”), one of our wholly-owned subsidiaries, received a Warning Letter (the “2019 Warning Letter”), dated March 6, 2019, from the FDA. The 2019 Warning Letter related to quality systems issues at TEI’s manufacturing facility located in Boston, Massachusetts (the “Boston facility”). The Boston facility manufactures extracellular bovine matrix products in our TT segment that are sold both in wound reconstruction and care and in private label channels. The letter resulted from an inspection held at that facility in October and November 2018 and did not identify any new observations that were not already provided in the Form 483 that followed the inspection. We submitted our initial response to the 2019 Warning Letter on March 28, 2019 and provide regular progress reports to the FDA as to its corrective actions. On October 28, 2021, the FDA initiated an inspection of the facility and at the conclusion of the inspection, issued an FDA Form 483 on November 12, 2021 (the “2021 Form 483”). We provided an initial response to the inspection observations. On March 1, 2023, the FDA commenced an inspection of the Boston facility and issued an FDA Form 483 at the conclusion of this inspection (the “2023 Form 483”). In May 2023, after consultation with the FDA, The Company initiated a voluntary global recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™, distributed between March 1, 2018 and May 22, 2023. On July 19, 2023, TEI received a Warning Letter, dated July 17, 2023, from the FDA related to quality system issues at the Boston facility (the “2023 Warning Letter”). The 2023 Warning Letter did not identify any new observations that had not already been provided in the 2023 Form 483. The Company has submitted periodic responses to the FDA for both the 2023 Form 483 and the 2023 Warning Letter. We are committed to resolving the matters identified in the Warning Letters and Form 483s and are continuing our significant efforts to remediate the observations.
Although the Warning Letters do not restrict the Company’s ability to seek FDA 510(k) clearance of products, PMAs for Class III devices to which the quality system regulation violations are reasonably related will not be approved until the violations have been addressed. We cannot give any assurances that the FDA will be satisfied with our response to the issues identified by the FDA or as to the expected date of the resolution of such issues. Until the issues cited by the FDA are resolved to the FDA’s satisfaction, the FDA may initiate additional regulatory action without further notice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.
As required by the 2023 Warning Letter, we retained an outside expert consultant to perform an audit of the Boston facility in March 2024. Since receiving the third-party audit findings for the Boston facility in March, the Company has reassessed its plans and timeline to resume the manufacture of PriMatrix® and SurgiMend®. In parallel, the Company has been furthering its plans to complete the construction and operationalization of its new tissue manufacturing facility in Braintree, Massachusetts. The Company announced in the second quarter of 2024 that it no longer plans to restart the manufacture of PriMatrix® and SurgiMend® at its Boston facility and will, instead, restart manufacturing of these products at the Braintree facility. The Company expects to operationalize the Braintree facility in the first half of 2026. As a result of these decisions, in the second quarter of 2024, the Company recorded a $4.6 million impairment charge, comprised of a $1.7 million impairment of an operating lease right-of-use asset and a $2.9 million write-off of fixed assets, which was recorded as a component of cost of goods sold in the condensed consolidated statements of operations. For further detail on the impairment, see Note 10. Leases and Related Party Leases.
The Company elected to perform impairment testing on certain definite-lived intangibles and goodwill in the first quarter of 2024, which resulted in an intangible impairment of $7.1 million. For further detail on the impairment testing, see Note 5. Goodwill and Other Intangible Assets.
Revenues of products manufactured in the Boston facility for the year ended December 31, 2022 were approximately 5.3% of consolidated revenues.
Optimization and Integration Activities
As a result of our ongoing acquisition strategy and significant growth in recent years, we have undertaken cost-saving initiatives to consolidate manufacturing operations, distribution facilities and transfer activities, eliminate duplicative positions, realign various sales and marketing activities, and expand and upgrade production capacity for our regenerative technology products. These efforts are expected to continue and while we expect a positive impact from ongoing restructuring, integration, and manufacturing transfer and expansion activities, such results remain uncertain.
As a result of both audits by regulatory agencies as well as our own reviews of the company’s quality management system, we are in the process of implementing a Compliance Master Plan (the “CMP”), a systematic and holistic approach to improving our quality management system across our manufacturing and supply network. The primary objectives of the CMP are to remediate quality system gaps, harmonize the quality management system across the company, and enhance the quality culture at the company.
39
RESULTS OF OPERATIONS
Executive Summary
Net loss for the three and nine months ended September 30, 2024 was $(10.7) million and $(26.4) million, or $(0.14) and $(0.34) per diluted share, as compared to net income of $19.5 million and $47.9 million or $0.24 and $0.59 per diluted share for the three and nine months ended September 30, 2023. The decrease in net income for the three and nine months ended September 30, 2024, was driven by impacts from quality and operational issues, along with costs related to the Acclarent acquisition.
Special Charges
Income before taxes includes the following special charges:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Acquisition, divestiture and integration-related charges$7,810 $5,832 $31,361 $18,056 
Structural optimization charges5,739 3,729 15,112 9,868 
EU medical device regulation10,578 13,490 35,109 34,172 
Boston recall / Braintree transition(1)
9,933 7,800 33,676 38,841 
Total$34,060 $30,851 $115,258 $100,937 
(1) This primarily includes idle capacity charges, inventory write offs, site transfer costs, quality remediation costs, right of use and fixed asset impairments.
The items reported above are reflected in the condensed consolidated statements of operations as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Cost of goods sold $17,803 $11,223 $55,689 $50,437 
Research and development3,218 5,448 14,645 13,878 
Selling, general and administrative13,056 14,302 45,021 37,371 
Other income(17)(122)(97)(749)
 Total$34,060 $30,851 $115,258 $100,937 
We typically define special charges as items for which the amounts and/or timing of such expenses may vary significantly from period to period, depending upon our acquisition, divestiture, integration and restructuring activities, and for which the amounts are non-cash in nature and are not expected to recur at the same magnitude. We believe that given our ongoing strategy of seeking acquisitions, our continuing focus on rationalizing our existing manufacturing and distribution infrastructure and our continuing review of various product lines in relation to our current business strategy, some of the special charges discussed above could recur with similar materiality in the future.
We believe that the separate identification of these special charges provides important supplemental information to investors regarding financial and business trends relating to our financial condition and results of operations. Investors may find this information useful in assessing the comparability of our operating performance from period to period, against the business model objectives that management has established, and against other companies in our industry. We provide this information to investors so that they can analyze our operating results in the same way that management does and to use this information in their assessment of our core business and valuation of the Company.
Revenues and Gross Margin
The Company’s revenues and gross margin on product revenues were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Segment Net Sales
Codman Specialty Surgical$270,782$268,205$828,977$787,371
Tissue Technologies110,052114,216338,904357,163
Total revenues$380,834$382,421$1,167,8811,144,534
Cost of goods sold180,596164,076534,892486,292
Gross margin on total revenues$200,238$218,345$632,989$658,242
Gross margin as a percentage of total revenues52.6 %57.1 %54.2 %57.5 %
40
Three Months Ended September 30, 2024 as Compared to Three Months Ended September 30, 2023
Revenues and Gross Margin
For the three months ended September 30, 2024, total revenues decreased by $1.6 million to $380.8 million from $382.4 million for the same period in 2023. Excluding the impacts of the Acclarent acquisition, the Boston recall and foreign currency impact, revenues declined low double digits compared to the same period in the previous year, driven by impacts from quality and operational issues.
In the CSS segment, revenues were $270.8 million which was an increase of $2.6 million, or 1.0% as compared to the prior-year period, inclusive of $31.0 million related to the Acclarent acquisition. Excluding the impact of the Acclarent acquisition, the Neurosurgery portfolio declined low double digits, primarily driven by lower sales due to temporary shipping holds in CSF Management and Dural Access & Repair.
In the TT segment, revenues were $110.1 million which was an decrease of $4.2 million, or 3.6% from the prior-year period. Excluding the impact of the Boston recall, the TT segment decreased high single-digits as compared to the same period in the prior year. This is primarily attributable to a decline in Integra Skin due to production challenges, partially offset by growth in our private label business, MicroMatrix® & Cytal, and Durasorb.
Gross margin was $200.2 million for the three months ended September 30, 2024, a decrease of $18.1 million from $218.3 million for the same period in 2023. Gross margin as a percentage of revenues was 52.6% for the three months ended September 30, 2024 and 57.1% for the same period in 2023. For the three months ended September 30, 2024, gross margins were impacted by expenses associated with quality and operational issues. For the three months ended September 30, 2023, gross margins were impacted by expenses associated with the Boston recall.
Operating Expenses
The following is a summary of operating expenses as a percent of total revenues:
 Three Months Ended September 30,
 20242023
Research and development7.2 %7.0 %
Selling, general and administrative46.5 %42.3 %
Intangible asset amortization1.0 %0.8 %
Total operating expenses54.7 %50.1 %
Total operating expenses, which consist of research and development, selling, general and administrative, and amortization expenses, increased by $16.6 million, or 8.7%, to $208.4 million in the three months ended September 30, 2024, compared to $191.8 million in the same period in 2023.
Research and Development
Research and development expenses for the three months ended September 30, 2024 increased by $0.8 million as compared to the same period in the prior year.
Selling, General and Administrative
Selling, general and administrative costs for the three months ended September 30, 2024 increased by $15.2 million as compared to the same period in the prior year due to higher spending in commercial selling activities for both legacy and Acclarent products.
Intangible Asset Amortization
Amortization expense (excluding amounts reported in cost of product revenues for technology-based intangible assets) for the three months ended September 30, 2024 was $3.8 million compared to $3.2 million for the same period in the prior year.
41
Non-Operating Income and Expenses
The following is a summary of non-operating income and expenses:
 Three Months Ended September 30,
Dollars in thousands20242023
Interest income$5,049 $4,607 
Interest expense(19,373)(13,062)
Other income, net2,112 471 
Total non-operating income and expense$(12,212)$(7,984)
Interest Income
Interest income for the three months ended September 30, 2024 increased by $0.4 million as compared to the same period in the prior year.
Interest Expense
Interest expense for the three months ended September 30, 2024 increased by $6.3 million as compared to the same period in the prior year primarily due to incremental borrowing to fund the Acclarent acquisition.
Other Income, net
Other income, net for the three months ended September 30, 2024 increased by $1.6 million compared to the same period in the prior year, primarily driven by favorable foreign exchange impact.
Income Taxes
Three Months Ended September 30,
Dollars in thousands20242023
Income before income taxes$(20,362)$18,609 
Income tax (benefit) expense(9,667)(888)
Effective tax rate47.5 %(4.8)%
The Company’s effective income tax rates for the three months ended September 30, 2024 and 2023 were 47.5% and (4.8)%, respectively. For the three months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower three month book income, as compared to the previous year. For the three months ended September 30, 2023,the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.3 million benefit related to the filing of prior year tax returns.
The effective tax rate may vary from period to period depending on, among other factors, the geographic and business mix of taxable earnings and losses, tax planning and settlements with various taxing authorities. We consider these factors and others, including the Company’s history of generating taxable earnings, in assessing our ability to realize tax assets on a quarterly basis.
Additionally, changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. The current U.S. administration has proposed tax reform which, if enacted, may increase the Company’s U.S. federal income tax liability. Further, legislation in foreign jurisdictions may be enacted, in response to the base erosion and profit-shifting project begun by the Organization for Economic Cooperation and Development (“OECD”). Such changes in the U.S. and non-U.S. jurisdictions could have an adverse effect on the Company's effective tax rate.
The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). Several of the jurisdictions in which we operate have already adopted some form of the model rules, which could impact the amount of taxes that the Company pays during 2024 and future taxable periods. The rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. At this time, the Company is projecting an immaterial expense related to Pillar 2 tax liability for the 2024 year. The Company will continue to analyze the new Pillar 2 laws and any related guidance to determine potential impacts. Such changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
42
While it is often difficult to predict the outcome or the timing of the resolution of a particular matter with the various federal, state, and foreign tax authorities, we believe that our reserves reflect the most probable outcome of known tax contingencies. Settlement of a particular issue would usually require the use of cash. A favorable resolution would be recognized as a reduction to our annual effective tax rate in the year of resolution. The Company’s tax reserves are presented in the balance sheet within other liabilities, except for amounts relating to items that we expect to pay in the coming year, which would be classified as current income taxes payable.
Nine Months Ended September 30, 2024 as Compared to Nine Months Ended September 30, 2023
Revenues and Gross Margin
For the nine months ended September 30, 2024, total revenues increased by $23.3 million to $1,167.9 million from $1,144.5 million for the same period in 2023. Excluding the impacts of the Acclarent acquisition, the Boston recall and foreign currency impact, revenues declined low single digits compared to the same period in the prior year, primarily driven by impacts from quality and operational issues.
In the CSS segment, revenues were $829.0 million, an increase of $41.6 million, or 5.3% from the prior period, inclusive of $62.3 million related to the Acclarent acquisition, and $5.2 million unfavorable foreign currency impact on revenue. Excluding these impacts, the Neurosurgery portfolio revenues declined low single digits, primarily driven by lower sales due to temporary shipping holds in CSF Management and Dural Access & Repair.
In the TT segment, revenues were $338.9 million, a decrease of $18.3 million, or 5.1% from the prior-year period. Excluding the impact of the Boston recall, the TT segment decreased mid single digits as compared to the same period in the prior year. This is primarily attributable to a decline in Integra Skin due to production challenges, partially offset by growth in our private label business, MicroMatrix® & Cytal, and Durasorb.
Gross margin was $633.0 million for the nine months ended September 30, 2024, a decrease of $25.3 million from $658.2 million for the same period in 2023. Gross margin as a percentage of total revenue decreased to 54.2% for the nine months ended September 30, 2024 from 57.5% in the same period in 2023. For the nine months ended September 30, 2024, gross margins were impacted by impairment charges associated with the Boston recall, Acclarent inventory step up, and expenses associated with quality and operational issues. For the nine months ended September 30, 2023 gross margins were impacted by expenses associated with the Boston recall.
Operating Expenses
The following is a summary of operating expenses as a percent of total revenues: 
 Nine Months Ended September 30,
 20242023
Research and development7.2 %7.0 %
Selling, general and administrative46.1 %43.1 %
Intangible asset amortization1.5 %0.8 %
Total operating expenses54.8 %50.9 %
Total operating expenses, which consist of selling, general and administrative expenses, research and development expenses, and amortization expenses, increased by $57.4 million, or 9.8% to $640.2 million in the nine months ended September 30, 2024, compared to $582.8 million in the same period in 2023.
Research and Development
Research and development expenses for the nine months ended September 30, 2024 increased by $4.3 million as compared to the same period in the prior year primarily due to the Acclarent acquisition.
Selling, General and Administrative
Selling, general and administrative costs increased by $45.0 million as compared to the same period in the prior year driven primarily by Acclarent acquisition costs and related commercial activities, as well as higher spending in commercial selling activities for legacy products.
Intangible Asset Amortization
Amortization expense (excluding amounts reported in cost of product revenues for technology-based intangible assets) for the nine months ended September 30, 2024 was $17.6 million compared to $9.3 million for the same period in the prior year. The increase is driven by the impairment of customer relationship intangible related to our Boston facility of $7.1 million.
43
We expect total annual amortization expense to be approximately $25.6 million for the remainder of 2024, $102.4 million in 2025, $102.2 million in 2026, $101.2 million in 2027, $97.6 million in 2028, $92.4 million in 2029 and $511.8 million thereafter.
Non-Operating Income and Expenses
The following is a summary of non-operating income and expenses:
Nine Months Ended September 30,
Dollars in thousands20242023
Interest income$15,147 $12,653 
Interest expense(51,648)(37,626)
Other income, net2,939 1,705 
Total non-operating income and expense$(33,562)$(23,268)
Interest Income
Interest income for the nine months ended September 30, 2024 increased by $2.5 million as compared to the same period in the prior year due to higher interest rates.
Interest Expense
Interest expense for the nine months ended September 30, 2024 increased by $14.0 million as compared to the same period in the prior year mainly due to incremental borrowing for the Acclarent acquisition.
Other Income, net
Other income, net for the nine months ended September 30, 2024, increased by $1.2 million as compared to the same period in the prior year, primarily driven by favorable foreign exchange impact.
Income Taxes
Nine Months Ended September 30,
Dollars in thousands20242023
Income before income taxes$(40,778)$52,211 
Income tax (benefit) expense(14,399)4,304 
Effective tax rate35.3 %8.2 %
The Company’s effective income tax rates for the nine months ended September 30, 2024 and 2023 were 35.3% and 8.2%, respectively. For the nine months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income and a $1.9 million shortfall from stock-based compensation, as compared to the prior year. For the nine months ended September 30, 2023, the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.8 million benefit related to the filing of prior year tax returns.
GEOGRAPHIC PRODUCT REVENUES AND OPERATIONS
We attribute revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
United States$290,192 $269,838 $856,646 $817,622 
Europe34,368 41,524 116,653 120,040 
Asia Pacific37,052 48,777 132,548 146,956 
Rest of World19,222 22,282 62,034 59,916 
Total Revenues$380,834 $382,421 $1,167,881 $1,144,534 
44
We generate significant revenues outside the U.S., a portion of which are U.S. dollar-denominated transactions conducted with customers that generate revenue in currencies other than the U.S. dollar. As a result, currency fluctuations between the U.S. dollar and the currencies in which those customers do business could have an impact on the demand for our products in foreign countries. Local economic conditions, regulatory compliance or political considerations, the effectiveness of our sales representatives and distributors, local competition and changes in local medical practice all may combine to affect our sales into markets outside the U.S.
Domestic revenues increased by $20.4 million for the three months ended September 30, 2024 compared to the same period in the prior year. European sales decreased by $7.2 million for the three months ended September 30, 2024 compared to the same period in the prior year. Sales to customers in Asia Pacific decreased by $11.7 million for the three months ended September 30, 2024. Sales to customers in the the Rest of World for the three months ended September 30, 2024 decreased by $3.1 million compared to the same period in the prior year. The increase in domestic revenues for the three months ended September 30, 2024 is primarily the result of the Acclarent acquisition, offset by a decline in sales of Integra Skin, Dural Access & Repair, and CSF Management. The decrease in international revenues for the three months ended September 30, 2024 was also the result of a decline in sales of Integra Skin, Dural Access & Repair, and CSF Management.
Domestic revenues increased by $39.0 million for the nine months ended September 30, 2024 compared to the same period in the prior year. European sales decreased by $3.4 million for the nine months ended September 30, 2024 compared to the same period in the prior year. Sales to customers in Asia Pacific decreased by $14.4 million for the nine months ended September 30, 2024. Sales to customers in the Rest of World for the nine months ended September 30, 2024 increased by $2.1 million compared to the same period in the prior year. The increase in domestic revenues for the nine months ended September 30, 2024 is primarily the result of the Acclarent acquisition, offset by a decline in sales of Integra Skin, Dural Access & Repair, and CSF Management. The decrease in international revenues for the nine months ended September 30, 2024 was also the result of a decline in sales of Integra Skin, Dural Access & Repair, and CSF Management. The international revenues were impacted by $5.2 million of unfavorable foreign exchange impact.
LIQUIDITY AND CAPITAL RESOURCES
Working Capital
Working capital consists of total current assets less total current liabilities as presented in the consolidated balance sheets. The Company’s working capital as of September 30, 2024 and December 31, 2023 was $187.0 million and $751.1 million, respectively. The decrease in working capital as compared to the prior year is primarily driven by $572.4 million of convertible notes, which became current during the year.
Cash and Cash Equivalents
The Company had cash and cash equivalents totaling approximately $215.2 million and $276.4 million at September 30, 2024 and December 31, 2023 respectively, which are valued based on Level 1 measurements in the fair value hierarchy. Level 1 inputs represent quoted prices in active markets for identical assets or liabilities. At September 30, 2024, our non-U.S. subsidiaries held approximately $183.5 million of cash and cash equivalents that are available for use outside the U.S. The Company asserts that it has the ability and intends to indefinitely reinvest the undistributed earnings from its foreign operations unless there is no material tax cost to remit the earnings into the U.S.
Short Term Investments
The Company had short term investments, primarily consisting of time deposits, which are valued based on Level 1 measurements in the fair value hierarchy, totaling approximately $62.4 million at September 30, 2024 compared to $32.7 million at December 31, 2023.

Cash Flows
Nine Months Ended September 30,
Dollars in thousands20242023
Net cash provided by operating activities$78,642 $81,205 
Net cash used in investing activities(386,559)(36,949)
Net cash provided by (used in) financing activities245,013 (223,035)
Effect of exchange rate fluctuations on cash1,659 (4,150)
45
Cash Flows Provided by Operating Activities
Operating cash flows for the nine months ended September 30, 2024 decreased by $2.6 million compared to the same period in 2023. Within operating cash flows, net income less non-cash adjustments decreased for the nine months ended September 30, 2024 by approximately $75.2 million as compared to the same period in 2023 primarily driven by costs related to the Acclarent acquisition, as well as costs associated with quality and operational issues.
The changes in assets and liabilities for the nine months ended September 30, 2024, net of business acquisitions, decreased cash flows by $19.0 million, mainly attributable to increases in prepaid and other current assets, and inventory, offset by decreases in accounts receivable.
The changes in assets and liabilities for the nine months ended September 30, 2023, net of business acquisitions, decreased cash flows by $91.7 million, mainly attributable to increases in inventory, other current assets, and decreases in accrued expenses and other current liabilities due to reduced payments processed during the year.
Cash Flows Used in Investing Activities
Uses of cash from investing activities for the nine months ended September 30, 2024 were $74.8 million paid for capital expenditures to support the investment in the new Braintree facility, as well as improvement initiatives at a number of our manufacturing facilities, and other technology investments, $282.0 million related to the Acclarent acquisition, and $49.0 million related to short term investments.
Sources of cash from investing activities for the nine months ended September 30, 2024 were $19.3 million for short term investments converted to cash.
Uses of cash from investing activities for the nine months ended September 30, 2023 related to $42.3 million paid for capital expenditures to support operations improvement initiatives at a number of our manufacturing facilities and other information technology investments.
Sources of cash from investing activities for the nine months ended September 30, 2023 were $5.4 million in proceeds from settlement of our net investment hedges.
Cash Flows Provided by or Used in Financing Activities
Uses of cash from financing activities in the nine months ended September 30, 2024 related to the repayments of $147.2 million under our Senior Credit Facility and Securitization Facility, $50.0 million related to the repurchase of treasury stock of under the share repurchase agreements, and $11.9 million related to payment of a contingent consideration. In addition, the Company had $3.4 million in cash taxes paid for net equity settlements.
Sources of cash from financing activities for the nine months ended September 30, 2024 were $451.1 million proceeds from borrowings of long-term indebtedness and $6.4 million proceeds from the exercise of stock options.
Uses of cash from financing activities in the nine months ended September 30, 2023 related to the repurchase of treasury stock of $275.0 million under the share repurchase agreements, repayments of $85.9 million under our Senior Credit Facility and Securitization Facility. In addition, there was $7.6 million attributable to debt issuance costs, as well as $5.5 million in cash taxes paid for net equity settlements.
Sources of cash from financing activities for the nine months ended September 30, 2023 were $146.9 million borrowing under our Senior Credit Facility and Securitization Facility and $4.1 million proceeds from the exercise of stock options.
Credit Agreement, Convertible Senior Notes, Securitization and Related Hedging Activities
See Note 6. Debt, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for a discussion of our Credit Agreement, the 2025 Notes and Securitization Facility and Note 7. Derivative Instruments, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for discussion of our hedging activities.
The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2024, the Company was in compliance with all such covenants. Our Consolidated Total Leverage Ratio was 3.99, with the covenant requirement at 4.5 at the end of September 30, 2024. Based on our current forecast for the next twelve months we expect to remain in compliance with the financial and negative covenants.
46
Share Repurchase Plan
See Note 11. Treasury Stock, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further details of our share repurchase programs.
Dividend Policy
We have not paid any cash dividends on our common stock since our formation. Our Senior Credit Facility limits the amount of dividends that we may pay. Any future determinations to pay cash dividends on our common stock will be at the discretion of the Board of Directors and will depend upon our financial condition, results of operations, cash flows and other factors deemed relevant by the Board of Directors.
Capital Resources
We believe that our cash and available borrowings under the Senior Credit Facility are sufficient to finance our operations and capital expenditures for the next 12 months and foreseeable future. Our future capital requirements will depend on many factors, including the growth of our business, the timing and introduction of new products and investments, strategic plans and acquisitions, among others. Additional sources of liquidity available to us include short term borrowings and the issuance of long term debt and equity securities.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet financing arrangements during the nine months ended September 30, 2024 that have or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our interests.
Contractual Obligations and Commitments
We will continue to have cash requirements to support seasonal working capital needs and capital expenditures, to pay interest, to service debt, and to fund acquisitions. As part of our ongoing operations, we enter into contractual arrangements that obligate us to make future cash payments.
Our primary obligations include principal and interest payments on the revolving credit facility and term loan component of the Senior Credit Facility, Securitization Facility and 2025 Notes. See Note 6. Debt, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for details. We also lease some of our manufacturing facilities and office buildings which have future minimum lease payments. See Note 10. Leases and Related Party Leases, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for a schedule of our future minimum lease payments. Amounts related to our other obligations, including employment agreements and purchase obligations were not material.
The Company has contingent consideration obligations related to prior and current year acquisitions and future pension contribution obligations. See Note 9. Retirement Plans, and Note 16. Commitments and Contingencies, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for details. The associated obligations are not fixed. We also have a liability for uncertain tax benefits including interest and penalties. We cannot make a reliable estimate of the period in which the uncertain tax benefits may be realized.
OTHER MATTERS
Critical Accounting Estimates
We based the discussion and analysis of our financial condition and results of operations upon our consolidated financial statements, which have been prepared in conformity with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. The critical accounting estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 did not materially change in the nine months ended September 30, 2024.
Recently Issued Accounting Standards
Information regarding new accounting pronouncements is included in Note 1. Basis of Presentation, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report), and is applicable to the current period’s unaudited condensed consolidated financial statements.
47
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, including changes in foreign currency exchange rates and interest rates that could adversely affect our results of operations and financial condition. To manage the volatility relating to these typical business exposures, we may enter into various derivative transactions when appropriate. We do not hold or issue derivative instruments for trading or other speculative purposes.
Foreign Currency Exchange and Other Rate Risks
We operate on a global basis and are exposed to the risk that changes in foreign currency exchange rates could adversely affect our financial condition, results of operations and cash flows. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros, British pounds, Swiss francs, Canadian dollars, Japanese yen, Mexican pesos, Brazilian reais, Australian dollars, and Chinese yuan. We manage the foreign currency exposure centrally, on a combined basis, which allows us to net exposures and to take advantage of any natural offsets. To mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, we periodically enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. We temporarily record realized and unrealized gains and losses on these contracts that qualify as cash flow hedges in other comprehensive income, and then recognize them in other income or expense when the hedged item affects net earnings.
From time to time, we enter into foreign currency forward exchange contracts to manage currency exposures for transactions denominated in a currency other than an entity’s functional currency. As a result, the impact of foreign currency gains/losses recognized in earnings are partially offset by gains/losses on the related foreign currency forward exchange contracts in the same reporting period. Refer to Note 7. Derivative Instruments, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further information.
We maintain written policies and procedures governing our risk management activities. With respect to derivatives, changes in hedged items are generally expected to be completely offset by changes in the fair value of hedge instruments. Consequently, foreign currency exchange contracts would not subject us to material risk due to exchange rate movements, because gains and losses on these contracts offset gains and losses on the assets, liabilities or transactions being hedged.
The results of operations discussed herein have not been materially affected by inflation.
Interest Rate Risk
Cash and Cash Equivalents - We are exposed to the risk of interest rate fluctuations on the interest income earned on our cash and cash equivalents. A hypothetical 100 basis points movement in interest rates applicable to our cash and cash equivalents outstanding at September 30, 2024 would impact interest income by approximately $2.2 million on an annual basis. We are subject to foreign currency exchange risk with respect to cash balances maintained in foreign currencies.
Debt - Our interest rate risk relates primarily to U.S. dollar SOFR-indexed borrowings. We use interest rate swap derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. These interest rate swaps fix the interest rate on a portion of our expected SOFR-indexed floating-rate borrowings. These interest rate swaps were designated as cash flow hedges as of September 30, 2024. The total notional amounts related to the Company's interest rate swaps were $1.3 billion with $625.0 million effective as of September 30, 2024. Based on our outstanding borrowings at September 30, 2024, a 100 basis points change in interest rates would have impacted interest expense on the unhedged portion of the debt by $6.4 million on an annualized basis. See Note 7. Derivative Instruments, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further information regarding interest rate swaps.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Management has designed our disclosure controls and procedures to provide reasonable assurance of achieving the desired control objectives.
48
As required by Exchange Act Rule 13a-15(b), we have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2024. Based upon this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2024 to provide such reasonable assurance.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
In response to business integration activities, we have and will continue to further align and streamline the design and operation of the financial control environment to be responsive to the changing business model.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Please refer to Note 16. Commitments and Contingencies, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further details on current legal proceedings.
ITEM 1A. RISK FACTORS
There have been no material changes in our risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent periodic reports filed with the SEC pursuant to the Exchange Act.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Recent Sale of Unregistered Securities:
None.
Purchases of Equity Securities:
The following table provides information about purchases by the Company during the quarter ended September 30, 2024 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act. Subject to applicable law, share repurchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1 under the Exchange Act, among other types of transactions and arrangements.
Issuer purchases of equity securities
PeriodTotal number of shares purchasedAverage price paid per share
Total number of shares purchased as part of publicly announced plans or programs(1)
Approximate dollar value of shares that may yet be purchased under the plans or program
07/01/2024 - 07/31/2024(2)
446,075 $24.81 446,075 
50,000,000(3)
08/01/2024 - 08/31/2024— $— — — 
09/01/2024 - 09/30/2024— $— — — 
Total446,075 446,075 
(1) On May 16, 2024, the Company entered into a $50 million accelerated share repurchase (“May 2024 ASR”) and received 1.3 million shares of common stock at the inception of the May 2024 ASR, which represented approximately 70% of the expected total shares under the May 2024 ASR.
(2) On July 30, 2024, the early exercise provision was exercised by the May 2024 ASR counterparty. The Company received an additional 0.4 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the May 2024 ASR.
49
(3) On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program, replacing the existing $225 million program authorized in April 2022, under which $75 million remained authorized at the time of its replacement. The program authorized in July 2023, which expires on December 31, 2025, allows the Company to repurchase its shares opportunistically from time to time. They May 2024 ASR was effected under this authorization. As of September 30, 2024, $50 million remained authorized under the July 2023 share repurchase authorization.The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.
According to the terms of our Senior Credit Facility, our ability to declare or make any dividend payments is limited. See Note 6. Debt, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for a description of working capital restrictions and limitation on the payment of dividends.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the quarter ended September 30, 2024, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
50
ITEM 6. EXHIBITS
Exhibits
3.1(a)
3.1(b)
3.1(c)
3.1(d)
3.1 (e)+
3.2
10.1*+
31.1+ 
31.2+ 
32.1+ 
32.2+ 
101.INS+# XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH+# XBRL Taxonomy Extension Schema Document
101.CAL+# XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+# XBRL Definition Linkbase Document
101.LAB+# XBRL Taxonomy Extension Labels Linkbase Document
101.PRE+# XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
 
*Indicates a management contract or compensatory plan or arrangement.
+Indicates this document is filed as an exhibit herewith.
#
The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed on November 4, 2024 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, is furnished electronically herewith.
51
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date:November 4, 2024/s/ Jan De Witte
 Jan De Witte
 President and Chief Executive Officer
(Principal Executive Officer)
Date:November 4, 2024/s/ Lea Knight
Lea Knight
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
Date:November 4, 2024/s/ Jeffrey A. Mosebrook
 Jeffrey A. Mosebrook
 Senior Vice President, Finance
(Principal Accounting Officer)

52
 EX-3.1(E) 2 iart-20240930xexx31e.htm EX-3.1(E) Document
Exhibit 3.1(e)
CERTIFICATE OF AMENDMENT TO THE AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION OF INTEGRA LIFESCIENCES HOLDINGS CORPORATION


Integra LifeSciences Holdings Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY:
 
FIRST: That the Board of Directors of the Corporation, acting in accordance with Sections 141 and 242 of the General Corporation Law of the State of Delaware adopted a resolution to amend Article SEVENTH of the Company’s Restated Certificate of Incorporation (the “Amendment”) so that, as amended, it shall be read in its entirety as follows:
  
SEVENTH: A director or officer of the Corporation shall have no personal liability to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer except to the extent that Section 102(b)(7) (or any successor provision) of the Delaware General Corporation Law, as amended from time to time, expressly provides that the liability of a director or officer may not be eliminated or limited.

SECOND: That said Amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 
IN WITNESS WHEREOF, the Corporation has caused this certificate to be signed by Stuart M. Essig, Ph.D. its Chairman of the Board of Directors this 9th day of May, 2024.
 
 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
  
  
 By:/s/ Stuart M. Essig, Ph.D.
  
Stuart M. Essig, Ph.D.
Chairman of the Board of Directors
  




 EX-10.1 3 iart-20240930xexx101.htm EX-10.1 Document
Exhibit 10.1
Notice of Grant of Award
and Award Agreement
Integra LifeSciences Holdings Corporation
ID: 51-0317849
1100 Campus Road
Princeton, New Jersey 08540
[ ]
[ ]
[ ]
Award Number: [ ]    
Plan: [ ]
ID: [ ]
Effective [ ], you have been granted [ ] Restricted Stock Units (RSUs) based on a closing price of US$[ ]. These units are restricted until the vest dates shown below, at which time you will receive shares of Integra LifeSciences Holdings Corporation (the Company) common stock.
The award will vest in increments in the dates shown:
Shares    Full Vest Date
[ ]    [ ]
[ ]    [ ]
[ ]    [ ]
By your signature and the Company’s signature below, you and the Company agree that this Award is granted under and governed by the terms and conditions of the Company’s Award Plan as amended and the Award Agreement, all of which are attached and made a part of this document.

Integra LifeSciences Holdings Corporation

Date



Exhibit 10.1
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONTRACT STOCK / RESTRICTED UNITS AGREEMENT
Pursuant to
2003 EQUITY INCENTIVE PLAN

CONTRACT STOCK / RESTRICTED UNITS AGREEMENT, dated as of [ ], by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ] (the “Executive”).
WHEREAS, the Company maintains the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “Plan”), the terms of which are hereby incorporated by reference and made part of this Agreement;
WHEREAS, the Plan provides for the award of Contract Stock on the terms and conditions set forth therein; and
WHEREAS, the Committee has determined that, as an inducement to the Executive to enter into or remain in the service of the Company, it would be to the advantage and in the best interest of the Company and its stockholders to grant to Executive an aggregate of [ ] shares of Contract Stock under the Plan in the form of restricted units (the “Units”), representing the right to receive an equal number of shares of common stock of the Company, par value $.01 per share (“Common Stock”), on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration the legal sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:
1. Definitions. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan, unless otherwise indicated.
2. Grant of Units. Executive is hereby granted, as of [ ] (the “Grant Date”), deferred compensation in the form of [ ] Units pursuant to the terms of this Agreement and the Plan. The Executive’s right to receive the shares of Common Stock underlying the Units shall be subject to forfeiture as provided in Section 4 of this Agreement.
3. Vesting.
    (a)    Subject to paragraph (b) and Section 4 below, the Units shall vest in cumulative installments as follows:
(i)    [ ] of the Units shall vest on the [ ] anniversary of the Grant Date;
(ii)    [ ] of the Units shall vest on the [ ] anniversary of the Grant Date; and
1
Exhibit 10.1
(iii)    [ ] of the Units shall vest on the [ ] anniversary of the Grant Date;
    (b)    One hundred percent (100%) of the then outstanding Units shall vest in the event that:
(i)    Executive incurs a Termination of Service (as defined below) (1) by reason of the Executive’s “Disability” (as defined in the Plan), or (2) by reason of the Executive’s death;
(ii)    a Change in Control occurs, and the Executive incurs a Qualifying Termination on or within twenty-four (24) months following the date of such Change in Control.
    (c)    For purposes of this Agreement, “Qualifying Termination” means a Termination of Service by the Company without Cause or by the Executive for Good Reason.    
    (d)    For purposes of this Agreement, “Termination of Service” shall mean the time when the Executive ceases to provide services to the Company and its Related Corporations and Affiliates as an employee or Associate for any reason with or without Cause, including, but not by way of limitation, a termination by resignation, discharge, death, or disability. A Termination of Service shall not include a termination where the Executive is simultaneously reemployed by, or remains employed by, or continues to provide services to, the Company and/or one or more of its Related Corporations and Affiliates or a successor entity thereto.
4. Forfeiture of Units. Immediately upon (i) if prior to a Change in Control or more than 24 months following a Change in Control, in either case, a Termination of Service for any reason other than the Executive’s death or Disability or (ii) if on or within 24 months following a Change in Control, a Termination of Service for any reason other than the Executive’s death, Disability or Qualifying Termination, the Executive shall forfeit any and all Units which have not vested or do not vest on or prior to such termination, and the Executive’s rights in any such Units which are not so vested shall terminate, lapse and expire (including the Executive’s right to receive the shares underlying such Units).
5. Dividend Equivalents. Executive shall be entitled to receive, with respect to all outstanding vested Units (as such Units may be adjusted under Section 9), dividend equivalent amounts equal to the regular quarterly cash dividend payable to holders of Common Stock (to the extent regular quarterly cash dividends are paid) as if Executive were an actual shareholder with respect to the number of shares of Common Stock equal to his outstanding vested Units. Such dividend equivalent amounts shall be aggregated on a quarterly basis while the Units are outstanding and paid to Executive within thirty (30) days following the first business day that occurs immediately following the 6-month period after the date of Executive’s “separation from service” from the Company (within the meaning of Section 409A(a)(2)(A)(i) of the Internal Revenue Code of 1986, as amended (the “Code”) and its corresponding regulations) (a “Separation from Service”). For the avoidance of doubt, such dividend equivalent amounts shall only be paid with respect to Units that are vested as of the applicable dividend payment date, and
2
Exhibit 10.1
Executive shall not be entitled to receive any dividend equivalent amounts with respect to Units that are not vested as of such dividend payment date. The dividend equivalents and any amounts that may become payable in respect thereof shall be treated separately from the Units and the rights arising in connection therewith for purposes of the designation of time and form of payments required by Code Section 409A.
6. Payment of Units.
    (a)    The shares of Common Stock underlying Units which are then vested under Section 3 shall be paid out to Executive within thirty (30) days following the first business day that occurs immediately following the 6-month period after the date of Executive’s Separation from Service.
(b)    All payments of shares of Common Stock underlying Units (“Unit Shares”) shall be made by the Company in the form of whole shares of Common Stock, and any fractional share shall be distributed in cash in an amount equal to the value of such fractional share determined based on the Fair Market Value (as defined in the Plan) as of the date immediately prior to such distribution.
    (d)    Except as otherwise provided in this Agreement, Executive shall not be deemed to be a holder of any Common Stock pursuant to a Unit until the date of the issuance of a certificate to him for such shares and, except as otherwise provided in this Agreement, Executive shall not have any rights to dividends or any other rights of a shareholder with respect to the shares of Common Stock covered by a Unit until such shares of Common Stock have been issued to him, which issuance shall not be unreasonably delayed.
    (e)    The Company shall be entitled to withhold in cash, shares or deduction from other compensation payable to the Executive any sums required by federal, state or local tax law to be withheld with respect to the grant, vesting, distribution or payment of the Units or the Unit Shares. In satisfaction of the foregoing requirement with respect to the grant, vesting, distribution or payment of the Units or Unit Shares, to the extent permitted by Section 409A of the Code, including Treas. Reg. Section 1.409A-3(j)(4)(vi), the Company shall withhold shares of Common Stock otherwise issuable upon payment of the Units having a Fair Market Value equal to the sums required to be withheld. In the event that the number of shares of Common Stock having a Fair Market Value equal to the sums required to be withheld is not a whole number of shares, the number of shares so withheld shall be rounded up to the nearest whole share.
    (f)    Executive’s right to receive payment of any amounts under this Agreement shall be an unfunded entitlement and shall be an unsecured claim against the general assets of the Company.
    (g)    After payment in accordance with this Section 6, the Unit Shares may not be sold, transferred or otherwise disposed of by Executive for a period of five days after receipt of such shares by Executive, except that no such restrictions shall apply in the case of a Change in Control or in the event that Unit Shares are sold or withheld in order to satisfy any obligations
3
Exhibit 10.1
Executive may have with respect to any applicable tax withholding requirements on vesting or receipt of Unit Shares (including, without limitation, pursuant to Section 6(e) above).
7. Clawback. Notwithstanding anything contained in the Plan or this Agreement to the contrary, the Units and shares of Common Stock represented by the Units shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the Units and shares of Common Stock under the Plan.
8. Representations. The Company represents and warrants that this Agreement has been authorized by all necessary action of the Company, has been approved by the Board and is a valid and binding agreement of the Company enforceable against it in accordance with its terms and that the Unit Shares will be issued pursuant to and in accordance with the Plan, will be listed with NASDAQ or the principal United States securities exchange on which the Common Stock is admitted to trading, and will be validly issued, fully paid and non-assessable shares. The Company further represents and warrants that the grant of Units under this Agreement has been approved by the Company’s Compensation Committee, that the Plan has and will have sufficient shares available to effect the distribution of the Unit Shares.
9. No Right to Employment. Nothing in this Agreement shall confer upon Executive the right to remain in employ of the Company or any subsidiary of the Company.
10. Nontransferability. This Agreement shall not be assignable or transferable by the Company (other than to successors of the Company) and this Agreement and the Units shall not be assignable or transferable by the Executive otherwise than by will or by the laws of descent and distribution, and the Units may be paid out during the lifetime of the Executive only to him. More particularly, but without limiting the generality of the foregoing, the Units may not be assigned, transferred (except as provided in the preceding sentence), pledged, or hypothecated in any way (whether by operation of law or otherwise), and shall not be subject to execution, attachment or similar process. Any attempted assignment, transfer, pledge, hypothecation or other disposition of the Units contrary to the provisions of this Agreement, and any levy of any attachment or similar process upon the Units, shall be null and void and without effect.
11. Entire Agreement. This Agreement contains all the understandings between the parties hereto pertaining to the matters referred to herein, and supersedes all undertakings and agreements, whether oral or in writing, previously entered into by them with respect thereto. The Executive represents that, in executing this Agreement, he does not rely and has not relied upon any representation or statement not set forth herein made by the Company with regard to the subject matter, basis or effect of this Agreement or otherwise.
12. Amendment or Modification; Waiver. No provision of this Agreement may be amended, modified or waived unless such amendment or modification is agreed to in writing, signed by the Executive and by a duly authorized officer of the Company, and such waiver is set
4
Exhibit 10.1
forth in writing and signed by the party to be charged. No waiver by any party hereto of any breach by another party hereto of any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.
13. Notices. Any notice to be given hereunder shall be in writing and shall be deemed given when delivered personally, sent by courier or telecopy or registered or certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below or to such other address as such party may subsequently give notice of hereunder in writing:
To the Executive: at Executive’s most recent address on the records of the Company
To the Company:
Integra LifeSciences Holdings Corporation
1100 Campus Road
Princeton NJ 08540
Attention: Chairman
Facsimile: 609-275-9006
(with a copy to the Company’s General Counsel)
Any notice delivered personally or by courier under this Section 13 shall be deemed given on the date delivered and any notice sent by telecopy or registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date telecopied or mailed.
14. Severability. If any provision of this Agreement or the application of any such provision to any party or circumstances shall be determined by any court of competent jurisdiction to be invalid and unenforceable to any extent, the remainder of this Agreement or the application of such provision to such person or circumstances, other than those to which it is so determined to be invalid and unenforceable, shall not be affected thereby, and each provision hereof shall be validated and shall be enforced to the fullest extent permitted by law.
15. Noncontravention. The Company represents that the Company is not prevented from entering into, or performing, this Agreement by the terms of any law, order, rule or regulation, its certificate of incorporation or by-laws, or any agreement to which it is a party.
16. Survivorship. The respective rights and obligations of the parties hereunder shall survive any termination of this Agreement or Executive’s employment to the extent necessary for the intended preservation of such rights and obligations.
17. Successors. This Agreement shall inure to the benefit of and be binding upon each successor of the Company, and upon the Executive’s beneficiaries, legal representatives or estate, as the case may be.
5
Exhibit 10.1
18. Construction. Except as would be in conflict with any specific provision herein, this Agreement is made under and subject to the provisions of the Plan as in effect on the Grant Date and, except as would conflict with the provisions of this Agreement, all of the provisions of the Plan as in effect on the Grant Date are hereby incorporated herein as provisions of this Agreement. In the event of any such conflict, the terms of this Agreement shall govern.
19. Governing Law. This agreement will be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflicts of laws principles.
20. Headings. All descriptive headings of sections and paragraphs in this Agreement are for convenience of reference only, and they form no part of this Agreement and shall not affect its interpretation.
21. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
22. Section 409A of the Code. This Agreement is intended to comply with the requirements of Section 409A of the Code and shall in all respects be administered and interpreted in accordance with Section 409A. Notwithstanding anything in the Agreement to the contrary, payment may only be made under the Agreement upon an event and in a manner permitted by Section 409A of the Code. If a payment is not made by the designated payment date under the Agreement, the payment shall be made by December 31 of the calendar year in which the designated date occurs. Any payment to be made upon a termination of employment under this Agreement may only be made upon a Separation from Service. To the extent that any provision of the Agreement would cause a conflict with the requirements of Section 409A of the Code or would cause the administration of the Agreement to fail to satisfy the requirements of Section 409A, such provision shall be deemed null and void to the extent permitted by applicable law.

[Signature page follows]
6
Exhibit 10.1
IN WITNESS WHEREOF, the parties hereto have executed this Contract Stock / Restricted Units Agreement as of the date first above written.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

            


By: ___________________________________
Name:     
Title:    [ ]



EXECUTIVE



[ ]

[Signature Page to Contract Stock / Restricted Units Agreement]
 EX-31.1 4 iart-20240930xexx311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Jan De Witte, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:November 4, 2024/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer


 EX-31.2 5 iart-20240930xexx312.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Lea Knight, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:November 4, 2024/s/ Lea Knight
Lea Knight
Executive Vice President and Chief Financial Officer


 EX-32.1 6 iart-20240930xexx321.htm EX-32.1 Document

Exhibit 32.1
Certification of Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Integra LifeSciences Holdings Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities Exchange Commission on the date hereof (the “Report”), I, Jan De Witte, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:November 4, 2024/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer


 EX-32.2 7 iart-20240930xexx322.htm EX-32.2 Document

Exhibit 32.2
Certification of Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Integra LifeSciences Holdings Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities Exchange Commission on the date hereof (the “Report”), I, Lea Knight, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:November 4, 2024/s/ Lea Knight
Lea Knight
Executive Vice President and Chief Financial Officer


 EX-101.SCH 8 iart-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - RETIREMENT PLANS link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - LEASES AND RELATED PARTY LEASES link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - TREASURY STOCK link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - NET INCOME PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - NET INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - BASIS OF PRESENTATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - DEBT - Contractual Maturity Table (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - RETIREMENT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - TREASURY STOCK - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - NET INCOME PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 iart-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 iart-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 iart-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Overnight Federal Funds Fed Funds Effective Rate Overnight Index Swap Rate [Member] Proceeds from warrant transactions Proceeds from Issuance of Warrants Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Acclarent Acquisition Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Durepair Regeneration Matrix Durepair Regeneration Matrix [Member] Durepair Regeneration Matrix Net proceeds from swaps designated as net investment hedges Payments for (Proceeds from) Derivative Instrument, Investing Activities Remaining amount under share repurchase Share Repurchase Program, Remaining Authorized, Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Cover [Abstract] Cover [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Directors Director [Member] Transferor's interests in transferred financial assets, unamortized issuance costs Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs Contract Liability Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Schedule of Operating Lease Maturities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Total derivatives designated as hedges — Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock options exercisable, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period FDA Approval Of Premarket Approval FDA Approval Of Premarket Approval [Member] FDA Approval Of Premarket Approval Number of renewal options (or more) Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Trade accounts receivable, allowance Accounts Receivable, Allowance for Credit Loss, Current Initial conversion rate Debt Instrument, Convertible, Conversion Ratio Position [Axis] Position [Axis] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Foreign currency swaps Currency Swap [Member] Reporting unit, measurement input Reporting Unit, Measurement Input Reporting Unit, Measurement Input BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Tissue Technologies Tissue Technologies [Member] Orthopedics and Tissue Technologies [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Fair Value and Presentation of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Proceeds from exercised stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Net Investment Hedges Net Investment Hedging [Member] Other Performance Measure, Amount Other Performance Measure, Amount Expected annual amortization expense, in 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] LEASES AND RELATED PARTY LEASES Lessee, Operating Leases [Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Lease liability - operating leases Non-current lease liabilities Long-term lease liabilities Operating Lease, Liability, Noncurrent Employees Employee [Member] Employee [Member] Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Cash Flow Hedges Cash Flow Hedging [Member] Securitization program outstanding borrowings, maximum limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Contract liabilities Short-term portion of contract liability Contract with Customer, Liability, Current United States UNITED STATES Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Service cost component Defined Benefit Plan, Service Cost Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Schedule of Long-term Debt Maximum Leverage Ratios Schedule of Long-Term Debt Instruments [Table Text Block] Operating Segments Operating Segments [Member] Income tax benefit from prior year income taxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock Treasury Stock, Common [Member] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Changes in Accumulated Other Comprehensive Loss by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Secured Debt Secured Debt [Member] Instruments Instruments [Member] Instruments [Member] Prepaid Expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Other Current Assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Net periodic benefit costs Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Rest of World Rest Of World [Member] Revenues from rest of the world. Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Codman tradename Trade Names [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Total costs and expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Interest payments, year one Interest Payments, Year One Interest Payments, Year One Compensation Amount Outstanding Recovery Compensation Amount Diluted net (loss) income per share: Earnings Per Share, Diluted [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Smaller Reporting Company Entity Small Business Period for extended lease Lessee, Operating Lease, Option to Extend Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Payment of debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accelerated shares repurchased Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other liabilities Other Liabilities [Member] Chief Executive Officer Chief Executive Officer [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Issuance of common stock through employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued expenses and other current liabilities Accrued Liabilities, Current Shares excluded from computation as their effect would be antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Notional amount terminated Derivative, Notional Amount, Terminated Derivative, Notional Amount, Terminated Operating lease expense Operating Lease, Expense Asset Acquisition [Axis] Asset Acquisition [Axis] Cross Currency Interest Rate Swap Two Cross Currency Interest Rate Contract Two [Member] Cross Currency Interest Rate Contract Two [Member] Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Weighted average interest rate on debt Debt, Weighted Average Interest Rate Interest Rate Swap Designated October 10, 2018 Tranche 2 Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Third Parties Third Parties [Member] Third Parties [Member] Total unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Arkis Arkis BioSciences Inc. [Member] Arkis BioSciences Inc. [Member] Current assets: Assets, Current [Abstract] Goodwill Goodwill at beginning of period Goodwill at end of period Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Derma Sciences Derma Sciences [Member] Derma Sciences [Member] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Cash taxes paid in net equity settlement Payment, Tax Withholding, Share-Based Payment Arrangement Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount INVENTORIES Inventory Disclosure [Text Block] Treasury stock (in shares) Balance, beginning of period, treasury stock (in shares) Balance, beginning of period, treasury stock (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Accrued compensation Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Employee-related Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Employee-related Liabilities Revenue Based Performance Milestones Revenue Based Performance Milestones [Member] Revenue Based Performance Milestones Stock Options Share-Based Payment Arrangement, Option [Member] Foreign currency forward contract Foreign Exchange Forward [Member] Interest payments, year two Interest Payments, Year Two Interest Payments, Year Two Goodwill [Roll Forward] Goodwill [Roll Forward] Estimated Fair Value Fair Value Asset (Liability) Derivative, Fair Value, Net 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Comprehensive income (See Note 14) Comprehensive (loss) income, net Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, outstanding shares (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Interest rates available Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Indefinite-lived intangible assets, measurement input Indefinite-Lived Intangible Assets, Measurement Input Intangible Assets, Indefinite-Lived, Measurement Input Basic net (loss) income per share: Earnings Per Share, Basic [Abstract] Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Current assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract] Write off of debt issuance costs Deferred Debt Issuance Cost, Writeoff Lease Contractual Term [Domain] Lease Contractual Term [Domain] Work in process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, Plant and Equipment, Net Interest Rate Swap Designated December 13, 2017 Tranche 3 Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Total liabilities Liabilities Convertible Debt Convertible Debt [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Estimated Useful Life Estimated useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Transferred to trade receivable from contract asset included in beginning of the year contract asset Contract with Customer, Asset, Reclassified to Receivable Current portion of lease liability - operating leases Current lease liabilities Less: Current lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued shares (in shares) Common Stock, Shares, Issued Other assets Other Assets [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Payments for asset acquisitions Payments For Asset Acquisitions Payments For Asset Acquisitions Secured long-term debt, securitization program Secured Long-Term Debt, Securitization Program Secured Long-Term Debt, Securitization Program Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Long-term borrowings under senior credit facility Secured Long-Term Debt, Noncurrent Gain (loss) recorded in AOCI, change in fair value Amount of Gain (Loss) Recognized in AOCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Europe Europe [Member] Common stock, authorized shares (in shares) Common Stock, Shares Authorized Interest rate adjustment Debt Instrument, Basis Spread Adjustment On Variable Rate Debt Instrument, Basis Spread Adjustment On Variable Rate Product warranty period (up to) Revenue, Product Warranty Period Revenue, Product Warranty Period Cash (paid) for business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Interest payments, year four Interest Payments, Year Four Interest Payments, Year Four Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted average common shares for diluted earnings per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Interest Rate Swap Designated March 31, 2023 Interest Rate Swap Designated March 31, 2023 [Member] Interest Rate Swap Designated March 31, 2023 Directors and Certain Executive Officers Directors and Certain Executive Officers [Member] Directors and Certain Executive Officers [Member] Other income, net Other Nonoperating Income (Expense) [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Expected annual amortization expense, remainder of 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Derivative Instruments, Gain (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders’ equity Balance, beginning of period Balance, end of period Equity, Attributable to Parent Prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Acclarent Inc. Acclarent Inc. [Member] Acclarent Inc. Related Party Related Party [Member] Option to extend lease, years Lessee, Operating Lease, Renewal Term Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Interest expense Interest Expense, Nonoperating Deferred income tax (benefit) provision Deferred Income Tax Expense (Benefit) Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Payments for Contingent Consideration Payment for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Letters of credit outstanding Letters of Credit Outstanding, Amount Selling, general and administrative Selling, General and Administrative Expense Other comprehensive income (loss), net of tax Net current-period other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Trade accounts receivable, net of allowances of $7,423 and $4,879 Accounts Receivable, after Allowance for Credit Loss, Current Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Cost of Sales Cost of Sales [Member] Asset impairment charges Asset Impairment Charges Plainsboro, New Jersey Manufacturing Facility Plainsboro, New Jersey Manufacturing Facility [Member] Plainsboro, New Jersey Manufacturing Facility Total long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Estimated fair value of plan assets Defined Benefit Plan, Plan Assets, Amount All Executive Categories All Executive Categories [Member] Stock options and restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Expected annual amortization expense, in 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Number of days from shipment to issue a credit Return Policy, Issue Of Credit, Number Of Days From Shipment Return Policy, Issue of Credit, Number of Days from Shipment Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ACQUISITIONS AND DIVESTITURES Mergers, Acquisitions and Dispositions Disclosures [Text Block] ASSETS Assets [Abstract] Document Type Document Type Derivative Contract [Domain] Derivative, Name [Domain] Derivative Contract [Domain] Line of credit, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Gain (loss) reclassified into other income Gain (Loss) on Derivative Instruments, Net, Pretax Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Net Sales and Profit by Segments Schedule of Geographic Revenue by Area Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Treasury stock, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Raw materials Inventory, Raw Materials and Purchased Parts, Net of Reserves Development Milestones Milestone Payment One [Member] Milestone Payment One [Member] Deferred compensation plan, fair value of assets Deferred Compensation Plan Assets Schedule of Changes in Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Number of contingent liabilities remaining Business Combination, Contingent Consideration, Number Of Liabilities Business Combination, Contingent Consideration, Number Of Liabilities Maximum Maximum [Member] Intangible asset amortization Amortization Amortization of Intangible Assets Contract liability, beginning of period Contract liability, end of period Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Long-term borrowings under securitization facility Secured Long-Term Debt, Securitization Program, Noncurrent Secured Long-Term Debt, Securitization Program, Noncurrent Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Short-term investments Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Proceeds from borrowings of long-term indebtedness Proceeds from Issuance of Secured Debt Impairment of goodwill Goodwill, Impairment Loss Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Deferred tax assets, net Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Weighted Average Life Finite-Lived Intangible Asset, Useful Life Interest payments, year three Interest Payments, Year Three Interest Payments, Year Three Defer payment and taxation, base salary, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Loss on settlement of derivative Gain (Loss) On Settlement Of Derivative Gain (Loss) On Settlement Of Derivative Other comprehensive gain (loss) OCI, before Reclassifications, Net of Tax, Attributable to Parent Neurosurgery Neurosurgery [Member] Neurosurgery [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] RETIREMENT PLANS Retirement Benefits [Text Block] Class of Stock [Line Items] Class of Stock [Line Items] Redemption price, percentage Debt Instrument, Redemption Price, Percentage Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Customer relationships Customer Relationships Customer Relationships [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Current liabilities: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract] Forecast Forecast [Member] Diluted (in dollars per share) Diluted net (loss) income per common share (in dollars per share) Earnings Per Share, Diluted Title of Individual [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Contract liabilities Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Accelerated share repurchases, additional shares received (in shares) Accelerated Share Repurchases, Additional Shares Received Accelerated Share Repurchases, Additional Shares Received Supplier relationships Supplier Relation Ships [Member] Supplier Relation Ships [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Lease liability - operating leases Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases Share-based compensation Share-Based Payment Arrangement, Noncash Expense Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Defined Benefit Pension Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Payments on debt Repayments of Secured Debt Inventories, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net (Benefit) provision for income taxes Income Tax Expense (Benefit) Convertible notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Wound Reconstruction and Care Regenerative Skin And Wound [Member] Regenerative Skin And Wound [Member] Notional Amount Current notional amount Aggregate Notional Amount Derivative, Notional Amount Corporate and other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Weighted-average period for cost recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total revenue, net Total Revenues Revenue from Contract with Customer, Excluding Assessed Tax Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations Derivative Instruments, Gain (Loss) [Table Text Block] Cross Currency Interest Rate Swap One Cross Currency Interest Rate Contract One [Member] Cross Currency Interest Rate Contract One [Member] Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Reported tax rate Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating (loss) income Operating income Operating Income (Loss) Variable Rate [Domain] Variable Rate [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Number of reportable segments Number of Reportable Segments Total liabilities and stockholders’ equity Liabilities and Equity Related Parties Related Parties [Member] Related Parties [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Hedging Designation [Axis] Hedging Designation [Axis] Operating lease, impairment loss Operating Lease, Impairment Loss DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Contractual Repayments of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type [Axis] Measurement Input Type [Axis] Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Contract Asset Change In Contract With Customer, Asset [Roll Forward] Change In Contract With Customer, Asset [Roll Forward] Accumulated Other Comprehensive Loss Total AOCI Attributable to Parent [Member] Performance obligations expected to be satisfied, expected timing Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Gains and Losses on Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories, net Inventories, net Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity State Entity Address, State or Province Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Commercial Sales Milestones Milestone Payment Two [Member] Milestone Payment Two [Member] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Accounts payable, trade Accounts Payable, Trade, Current Contract asset, net of transferred to trade receivables on contracts during the period Contract With Customer, Asset, Net Of Reclassified To Receivable Contract With Customer, Asset, Net Of Reclassified To Receivable Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Purchase price of business combination Purchase price of business acquisition Business Combination, Consideration Transferred LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Annual rate of lease agreement Annual Rate Of Lease Agreement Annual rate of lease agreement. Balance, Beginning of Period Balance, End of Period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Asia Pacific Asia Pacific [Member] Fixed Interest Rate Fixed Rate Derivative, Fixed Interest Rate Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Long-term portion of contract liability Contract with Customer, Liability, Noncurrent Right of use asset - operating leases ROU assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Final working capital adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative, by Nature [Axis] Derivative Instrument [Axis] Other Income Other Income [Member] Exercise Price Award Exercise Price Lease Contractual Term [Axis] Lease Contractual Term [Axis] NET INCOME PER SHARE Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Schedule of Comprehensive Income (Loss) Comprehensive Income (Loss) [Table Text Block] Issuance of common stock through employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Subsequent Event Subsequent Event [Member] Costs and expenses: Costs and Expenses [Abstract] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Product Warranties Extended Product Warranty, Policy [Policy Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Other than options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Debt instrument, securitization facility, agreement term (in years) Debt Instrument, Securitization Facility, Agreement Term Debt Instrument, Securitization Facility, Agreement Term Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Interest Rate Swap Designated December 13, 2017 Tranche 2 Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 2 Swingline Loans Swingline Loan [Member] Swingline Loan [Member] Segments [Domain] Segments [Domain] Segment Profit Segment Reporting Information, Profit (Loss) [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Share repurchase program, excise tax Share Repurchase Program, Excise Tax Contingent consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Expected annual amortization expense, in 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Depreciation and amortization Other Depreciation and Amortization Trademarks and Trade Names Trademarks and Trade Names [Member] Leased facilities Building [Member] Reporting Unit [Axis] Reporting Unit [Axis] PEO PEO [Member] 2025 Notes Two Thousand Twenty Five Senior Convertible Notes [Member] Two Thousand Twenty Five Senior Convertible Notes [Member] Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Cross Currency Interest Rate Swap Three Cross Currency Interest Rate Contract Three [Member] Cross Currency Interest Rate Contract Three [Member] Fair value Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Other income, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Accelerated share repurchases, shares received at inception (in shares) Accelerated Share Repurchases, Shares Received at Inception Accelerated Share Repurchases, Shares Received at Inception Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Interest Rate Swap Designated October 10, 2018 Tranche 1 Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Treasury stock, at cost; 14,454 shares and 12,751 shares at September 30, 2024 and December 31, 2023, respectively Treasury stock Treasury Stock, Common, Value Remainder of 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Call Option Call Option [Member] Notional amount settled Derivative, Notional Amount, Settled Derivative, Notional Amount, Settled Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Cost, amortization Cost, Amortization Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Fair value in excess of carrying amount, percent Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Segment Net Sales Segment Reporting Information, Operating Income (Loss) [Abstract] Recognition of revenue included in beginning of year contract liability Contract With Customer, Liability, Net Of Revenue Recognized Contract With Customer, Liability, Net Of Revenue Recognized Local Phone Number Local Phone Number Accelerated share repurchase program, receipt (payment) Accelerated Share Repurchases, Settlement (Payment) or Receipt Cross Currency Interest Rate Swap Four Cross Currency Interest Rate Contract Four [Member] Cross Currency Interest Rate Contract Four Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Liability Class [Axis] Liability Class [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Performance Stock and Restricted Stock Awards Performance Stock And Restricted Stock Awards [Member] Performance Stock And Restricted Stock Awards [Member] Deferred tax liabilities Deferred Income Tax Liabilities, Net Interest expense Interest Expense [Member] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Accelerated shares repurchased (shares) Stock Repurchased During Period, Shares Requisite service periods of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Other non-current assets Increase (Decrease) in Other Operating Assets Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Interest income Interest Income [Member] Intangible assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Total derivatives designated as hedges — Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Codman Specialty Surgical Codman Specialty Surgical Codman Specialty Surgical [Member] Codman Specialty Surgical [Member] 2023 Share Repurchase Program 2023 Share Repurchase Program [Member] 2023 Share Repurchase Program Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Non-cash lease expense Noncash Lease Expense Noncash Lease Expense Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cost Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill. Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Non-cash impairment charges Impairment of Intangible Assets, Finite-Lived COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Expected annual amortization expense, thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Debt Disclosure [Abstract] Debt Disclosure [Abstract] ROU assets obtained in exchange for lease liabilities, net of modifications: Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Impairment, long-lived asset, held-for-use Impairment, Long-Lived Asset, Held-for-Use Common Stock Common Stock [Member] Measure: Measure [Axis] Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Preferred stock, authorized shares (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Accelerated share repurchases, percentage of expected total repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Grants in period, net of forfeitures (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Five Year Option Lease From November 1, 2034 Through October 31, 2039 Five Year Option Lease Period Two [Member] Five-Year Option Lease Period Two Accelerated stock based compensation expenses Share-Based Payment Arrangement, Accelerated Cost Segment Reporting [Abstract] Segment Reporting [Abstract] Weighted average interest rate, accounts receivable securitization revolving loan facility Debt, Weighted Average Interest Rate, From Securitization Debt, Weighted Average Interest Rate, From Securitization Entity Central Index Key Entity Central Index Key Short Short [Member] Completed Technology, Surgimend Completed Technology, SurgiMend [Member] Completed Technology, SurgiMend Scenario [Axis] Scenario [Axis] Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Items Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Minimum settled in cash per principal amount Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share SEGMENT AND GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Number of products offered (more than) Segment Reporting Information, Number Of Products Offered Number of products sold by a segment ACell ACell [Member] ACell Change in fair value of contingent consideration liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Change in fair value of contingent consideration and others Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Restricted Stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Standby Letters of Credit Standby Letters of Credit [Member] Completed Technology, PriMatrix Completed Technology, PriMatrix [Member] Completed Technology, PriMatrix Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Operating Activities [Domain] Consolidation Items [Domain] Position [Domain] Position [Domain] Reporting unit, fair value increase (decrease), percent Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Fair Value Increase (Decrease), Percent Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Fair Value Increase (Decrease), Percent City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Maximum average conversion value of notes Debt Instrument, Maximum Average Conversion Value Of Notes Debt Instrument, Maximum Average Conversion Value Of Notes Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Contingent consideration, estimated fair value Business Combination, Contingent Consideration, Liability Trademarks/brand names Trademarks Brand Names [Member] Trademarks Brand Names. Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Current portion of borrowings under senior credit facility Term loan component of senior credit facility Secured Debt, Current Completed technology Completed Technology [Member] Completed technology. BioD Earnout Payments and Medihoney Earnout Payments BioD Earnout Payments and Medihoney Earnout Payments [Member] BioD Earnout Payments and Medihoney Earnout Payments [Member] Purchases of treasury stock Payments for Repurchase of Common Stock 2027 Long-Term Debt, Maturity, Year Three Revenue of acquiree since acquisition date Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Gain expected to be reclassified to earnings in the next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Other Intangible Assets Other Intangible Assets [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Expected performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage INCOME TAXES Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net (loss) income per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Total current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Retained earnings Retained Earnings (Accumulated Deficit) Long Long [Member] Contract liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract With Customer, Liability, Current Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract With Customer, Liability, Current Codman Codman [Member] Codman [Member] ACell, Inc. ACell, Inc. [Member] ACell, Inc. Inventories Increase (Decrease) in Inventories Interest payments, remainder of fiscal year Interest Payments, Reminder Of Fiscal Year Interest Payments, Reminder Of Fiscal Year Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Incremental financing costs capitalized Debt Issuance Costs, Gross Other Long-term Liabilities Other Noncurrent Liabilities [Member] 2026 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease liabilities Total lease liabilities Operating Lease, Liability Transferor's interests in transferred financial assets, issuance costs Transferor's Interests In Transferred Financial Assets, Issuance Costs Transferor's Interests In Transferred Financial Assets, Issuance Costs Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Performance Stock Performance Shares [Member] Credit Facility [Axis] Credit Facility [Axis] Measurement Input, Long-Term Revenue Growth Rate Measurement Input, Long-Term Revenue Growth Rate [Member] Amendment Flag Amendment Flag Interest Rate Swap Designated October 10, 2018 Tranche 3 Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Entity Registrant Name Entity Registrant Name Trade accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Cost of call transactions Payments For Option Index To Issuers Equity Payments For Options Indexed to Issuer's Equity Convertible securities Convertible Debt, Current Fair Value as of Grant Date Award Grant Date Fair Value Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Leased vehicles Vehicles [Member] Debt issuance costs capitalized Debt Issuance Costs, Net Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] DEBT Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Convertible notes, maximum borrowing capacity Debt Instrument, Face Amount Supplemental Cash Flow Information Cash Flow, Lessee [Table Text Block] Cash Flow, Lessee [Table Text Block] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Payment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Securitization facility, outstanding borrowings, fair value Securitization Facility, Fair Value Of Amount Outstanding Securitization Facility, Fair Value Of Amount Outstanding Entity Postal Zip Code Entity Address, Postal Zip Code Number of contingent liabilities Business Acquisition, Number Of Contingent Liabilities Business Acquisition, Number Of Contingent Liabilities Interest Rate Swap Interest rate swap Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock; $0.01 par value; 240,000 authorized shares; 91,588 and 90,920 issued at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Contract liability, acquired with Acclarent Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Impairment of indefinite-lived intangible assets Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] 2028 Long-Term Debt, Maturity, after Year Three Long-Term Debt, Maturity, after Year Three Other Current Liabilities Other Current Liabilities [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Long-term convertible securities Convertible Debt, Noncurrent Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock; no par value; 15,000 authorized shares; none outstanding Preferred Stock, Value, Issued Reporting Unit [Domain] Reporting Unit [Domain] Line of credit facility, fair value of amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Basic (in dollars per share) Basic net (loss) income per common share (in dollars per share) Earnings Per Share, Basic Income tax benefit from excess tax benefits from share-based payment arrangement Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Operating cash flows from operating leases Operating Lease, Payments Accrued expenses and other current liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period September 30, 2026 and the last day of each fiscal quarter thereafter Debt Covenant Period 4 [Member] Debt Covenant Period 4 Total current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Amortization Amortization Schedule of Goodwill [Table] Goodwill [Table] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Foreign currency translation Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Net Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill. Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Maximum Consolidated Total Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average common shares outstanding (See Note 13): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Assets Plan modification, compensation expense Share-Based Payment Arrangement, Plan Modification, Incremental Cost Maximum selling price of the company's common stock of the conversion price Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Expected annual amortization expense, in 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of goods sold Cost of Goods and Services Sold Contingent consideration, maximum undiscounted payment amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Line of credit facility outstanding Long-Term Line of Credit Awards granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other liabilities Other Liabilities, Noncurrent TREASURY STOCK Treasury Stock [Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Schedule of Effective Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Plan modification, expiration period (in months) Share-Based Payment Arrangement, Plan Modification, Expiration Period Share-Based Payment Arrangement, Plan Modification, Expiration Period Termination Date Trading Arrangement Termination Date Intercompany loan quarterly payments Intercompany Loan, Quarterly Payment Intercompany Loan, Quarterly Payment Warrant strike price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Long-Term Debt, Maturity, Year One STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Upfront payment Asset Acquisition, Consideration Transferred Entity City Entity Address, City or Town Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] March 31, 2023 through September 30, 2024 Debt Covenant Period 1 [Member] Debt Covenant Period 1 Debt Instrument [Axis] Debt Instrument [Axis] Proceeds from maturities of short term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Net (loss) income Net (Loss) Income Net (loss) income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Five Year Option Lease From November 1, 2029 Through October 31, 2034 Five Year Option Lease Period One [Member] Five-Year Option Lease Period One ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Interest Rate Swap Designated December 15, 2020 Tranche 2 Interest Rate Swap Designated December 15, 2020 Tranche 2 [Member] Interest Rate Swap Designated December 15, 2020 Tranche 2 Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Mergers, Acquisitions and Dispositions [Abstract] Mergers, Acquisitions and Dispositions Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax REVENUES FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address Entity Address, Address Line One Surgical Innovation Associates, Inc. Surgical Innovation Associates Inc [Member] Surgical Innovation Associates Inc Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Expected annual amortization expense, in 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Interest Rate Swap Designated December 18, 2018 Tranche 1 Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Reporting unit, measurement input increase (decrease) Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Measurement Input Increase (Decrease) Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Measurement Input Increase (Decrease) Finished goods Inventory, Finished Goods, Net of Reserves Short-term investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] December 31, 2025 through June 30, 2026 Debt Covenant Period 3 [Member] Debt Covenant Period 3 [Member] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Cross-currency swap Cross Currency Interest Rate Contract [Member] Private Label Private Label [Member] Private Label [Member] All other All Other [Member] All Other [Member] Insider Trading Arrangements [Line Items] Contract asset, beginning of period Contract asset, end of Period Contract with Customer, Asset, after Allowance for Credit Loss Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued expenses and other current liabilities. ENT ENT [Member] ENT Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Intangible asset acquired, discount rate (percent) Business Combination, Intangible Asset Acquired, Discount Rate Business Combination, Intangible Asset Acquired, Discount Rate 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Interest Rate Swap Designated December 15, 2020 Tranche 1 Interest Rate Swap Designated December 15, 2020 Tranche 1 [Member] Interest Rate Swap Designated December 15, 2020 Tranche 1 Accounts payable, trade Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Contract liability, net of revenue recognized on contracts during the period Contract with Customer, Liability, Revenue Recognized Interest Rate Swap Designated December 18, 2018 Tranche 2 Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Amount of Gain (Loss) Reclassified from AOCI into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Right of use asset - operating leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases Initial strike price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Pension liability adjustment, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Current portion of lease liability - operating leases Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability, Operating Leases Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability, Operating Leases Taxes Collected from Customers Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Related Party [Axis] Related and Nonrelated Parties [Axis] Basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] December 31, 2024 through September 30, 2025 Debt Covenant Period 2 [Member] Debt Covenant Period 2 Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Property, plant and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Purchases of short term investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Amortization of debt issuance costs and expenses associated with debt refinancing Amortization Of Debt Issuance Costs And Debt Refinanced Fees Amortization Of Debt Issuance Costs And Debt Refinanced Fees Entity Filer Category Entity Filer Category Less: Amounts reclassified from accumulated other comprehensive income, net Gain (loss) reclassified from AOCI Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Balance, beginning of period, (in shares) Balance, end of period (in shares) Shares, Issued Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Senior Credit Facility Senior Credit Facility [Member] Senior Credit Facility. Loss Contingencies [Line Items] Loss Contingencies [Line Items] Change in unrealized loss/(gain) on derivatives, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name EX-101.PRE 12 iart-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
 9 Months Ended
Sep. 30, 2024
Nov. 01, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 000-26224  
Entity Registrant Name INTEGRA LIFESCIENCES HOLDINGS CORP  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 51-0317849  
Entity Address 1100 Campus Road  
Entity City Princeton  
Entity State NJ  
Entity Postal Zip Code 08540  
City Area Code 609  
Local Phone Number 275-0500  
Title of 12(b) Security Common Stock, Par Value $.01 Per Share  
Trading Symbol IART  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   77,163,524
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0000917520  
Current Fiscal Year End Date --12-31  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Total revenue, net $ 380,834 $ 382,421 $ 1,167,881 $ 1,144,534
Costs and expenses:        
Cost of goods sold 180,596 164,076 534,892 486,292
Research and development 27,435 26,596 84,167 79,908
Selling, general and administrative 177,193 161,948 538,463 493,513
Intangible asset amortization 3,760 3,208 17,575 9,342
Total costs and expenses 388,984 355,828 1,175,097 1,069,055
Operating (loss) income (8,150) 26,593 (7,216) 75,479
Interest income 5,049 4,607 15,147 12,653
Interest expense (19,373) (13,062) (51,648) (37,626)
Other income, net 2,112 471 2,939 1,705
(Loss) income before income taxes (20,362) 18,609 (40,778) 52,211
(Benefit) provision for income taxes (9,667) (888) (14,399) 4,304
Net (loss) income $ (10,695) $ 19,497 $ (26,379) $ 47,907
Net (loss) income per share        
Basic (in dollars per share) $ (0.14) $ 0.24 $ (0.34) $ 0.59
Diluted (in dollars per share) $ (0.14) $ 0.24 $ (0.34) $ 0.59
Weighted average common shares outstanding (See Note 13):        
Basic (in shares) 76,448 79,690 77,196 80,842
Diluted (in shares) 76,448 79,811 77,196 81,112
Comprehensive income (See Note 14) $ (16,823) $ 16,412 $ (36,126) $ 39,387
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 215,157 $ 276,402
Short-term investments 62,441 32,694
Trade accounts receivable, net of allowances of $7,423 and $4,879 248,298 259,327
Inventories, net 436,930 389,608
Prepaid Expenses 86,326 67,362
Other Current Assets 50,370 32,643
Total current assets 1,099,522 1,058,036
Property, plant and equipment, net 390,906 340,199
Right of use asset - operating leases 146,342 156,184
Intangible assets, net 1,209,548 1,067,833
Goodwill 1,116,535 1,055,462
Deferred tax assets, net 48,936 46,080
Other assets 54,014 58,194
Total assets 4,065,803 3,781,988
Current liabilities:    
Current portion of borrowings under senior credit facility 29,063 14,531
Current portion of lease liability - operating leases 15,039 15,284
Convertible securities 572,442 0
Accounts payable, trade 77,666 92,326
Contract liabilities 9,990 8,540
Accrued compensation 76,424 75,455
Accrued expenses and other current liabilities 131,939 100,844
Total current liabilities 912,563 306,980
Long-term borrowings under senior credit facility 1,132,292 825,563
Long-term borrowings under securitization facility 72,800 89,200
Long-term convertible securities 0 570,255
Lease liability - operating leases 167,808 166,849
Deferred tax liabilities 68,945 35,317
Other liabilities 189,808 199,940
Total liabilities 2,544,216 2,194,104
Stockholders’ equity:    
Preferred stock; no par value; 15,000 authorized shares; none outstanding 0 0
Common stock; $0.01 par value; 240,000 authorized shares; 91,588 and 90,920 issued at September 30, 2024 and December 31, 2023, respectively 916 909
Additional paid-in capital 1,316,854 1,302,484
Treasury stock, at cost; 14,454 shares and 12,751 shares at September 30, 2024 and December 31, 2023, respectively (691,810) (647,262)
Accumulated other comprehensive loss (24,854) (15,106)
Retained earnings 920,481 946,859
Total stockholders’ equity 1,521,587 1,587,884
Total liabilities and stockholders’ equity $ 4,065,803 $ 3,781,988
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Trade accounts receivable, allowance $ 7,423 $ 4,879
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, authorized shares (in shares) 15,000,000 15,000,000
Preferred stock, outstanding shares (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 240,000,000 240,000,000
Common stock, issued shares (in shares) 91,588,000 90,920,000
Treasury stock (in shares) 14,454,000 12,751,000
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
OPERATING ACTIVITIES:    
Net (Loss) Income $ (26,379) $ 47,907
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 103,304 92,527
Non-cash impairment charges 12,173 0
Deferred income tax (benefit) provision (13,743) 2,963
Share-based compensation 17,225 14,350
Amortization of debt issuance costs and expenses associated with debt refinancing 4,193 4,731
Non-cash lease expense (129) 2,120
Loss (gain) on disposal of property and equipment 1,337 (4)
Change in fair value of contingent consideration and others (319) 8,278
Changes in assets and liabilities:    
Accounts receivable 38,861 5,050
Inventories (27,579) (43,350)
Prepaid expenses and other current assets (34,401) (21,700)
Other non-current assets (1,745) (8,774)
Accounts payable, accrued expenses and other current liabilities 2,686 (22,141)
Contract liabilities 1,822 141
Other non-current liabilities 1,336 (893)
Net cash provided by operating activities 78,642 81,205
INVESTING ACTIVITIES:    
Purchases of property and equipment (74,818) (42,330)
Cash (paid) for business acquisitions, net of cash acquired (281,994) 0
Purchases of short term investments (48,997) 0
Proceeds from maturities of short term investments 19,250 0
Net proceeds from swaps designated as net investment hedges 0 5,381
Net cash used in investing activities (386,559) (36,949)
FINANCING ACTIVITIES:    
Proceeds from borrowings of long-term indebtedness 451,100 146,900
Payments on debt (147,188) (85,900)
Payment of debt issuance costs 0 (7,578)
Purchases of treasury stock (50,000) (275,000)
Payments for Contingent Consideration (11,923) 0
Proceeds from exercised stock options 6,398 4,092
Cash taxes paid in net equity settlement (3,374) (5,549)
Net cash provided by (used in) financing activities 245,013 (223,035)
Effect of exchange rate changes on cash and cash equivalents 1,659 (4,150)
Net decrease in cash and cash equivalents (61,245) (182,929)
Cash and cash equivalents at beginning of period 276,402 456,661
Cash and cash equivalents at end of period $ 215,157 $ 273,732
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Balance, beginning of period, (in shares) at Dec. 31, 2022   90,476,000        
Balance, beginning of period at Dec. 31, 2022 $ 1,804,403 $ 905 $ (362,862) $ 1,276,977 $ 10,265 $ 879,118
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2022     (6,823,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income 24,226         24,226
Other comprehensive income (loss), net of tax (3,198)       (3,198)  
Issuance of common stock through employee stock purchase plan (in shares)   21,000        
Issuance of common stock through employee stock purchase plan 1,107     1,107    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)   316,000 16,000      
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (4,011) $ 1 $ 846 (4,858)    
Share-based compensation 3,611 $ 2   3,609    
Accelerated shares repurchased (shares)     (2,111,000)      
Accelerated shares repurchased (151,200)   $ (119,662) (31,538)    
Balance, end of period (in shares) at Mar. 31, 2023   90,813,000        
Balance, end of period at Mar. 31, 2023 1,674,938 $ 908 $ (481,678) 1,245,297 7,067 903,344
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2023     (8,918,000)      
Balance, beginning of period, (in shares) at Dec. 31, 2022   90,476,000        
Balance, beginning of period at Dec. 31, 2022 1,804,403 $ 905 $ (362,862) 1,276,977 10,265 879,118
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2022     (6,823,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income 47,907          
Balance, end of period (in shares) at Sep. 30, 2023   90,935,000        
Balance, end of period at Sep. 30, 2023 1,579,221 $ 909 $ (612,777) 1,262,319 1,745 927,025
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2023     (11,823,000)      
Balance, beginning of period, (in shares) at Mar. 31, 2023   90,813,000        
Balance, beginning of period at Mar. 31, 2023 1,674,938 $ 908 $ (481,678) 1,245,297 7,067 903,344
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2023     (8,918,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income 4,184         4,184
Other comprehensive income (loss), net of tax (2,237)       (2,237)  
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)   68,000        
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 1,007 $ 1 $ 21 985    
Share-based compensation 5,268     5,268    
Accelerated shares repurchased (shares)     (609,000)      
Accelerated shares repurchased 0   $ (32,125) 32,125    
Balance, end of period (in shares) at Jun. 30, 2023   90,881,000        
Balance, end of period at Jun. 30, 2023 1,683,160 $ 909 $ (513,782) 1,283,675 4,830 907,528
Balance, beginning of period, treasury stock (in shares) at Jun. 30, 2023     (9,527,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income 19,497         19,497
Other comprehensive income (loss), net of tax (3,085)       (3,085)  
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)   54,000        
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 441   $ 17 424    
Share-based compensation 5,457     5,457    
Accelerated shares repurchased (shares)     (2,296,000)      
Accelerated shares repurchased (126,249)   $ (99,012) (27,237)    
Balance, end of period (in shares) at Sep. 30, 2023   90,935,000        
Balance, end of period at Sep. 30, 2023 1,579,221 $ 909 $ (612,777) 1,262,319 1,745 927,025
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2023     (11,823,000)      
Balance, beginning of period, (in shares) at Dec. 31, 2023   90,920,000        
Balance, beginning of period at Dec. 31, 2023 $ 1,587,884 $ 909 $ (647,262) 1,302,484 (15,106) 946,859
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2023 (12,751,000)   (12,751,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income $ (3,281)         (3,281)
Other comprehensive income (loss), net of tax 4,460       4,460  
Issuance of common stock through employee stock purchase plan (in shares)   23,000        
Issuance of common stock through employee stock purchase plan 965     965    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)   541,000 16,000      
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 2,312 $ 2 $ 840 1,470    
Share-based compensation 5,612 $ 4   5,608    
Accelerated shares repurchased 0          
Balance, end of period (in shares) at Mar. 31, 2024   91,484,000        
Balance, end of period at Mar. 31, 2024 1,597,952 $ 915 $ (646,422) 1,310,527 (10,646) 943,578
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2024     (12,735,000)      
Balance, beginning of period, (in shares) at Dec. 31, 2023   90,920,000        
Balance, beginning of period at Dec. 31, 2023 $ 1,587,884 $ 909 $ (647,262) 1,302,484 (15,106) 946,859
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2023 (12,751,000)   (12,751,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income $ (26,379)          
Other comprehensive income (loss), net of tax (9,748)          
Balance, end of period (in shares) at Sep. 30, 2024   91,588,000        
Balance, end of period at Sep. 30, 2024 $ 1,521,587 $ 916 $ (691,810) 1,316,854 (24,854) 920,481
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2024 (14,454,000)   (14,454,000)      
Balance, beginning of period, (in shares) at Mar. 31, 2024   91,484,000        
Balance, beginning of period at Mar. 31, 2024 $ 1,597,952 $ 915 $ (646,422) 1,310,527 (10,646) 943,578
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2024     (12,735,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income (12,402)         (12,402)
Other comprehensive income (loss), net of tax (8,080)       (8,080)  
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)   107,000        
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (80) $ 1 $ 20 (101)    
Share-based compensation 7,305     7,305    
Accelerated shares repurchased (shares)     (1,273,000)      
Accelerated shares repurchased (50,500)   $ (34,351) (16,149)    
Balance, end of period (in shares) at Jun. 30, 2024   91,591,000        
Balance, end of period at Jun. 30, 2024 1,534,195 $ 916 $ (680,753) 1,301,582 (18,726) 931,176
Balance, beginning of period, treasury stock (in shares) at Jun. 30, 2024     (14,008,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income (10,695)         (10,695)
Other comprehensive income (loss), net of tax (6,128)       (6,128)  
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)   (3,000)        
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (171) $ 0 $ 10 (181)    
Share-based compensation 4,386     4,386    
Accelerated shares repurchased (shares)     (446,000)      
Accelerated shares repurchased 0   $ (11,067) 11,067    
Balance, end of period (in shares) at Sep. 30, 2024   91,588,000        
Balance, end of period at Sep. 30, 2024 $ 1,521,587 $ 916 $ (691,810) $ 1,316,854 $ (24,854) $ 920,481
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2024 (14,454,000)   (14,454,000)      
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the September 30, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2024 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and, in January 2021, subsequently amended the initial guidance in: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to a SOFR-indexed rate. (See Note 6. Debt). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR. The Company has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.
Cash and cash equivalents
The Company had cash and cash equivalents, primarily consisting of cash on-hand as well as time deposits with original maturities of three months or less and money market funds which are highly liquid and readily convertible to cash, totaling approximately $215.2 million and $276.4 million at September 30, 2024 and December 31, 2023 respectively. Time deposits with original maturities of three months or less and money market funds are valued based on Level 1 measurements in the fair value hierarchy established within FASB Topic 820, Fair Value Measurement (“ASC 820”). Level 1 inputs represent quoted prices in active markets for identical assets or liabilities.
Short-term investments
The Company had short term investments, primarily consisting of time deposits with original maturities between three months and one year, which are valued based on Level 1 measurements in the fair value hierarchy, totaling approximately $62.4 million at September 30, 2024 compared to $32.7 million at December 31, 2023.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.3
ACQUISITIONS AND DIVESTITURES
 9 Months Ended
Sep. 30, 2024
Mergers, Acquisitions and Dispositions [Abstract]  
ACQUISITIONS AND DIVESTITURES ACQUISITIONS AND DIVESTITURES
Acquisition of Acclarent, Inc.
On April 1, 2024, the Company completed the acquisition of all of the outstanding capital stock of Acclarent, Inc. (“Acclarent”), a developer and marketer of medical devices used in ear, nose, throat (“ENT”) procedures, from Ethicon, Inc., a subsidiary of Johnson & Johnson, for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. In September 2024, the Company finalized the working capital adjustment in the amount of $4.2 million, which resulted in a reduction to goodwill. This adjustment will be settled during the three months ending December 31, 2024. The addition of Acclarent’s ENT product portfolio, including sinus balloon dilation, eustachian tube balloon dilation, and surgical navigation systems technologies, and dedicated salesforce will enhance the Company’s position in the ENT specialty device market.
Acclarent’s results of operations have been reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition. The Company recorded revenue from Acclarent of approximately $62.3 million, in the consolidated statements of operations and comprehensive income for the nine months ended September 30, 2024. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company’s operations.
Assets Acquired and Liabilities Assumed at Fair Value
The Acclarent acquisition has been accounted for using the acquisition method of accounting in accordance with FASB Topic ASC 805, Business Combinations (“ASC 805”). This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date. The Company estimated fair values at the date of acquisition for the preliminary allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed. The Company has not completed its analysis regarding the assets acquired and liabilities assumed. Therefore, the allocation to intangible assets, goodwill, and income taxes are preliminary and subject to finalization. During the measurement period ending no later than one year after the acquisition date, the Company will continue to obtain information to assist in finalizing the fair values of the net assets acquired, which may differ materially from these preliminary estimates. If any measurement period adjustment is material, the Company will record such adjustment, including any related impact on net income, in the reporting period in which the adjustment is determined.
The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date:
Dollars in thousandsEstimated Fair ValueEstimated Useful Life
Current assets:
Cash$— 
Trade accounts receivable, net 23,716 
Inventories, net20,294 
Prepaid expenses273 
Other current assets476 
Total current assets$44,759 
Property, plant and equipment, net7,716 
Right of use asset - operating leases989 
Intangible assets, net
Completed technology202,000 12 years
Trademarks/brand names3,000 5 years
All other17,000 4 years
Goodwill61,396 
Deferred tax assets6,863 
Total assets acquired$343,723 
Current liabilities:
Accounts payable, trade3,989 
Contract liabilities3,984 
Accrued compensation1,037 
Accrued expenses and other current liabilities2,278 
Current portion of lease liability - operating leases365 
Total current liabilities$11,653 
Lease liability - operating leases624 
Deferred tax liabilities53,635 
Total liabilities assumed65,912 
Net assets acquired$277,811 
The carrying value of trade accounts receivable, prepaid expenses, other current assets, accounts payable, contract liabilities, accrued compensation, accrued expenses and other current liabilities, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.
Intangible Assets
The estimated fair value of the intangible assets acquired was determined using the multi-period, excess earnings method of the income approach, which estimates value based on the present value of future economic benefits attributable to the intangible assets. The significant assumptions used in developing the valuation included the estimated annual net cash flows including application of forecasted revenue, the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. Preliminary assumptions may change and may result in significant changes to the final valuation. The intangible assets acquired have a weighted average useful life of 11 years.
The Company used a discount rate of 12.2% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.
Goodwill
Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill has been allocated to the Codman Specialty Surgical segment, as shown in Note 5. Goodwill and Other Intangible Assets. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.
Deferred Tax Liabilities
Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.
Acquisition of Durepair®
On October 2, 2024, the Company completed the acquisition of the product rights for Durepair® Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $45.0 million. The Company made a cash payment of $10.0 million upon the closing of the acquisition and will make additional cash payments of $15.0 million upon the first anniversary of the acquisition and $20.0 million upon the second anniversary of the acquisition.
The Company will account for the acquisition of the product rights for Durepair, which consist of certain patents and trademarks, regulatory approvals, and other records, as an asset acquisition in accordance with ASC 805 because the acquisition does not include an assembled workforce and substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset and, thus, the assets are not considered a business.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES FROM CONTRACTS WITH CUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Estimates
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset$(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period$7,828 
Contract asset, September 30, 2024
$7,828 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability$(6,616)
Contract liability, acquired with Acclarent$3,984 
Contract liability, net of revenue recognized on contracts during the period$4,447 
Foreign currency translation$21 
Contract liability, September 30, 2024
$18,088 
At September 30, 2024, the short-term portion of the contract liability of $10.0 million and the long-term portion of $8.1 million are included in current liabilities and other liabilities, respectively, in the consolidated balance sheets.
As of September 30, 2024, the Company is expected to recognize revenue of approximately 55% of unsatisfied (or partially unsatisfied) performance obligations as revenue within 12 months, with the remaining balance to be recognized thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Neurosurgery$175,956 $209,229 $583,726 $607,902 
Instruments54,238 49,920 153,148 152,523 
ENT(1)
40,588 9,056 92,103 26,946 
Total Codman Specialty Surgical270,782 268,205 828,977 787,371 
Wound Reconstruction and Care80,460 88,071 249,032 280,129 
Private Label29,592 26,145 89,872 77,034 
Total Tissue Technologies110,052 114,216 338,904 357,163 
Total revenue$380,834 $382,421 $1,167,881 $1,144,534 
(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.
See Note 15. Segment and Geographic Information, for details of revenues based on the location of the customer.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.3
INVENTORIES
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories, net consisted of the following:
Dollars in thousandsSeptember 30, 2024December 31, 2023
Finished goods$219,347 $196,402 
Work in process85,493 74,035 
Raw materials132,090 119,171 
Total inventories, net$436,930 $389,608 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2024 were as follows:
Dollars in thousandsCodman Specialty
Surgical		Tissue TechnologiesTotal
Goodwill at December 31, 2023$666,937 $388,525 $1,055,462 
Acclarent Acquisition 61,396 — 61,396 
Foreign currency translation(210)(113)(323)
Goodwill at September 30, 2024
$728,123 $388,412 $1,116,535 
The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with FASB ASC Topic 350, Intangibles—Goodwill and Other (“ASC 350”). Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.
The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test uses a combination of both an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and EBITDA
multiples. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins, and a discount rate for each reporting unit. Discount rates are determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and slight changes in these assumptions could have a significant impact on the concluded value. The estimates and assumptions applied represent a Level 3 measurement in the fair value hierarchy. Level 3 inputs are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
For goodwill, during the third quarter of 2024, the Company elected to bypass the qualitative evaluations of its Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units and perform quantitative tests. The quantitative test for the Tissue Technologies reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was not less than its carrying amount, with 21.2% headroom. The quantitative test for the Neurosurgery reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.0% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was not less than its carrying amount, with 11.7% headroom. The quantitative test for the Instruments and ENT reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 11.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Instruments and ENT reporting unit was not less than its carrying amount, with 22.1% headroom. Based on the results of these quantitative tests, the Company recorded no impairment of goodwill for Tissue Technologies, Neurosurgery, or Instruments and ENT reporting units.
The Company performed a hypothetical sensitivity analysis of the fair value for each reporting unit by increasing the discount rate by 50 basis points, decreasing the terminal growth rate by 50 basis points, and holding all other assumptions constant, which resulted in a decrease to the estimated fair value of the Tissue Technology reporting unit by 4.5%, a decrease to the estimated fair value of the Neurosurgery reporting unit by 3.8%, and a decrease to the estimated fair value of the Instruments and ENT reporting unit by 3.5%. Based on the results of the hypothetical sensitivity analyses, the Company would still not have recorded an impairment of goodwill for Tissue Technologies, Neurosurgery, or Instruments and ENT reporting units.
For intangible assets with indefinite lives, the Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test during the third quarter 2024. In performing this test, the Company utilized a discount rate of 13.0%. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.
Other Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 September 30, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology17 years$1,427,186 $(509,825)$917,361 
Customer relationships12 years168,396 (138,022)30,374 
Trademarks/brand names27 years101,896 (41,833)60,063 
Codman tradenameIndefinite174,118 — 174,118 
Supplier relationships30 years30,211 (18,882)11,329 
All other6 years23,154 (6,851)16,303 
$1,924,961 $(715,413)$1,209,548 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
Total amortization of intangible assets for the three and nine months ended September 30, 2024 was $25.6 million and $78.7 million, respectively. Of these amounts, $21.8 million and $61.1 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.
Total amortization of intangible assets for the three and nine months ended September 30, 2023 was $20.9 million and $62.1 million, respectively. Of these amounts, $17.7 million and $52.8 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold, with the remainder included in intangible amortization in the statement of operations.
Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $25.6 million for the remainder of 2024, $102.4 million in 2025, $102.2 million in 2026, $101.2 million in 2027, $97.6 million in 2028, $92.4 million in 2029 and $511.8 million thereafter.
The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
In the first quarter of 2024, due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform quantitative impairment testing on certain definite-lived intangible assets including completed technology and customer relationships in accordance with FASB ASC Topic 360, Property, Plant and Equipment. The Company recorded an impairment charge related to the definite-lived intangible asset associated with the customer relationships of $7.1 million in intangible asset amortization in the consolidated statement of operations. With respect to the definite-lived intangible assets associated with the completed technology of SurgiMend® and PriMatrix®, the Company determined that the carrying amount of these definite-lived intangible assets were recoverable and, therefore, the intangible assets were not deemed to be impaired. In the second quarter of 2024, the Company approved a plan to transition the commercial distribution of SurgiMend® and PriMatrix® from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts (the “Braintree facility”). The Company considered the impact to the update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility on the assumptions used in the quantitative assessment of the definite-lived intangible assets completed in the first quarter of 2024, which did not require further evaluation for impairment. The carrying values of SurgiMend® and PriMatrix® are $34.6 million and $25.5 million, respectively, as of September 30, 2024.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
Amendment to the Seventh Amended and Restated Senior Credit Agreement
On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of the Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The March 2023 Amendment extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775.0 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans. The terms of the Senior Credit Facility limit the amount of dividends we may pay.
The Company’s maximum Consolidated Total Leverage Ratio (as defined in the March 2023 Amendment) in the financial covenants is outlined below. Concurrent with the Durepair acquisition (see Note 2. Acquisitions and Divestitures), in accordance with the terms of the March 2023 Amendment, the Company elected to increase the maximum Consolidated Total Leverage Ratio to 5.00 from the fiscal quarter ending December 31, 2024 through the fiscal quarter ending September 30, 2025.
Fiscal Quarter EndingMaximum Consolidated Total Leverage Ratio
March 31, 2023 through September 30, 2024
4.50 to 1.00
December 31, 2024 through September 30, 2025
5.00 to 1.00
December 31, 2025 through June 30, 2026
4.25 to 1.00
September 30, 2026 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%), or
ii.The highest of:
1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%;
2.the prime lending rate of Bank of America, N.A.; or
3.the one-month Term SOFR plus 1.00%.
The applicable rates are based on the Company’s Consolidated Total Leverage Ratio (defined, as of any date of determination, as the ratio of (a) Consolidated Funded Indebtedness as of such date (as defined in the Credit Agreement) less cash that is not subject to any restriction on the use or investment thereof to (b) Consolidated EBITDA (as defined by the Seventh Amended and Restated Credit Agreement (the “Credit Agreement”)), for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility component of the Senior Credit Facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2024, the Company was in compliance with all such covenants. The Company capitalized $7.6 million in deferred financing costs in connection with the modification of the Senior Credit Facility and wrote off $0.2 million of previously capitalized financing costs during the first quarter of 2023.
At September 30, 2024 and December 31, 2023 there was $400.0 million and $70.0 million, respectively, outstanding under the revolving credit facility component of the Senior Credit Facility. At September 30, 2024 and December 31, 2023, there was $765.3 million and $775.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.4% and 6.8%, respectively. As of September 30, 2024 and December 31, 2023 there was $29.1 million and $14.5 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.
The fair value of the term loan and revolving portion of the Senior Credit Facility at September 30, 2024 was $756.3 million, and $395.3 million, respectively. The fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
Letters of credit outstanding as of September 30, 2024 and December 31, 2023 totaled $1.7 million. There were no amounts drawn under the letters of credit outstanding as of September 30, 2024.
Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:
As of September 30, 2024
Principal Repayment
Dollars in thousands
Remainder of 2024
$4,844 
2025
33,906 
2026
38,750 
2027
53,281 
2028634,531 
$765,312 
Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $12.3 million for the remainder of 2024, $48.1 million in 2025, $45.6 million in 2026, $42.6 million in 2027, and $9.4 million in 2028. Interest is calculated on the term loan portion of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Credit Agreement. As the revolving credit facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.
Any outstanding borrowings on the revolving credit facility component of the Senior Credit Facility are due on March 24, 2028.
Convertible Senior Notes
On February 7, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”) pursuant to an indenture, dated as of February 7, 2020 (the “Original Indenture”), between the Company and Citibank, N.A., as trustee. The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. In connection with this offering, the Company capitalized $13.2 million of financing fees.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on an initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company’s common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period specified in the Original Indenture; (3) if the Company calls the notes for optional redemption as described in the Original Indenture; or (4) if specified corporate transactions occur. As of September 30, 2024, none of these conditions existed and the 2025 Notes are classified as current convertible securities on the consolidated balance sheet, as they are due within one year.
On December 9, 2020, the Company entered into the first supplemental indenture to the Original Indenture (the “First Supplemental Indenture” and, together with Original Indenture, the “Indenture”), pursuant to which the Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement (as defined in the First Supplemental Indenture) for a conversion of the 2025 Notes, the Specified Dollar Amount (as defined in the First Supplemental Indenture) that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.
Holders of the 2025 Notes will have the right to require the Company to repurchase for cash all or a portion of their 2025 Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the Indenture). The Company will also be required to increase the conversion rate for holders who convert their 2025 Notes in connection with certain Fundamental Changes (as defined in the Original Indenture) occurring prior to the maturity date or following delivery by the Company of a notice of redemption.
In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
At September 30, 2024, the carrying amount of the liability of the 2025 Notes was $575.0 million. The fair value of the 2025 Notes at September 30, 2024 was $547.7 million. Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quotes. The 2025 Notes are valued based on Level 1 measurements in the fair value hierarchy. Level 1 inputs represent quoted prices in active markets for identical assets or liabilities.
Securitization Facility
In 2018, the Company entered into an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2024, the Company was in compliance with the covenants and none of the termination events had occurred.
On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December 2023 Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, three years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.
At September 30, 2024 and December 31, 2023, the Company had $72.8 million and $89.2 million, respectively, of outstanding borrowings under its Securitization Facility at an interest rate of 5.9% and 6.4%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2024 was $71.2 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS
 9 Months Ended
Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR.
The Company held the following interest rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month Term SOFR Loan— 150,000 December 13, 2017July 1, 2019June 28, 20242.423 %— 2,105 
1-month Term SOFR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %1,246 4,978 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %525 1,349 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %515 1,312 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %501 1,346 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %1,425 3,015 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %1,616 3,052 
1-month Term SOFR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %22,809 22,965 
1-month Term SOFR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,159 5,263 
Basis Swap (1)
—— March 31, 2023March 24, 2023December 31, 2027N/A(1,949)0(1,829)
$1,325,000 $1,475,000 $31,847 $43,556 
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time
The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three and nine months ended September 30, 2024, the Company recorded a loss of $17.1 million and a gain of $2.7 million, respectively, in AOCI related to the change in fair value of the interest rate swaps. For the three and nine months ended September 30, 2023 the Company recorded a gain of $15.3 million and $23.5 million, respectively, in AOCI related to the change in fair value of the interest rate swaps.
For the three and nine months ended September 30, 2024, the Company recorded gains of $4.1 million and $14.4 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. For the three and nine months ended September 30, 2023 the Company recorded gains of $5.0 million and $12.9 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2024 within the next twelve months is $7.1 million.
The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.
Foreign Currency Hedging
From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.
On September 22, 2023, the Company amended the CHF denominated intercompany loan to partially settle CHF 20.0 million and extend the termination date to September 2024 and as a result, the Company terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $48.5 million. Simultaneously, the Company entered into a cross-currency swap agreement to hedge a notional amount of CHF 28.5 million equivalent to $31.5 million of this amended intercompany loan into U.S. dollars. On September 23, 2024, the Company settled this cross-currency swap designated as a cash flow hedge of an intercompany loan. Based on the closing exchange rates, the loss upon settlement was approximately $2.3 million which was offset by the gain on the settlement of the intercompany loan.
On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.
The Company held the following cross-currency rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay CHFDecember 21, 2020December 22, 20253.00%CHF333,887 351,137 (30,892)(38,324)
Receive U.S.$3.98%$374,817 394,183 
Pay CHFSeptember 22, 2023September 23, 20242.40%CHF— 28,500 — (2,348)
Receive U.S.$6.27%$— 31,457 
Total$(30,892)$(40,672)
The cross-currency swaps designated as cash flow hedges are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2024, the Company recorded a loss of $16.6 million and a gain of $13.5 million, respectively, in AOCI related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded gains of $13.8 million and $3.1 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2024 the Company recorded a loss of $23.2 million and a gain of $5.4 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans. For the three and nine months ended September 30, 2023, the Company recorded a gain of $15.3 million and $3.3 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.
For the three and nine months ended September 30, 2024, the Company recorded a gain of $1.1 million and $3.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded a gain of $1.5 million and $4.4 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of September 30, 2024 within the next twelve months is $0.7 million. As of September 30, 2024, the Company does not expect any gains or losses will be reclassified into earnings because the original forecasted transactions will not occur.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business.
On May 2, 2024, the Company entered into a cross-currency swap agreement with a notional amount of CHF 68.5 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.
On October 1, 2018, May 24, 2022, and November 21, 2023, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2024 and December 31, 2023, respectively (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 2,106 2,475 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,211 288,210 (48,153)(48,047)
Receive U.S.$1.94%$300,000 300,000 
Pay CHFNovember 17, 2023December 17, 2029—%CHF66,525 66,525 (5,248)(4,037)
Receive U.S.$2.54%$75,000 75,000 
Pay CHFMay 6, 2024December 18, 2030—%CHF68,483 — (6,071)— 
Receive U.S.$2.74%$75,000 — 
Total(57,366)(49,609)
The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2024, the Company recorded a loss of $21.1 million and $0.4 million, respectively, in AOCI related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded a gain of $6.1 million and a loss of $4.1 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2024, the Company recorded a gain of $2.7 million and $7.4 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded gains of $1.8 million and $6.0 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2024 within the next twelve months is $9.6 million.
Foreign Currency Forward Contracts
The Company has entered into a hedge for forecasted intercompany purchases denominated in foreign currencies through the use of forward contracts designated as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in accumulated comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs.
In the first and third quarter of 2024, the Company entered into foreign currency forwards to mitigate the exchange rate risk of CHF denominated intercompany purchases. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2024 the notional amount of foreign currency forward contracts was 10.4 million CHF.
For the three and nine months ended September 30, 2024 the Company recorded a gain of $0.5 million and a loss of $0.2 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts and a loss of $0.1 million and $0.3 million, respectively, in cost of goods sold included in the consolidated statements of operations.
For the three and nine months ended September 30, 2023 the Company recorded a gain of $0.1 million and $0.3 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts and a gain of $0.1 million and $0.4 million, respectively, in cost of goods sold included in the consolidated statements of operations.
On October 16, 2024, the Company entered into forward currency forwards with a notional amount of 5.2 million CHF to mitigate the exchange rate risk of Swiss franc denominated intercompany purchases. These contracts settle at various dates within twelve months of execution.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:
Fair Value as of
Location on Balance Sheet (1):
September 30, 2024December 31, 2023
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap
$7,335 $14,675 
Cross-currency swap708 537 
Foreign currency forward contracts292 — 
Net Investment Hedges
Cross-currency swap5,764 2,938 
Other assets
Cash Flow Hedges
Interest rate swap26,461 30,710 
Net Investment Hedges
Cross-currency swap— 1,470 
Total derivatives designated as hedges — Assets$40,560 $50,330 
Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap$265 $579 
Cross-currency swap— 4,813 
Foreign currency forward contracts— — 
Net Investment Hedges
Cross-currency swap2,120 2,903 
Other liabilities
Cash Flow Hedges
Interest rate swap1,684 1,250 
Cross-currency swap31,600 36,396 
Net Investment Hedges
Cross-currency swap61,010 51,114 
Total derivatives designated as hedges — Liabilities$96,679 $97,055 
(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2024 and 2023:
Dollars in thousandsBalance in AOCI
Beginning of
Quarter		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Three Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap$53,116 $(17,133)$4,135 $31,848 Interest expense
Cross-currency swap(16,867)(16,625)(22,089)(11,403)Other income, net
Foreign Currency Forward Contract(430)474 (119)163 Cost of Sales
Net Investment Hedges
Cross-currency swap(29,466)(21,051)2,739 (53,256)Interest income
$6,353 $(54,335)$(15,334)$(32,648)
Three Months Ended September 30, 2023
Cash Flow Hedges
Interest rate swap$56,901 $15,317 $4,964 $67,254 Interest expense
Cross-currency swap(18,925)13,796 15,347 (20,476)Other income, net
Foreign Currency Forward Contract$(123)$98 $87 $(112)
Net Investment Hedges
Cross-currency swap(21,239)6,051 1,772 (16,960)Interest income
$16,614 $35,262 $22,170 $29,706 
Dollars in thousandsBalance in AOCI
Beginning of
Year		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Nine Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap$43,556 $2,678 $14,386 $31,848 Interest expense
Cross-currency swap(15,763)13,505 9,145 (11,403)Other income (expense), net
Foreign currency forward contract— (159)(322)163 Cost of sales
Net Investment Hedges
Cross-currency swap(45,498)(364)7,394 (53,256)Interest income
$(17,705)$15,660 $30,603 $(32,648)
Nine Months Ended September 30, 2023
Cash Flow Hedges
Interest rate swap$56,712 $23,477 $12,935 $67,254 Interest expense
Cross-currency swap(20,271)3,114 3,319 (20,476)Other income (expense), net
Foreign currency forward contract— $333 $445 (112)
Net Investment Hedges
Cross-currency swap(6,914)(4,066)5,980 (16,960)Interest income
$29,527 $22,858 $22,679 $29,706 
Derivative Instruments not Designated Hedges:
During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $4.6 million as of September 30, 2024.
The fair value of the foreign currency swaps not designated as hedges was $1.1 million and $1.2 million as of September 30, 2024 and December 31, 2023, respectively. The following table summarizes the gains on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsThree Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Foreign currency swaps10 135 385 778 
Total$10 $135 $385 $778 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.3
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
As of September 30, 2024, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).
Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.
Stock Options
As of September 30, 2024, there were approximately $3.5 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 243,964 stock options granted during the nine months ended September 30, 2024. For the nine months ended September 30, 2024, the weighted average grant date fair value for stock options granted was $15.68 per option.
Awards of Restricted Stock and Performance Stock
Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2024, there was approximately $35.4 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 737,623 restricted stock awards and 263,350 performance stock awards during the nine months ended September 30, 2024. For the nine months ended September 30, 2024, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $34.45 and $36.22 per award, respectively.
The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.
CEO Separation
On February 27, 2024, the Company announced that Mr. De Witte would retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process and entered into a letter agreement with Mr. De Witte to modify his current employment agreement and put forth the form of a post-employment consulting agreement. The Company applied modification accounting to the outstanding equity-based awards granted to Mr. De Witte as of that date, which revalued and accelerated stock-based compensation associated with equity-based awards granted to him over his expected service period to the Company. Pursuant to this letter agreement, Mr. De Witte’s unvested equity-based awards will continue to vest during his continued service period to the Company and vested stock options were modified such that they will remain exercisable until the lesser of (a) the stated term of the stock options and (b) six months following his cessation of continued service to the Company. As a result of the modifications, the Company recorded incremental stock-based compensation expense of $1.4 million during the nine months ended September 30, 2024. The Company will record a total of $1.9 million in accelerated stock-based compensation expenses for the twelve months ended December 31, 2024 that would not have been recognized if Mr. De Witte had not announced his retirement from Integra.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.3
RETIREMENT PLANS
 9 Months Ended
Sep. 30, 2024
Retirement Benefits [Abstract]  
RETIREMENT PLANS RETIREMENT PLANS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany, India and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2024 were $0.4 million and $1.3 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.8 million and $2.4 million for the three and nine months ended September 30, 2024, respectively, are included in other income, net in the consolidated statements of operations.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2023 were $0.3 million and $0.9 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.5 million and $1.6 million for the three and nine months ended September 30, 2023, respectively, are included in other income, net in the consolidated statements of operations.
The estimated fair values of plan assets were $43.4 million and $45.7 million as of September 30, 2024 and December 31, 2023, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2024 and December 31, 2023. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.
Deferred Compensation Plan
The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $6.5 million and $6.1 million as of September 30, 2024 and December 31, 2023, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES AND RELATED PARTY LEASES
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
LEASES AND RELATED PARTY LEASES LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2024. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the nine months ended September 30, 2024 and September 30, 2023 was $18.8 million and $17.9 million, respectively, which includes $0.2 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases were as follows:
Dollars in thousands, except lease term and discount rateSeptember 30, 2024
December 31, 2023
ROU assets$146,342 $156,184 
Current lease liabilities15,039 15,284 
Non-current lease liabilities167,808 166,849 
Total lease liabilities$182,847 $182,133 
Weighted average remaining lease term (in years):
Leased facilities16.2 years16.3 years
Leased vehicles2.2 years1.9 years
Weighted average discount rate:
Leased facilities5.6 %5.9 %
Leased vehicles2.6 %2.7 %
Supplemental cash flow information related to leases for the nine months ended September 30, 2024 and 2023 were as follows:
Dollars in thousandsSeptember 30, 2024
September 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$18,255 $14,778 
ROU assets obtained in exchange for lease liabilities, net of modifications:
Operating leases$1,575 $19,540 
Future minimum lease payments under operating leases at September 30, 2024 were as follows:
Dollars in thousandsRelated PartiesThird PartiesTotal
Remainder of 2024
$74 $6,057 $6,131 
2025296 23,016 23,312 
2026296 21,317 21,613 
2027296 19,425 19,721 
2028296 17,163 17,459 
2029246 16,306 16,552 
Thereafter— 165,343 165,343 
Total minimum lease payments$1,504 $268,627 $270,131 
Less: Imputed interest87,284 
Total lease liabilities182,847 
Less: Current lease liabilities15,039 
Long-term lease liabilities167,808 
There were no future minimum lease payments under finance leases at September 30, 2024.
Related Party Leases
The Company leases one of its manufacturing facilities in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
Lease Impairment Charge
The Company approved a plan to transition the commercial distribution of PriMatrix® and SurgiMend® from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts and permanently cease use of the Boston facility. As a result, in the second quarter of 2024, the Company recorded a $4.6 million impairment charge, as the carrying amounts of the operating lease right-of-use asset and fixed assets related to the Boston facility exceeded their fair values based on the Company’s estimates of future discounted cash flows through the end of the lease term and the end of their remaining useful lives, respectively. The $4.6 million impairment charge was comprised of a $1.7 million impairment of an operating lease right-of-use asset and a $2.9 million write-off of fixed assets, which was recorded as a component of cost of goods sold in the condensed consolidated statements of operations.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.3
TREASURY STOCK
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
TREASURY STOCK TREASURY STOCK
As of September 30, 2024 and December 31, 2023, there were 14.5 million and 12.8 million shares of treasury stock outstanding with a cost of $691.8 million and $647.3 million, at a weighted average cost per share of $47.86 and $50.76, respectively.
On May 16, 2024, the Company entered into a $50 million accelerated share repurchase (“May 2024 ASR”) and received 1.3 million shares of common stock at inception of the May 2024 ASR, which represented approximately 70% of the expected total shares under the May 2024 ASR. On July 31, 2024, the early exercise provision was exercised by the May 2024 ASR counterparty. The Company received an additional 0.4 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the May 2024 ASR.
On August 15, 2023, the Company entered into a $125 million accelerated share repurchase (“August 2023 ASR”) and received 2.3 million shares of common stock at inception of the August 2023 ASR, which represented approximately 80% of the expected total shares under the August 2023 ASR. On October 18, 2023 the early exercise provision was exercised by the August 2023 ASR counterparty. The Company received an additional 0.9 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the August 2023 ASR.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase (“January 2023 ASR”) and received 2.1 million shares of common stock at inception of the January 2023 ASR, which represented approximately 80% of the expected total shares under the January 2023 ASR. The settlement of the January 2023 ASR agreement was completed in the second quarter of 2023, where the Company received 0.6 million shares, determined using the volume-weighted average price of the Company’s common stock during the term of the January 2023 ASR.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “Inflation Act”) was signed into law. The Inflation Act implements a new excise tax of 1% on the net share repurchases made by the Company effective for share repurchases performed January 1, 2023, or after. In October 2024, the Company made an excise tax payment of $2.5 million related to the January 2023 ASR and the August 2023 ASR.
On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program. As of September 30, 2024, $50 million remained authorized. The program, which was authorized in July 2023 and expires on December 31, 2025, allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The following table provides a summary of the Company’s effective tax rate:
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Reported tax rate47.5 %(4.8)%35.3 %8.2 %
The Company’s effective income tax rates for the three months ended September 30, 2024 and 2023 were 47.5% and (4.8)%, respectively. For the three months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income realized during the third quarter. For the three months ended September 30, 2023,the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.3 million benefit related to the filing of prior year tax returns.
The Company’s effective income tax rates for the nine months ended September 30, 2024 and 2023 were 35.3% and 8.2%, respectively. For the nine months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income and a $1.9 million shortfall from stock-based compensation, as compared to the prior year. For the nine months ended September 30, 2023, the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.8 million benefit related to the filing of prior year tax returns.
Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Act was signed into law. The Company did not experience a material impact on the Company’s effective tax rate under the Inflation Act. Further, legislation in foreign jurisdictions may be enacted, in continued response to the base erosion and profit-sharing (“BEPS”) project begun by the Organization for Economic Cooperation and Development (“OECD”).
The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). Several of the jurisdictions that the Company operates in have already adopted some form of the model rules, which could impact the amount of taxes that the Company pays after 2023. However, the rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. At this time, the Company is projecting an immaterial amount related to Pillar 2 tax liability for the year ending December 31, 2024. Related changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.3
NET INCOME PER SHARE
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
NET INCOME PER SHARE NET INCOME PER SHARE
Basic and diluted net income per share was as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 Dollars in thousands, except per share amounts2024202320242023
Basic net (loss) income per share:
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Weighted average common shares outstanding76,448 79,690 77,196 80,842 
Basic net (loss) income per common share$(0.14)$0.24 $(0.34)$0.59 
Diluted net (loss) income per share:
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Weighted average common shares outstanding — Basic76,448 79,690 77,196 80,842 
Effect of dilutive securities:
Stock options and restricted stock— 121 — 270 
Weighted average common shares for diluted earnings per share76,448 79,811 77,196 81,112 
Diluted net (loss) income per common share$(0.14)$0.24 $(0.34)$0.59 
Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Common stock of approximately 1.3 million and 0.6 million shares at September 30, 2024, and 2023, respectively, were not included in the computation of diluted net (loss) income per share because their effect would have been anti-dilutive.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.3
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME
Comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Foreign currency translation adjustment5,386 (9,541)(2,558)(16,378)
Change in unrealized loss/(gain) on derivatives, net of tax(11,044)6,790 (6,714)7,858 
Pension liability adjustment, net of tax(470)(334)(475)— 
Comprehensive (loss) income, net$(16,823)$16,412 $(36,126)$39,387 
Changes in accumulated other comprehensive (loss) income by component between December 31, 2023 and September 30, 2024 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at January 1, 2024
$21,489 $2,712 $(39,307)$(15,106)
Other comprehensive gain (loss)11,632 (475)3,129 14,286 
Less: Amounts reclassified from accumulated other comprehensive income, net18,346 — 5,688 24,034 
Net current-period other comprehensive gain (loss)(6,714)(475)(2,559)(9,748)
Balance at September 30, 2024
$14,775 $2,237 $(41,866)$(24,854)
For the nine months ended September 30, 2024, the Company reclassified a gain of $7.3 million and $16.8 million from accumulated other comprehensive income to other income, net and interest income, respectively.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices; and (iii) the ENT business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.
•The Tissue Technologies segment consists of the Wound Reconstruction and Care business, which includes offerings such as skin and wound repair products, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The Tissue Technologies segment includes the Company’s private label business.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2024 and 2023 are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Segment Net Sales
Codman Specialty Surgical$270,782 $268,205 $828,977 $787,371 
Tissue Technologies
110,052 114,216 338,904 357,163 
Total revenues$380,834 $382,421 $1,167,881 $1,144,534 
Segment Profit
Codman Specialty Surgical$100,538 $105,170 $368,171 $332,444 
Tissue Technologies
28,482 31,789 96,33592,132 
Segment profit129,020 136,959 464,506 424,576 
Amortization(3,760)(3,208)(17,575)(9,342)
Corporate and other(133,410)(107,158)(454,147)(339,755)
Operating income$(8,150)$26,593 $(7,216)$75,479 
The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
United States$290,192 $269,838 $856,646 $817,622 
Europe34,368 41,524 116,653 120,040 
Asia Pacific37,052 48,777 132,548 146,956 
Rest of World19,222 22,282 62,034 59,916 
Total Revenues$380,834 $382,421 $1,167,881 $1,144,534 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded and actual results may differ from these estimates. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.
On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra Life Sciences claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer to the contingent consideration section of this footnote for additional information on the ACell contingent considerations. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.
On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to defend the matter vigorously.
On March 17, 2021, a complaint was filed against the Company in the Court of Common Pleas of Philadelphia County in Pennsylvania asserting product liability claims relating to a surgical procedure in which the Company’s CUSA® Clarity allegedly was used. The plaintiff seeks damages against the Company based upon plaintiff’s claim that the CUSA® Clarity did not function as intended. The plaintiff also asserts separate claims against the surgeon and the hospital. In the third quarter of 2024, a settlement was reached, which has since been paid by the Company’s insurance carriers.
Contingent Consideration
The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2024 and September 30, 2023 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2024 and September 30, 2023 is as follows (in thousands):
Nine Months Ended September 30, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Payment(12,400)
Change in fair value of contingent consideration liabilities (3,019)Research and development137 — 3,100 Selling, general and administrative
Balance as of September 30, 202412,736 2,694 300 59,400 
Short-Term $8,320 $— $— $19,600 Accrued expenses and other current liabilities
Long-Term4,416 2,694 300 39,800 Other liabilities
Total12,736 2,694 300 59,400 
Nine Months Ended September 30, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,600 
Change in fair value of contingent consideration liabilities1,991 Research and development1,887 (2,200)6,600 Selling, general and administrative
Balance as of September 30, 2023
$14,886 $2,117 $1,500 $64,200 
Short-Term $4,373 $— $503 $13,000 Accrued expenses and other current liabilities
Long-Term10,513 2,117 997 51,200 Other liabilities
Total14,886 2,117 1,500 64,200 
Arkis BioSciences Inc.
As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date.
Derma Sciences, Inc.
The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains, which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million.
ACell, Inc.
As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date.
Surgical Innovations Associates, Inc.
As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on (1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as (2) the approval by the FDA of the pre-market approval ("PMA") application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). In the second quarter of 2024, the Company paid out $12.4 million related to the 2023 performance year. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date.
Other Commitments
In October 2024, the Company entered into a definitive agreement to acquire a manufacturing facility in Plainsboro, New Jersey for $10 million in cash at closing. The manufacturing facility is currently leased by the Company. The transaction is expected to close in the first quarter of 2025.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net (Loss) Income $ (10,695) $ (12,402) $ (3,281) $ 19,497 $ 4,184 $ 24,226 $ (26,379) $ 47,907
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION (Policies)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the September 30, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2024 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and, in January 2021, subsequently amended the initial guidance in: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to a SOFR-indexed rate. (See Note 6. Debt). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR. The Company has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.
Cash and cash equivalents
Cash and cash equivalents
The Company had cash and cash equivalents, primarily consisting of cash on-hand as well as time deposits with original maturities of three months or less and money market funds which are highly liquid and readily convertible to cash, totaling approximately $215.2 million and $276.4 million at September 30, 2024 and December 31, 2023 respectively. Time deposits with original maturities of three months or less and money market funds are valued based on Level 1 measurements in the fair value hierarchy established within FASB Topic 820, Fair Value Measurement (“ASC 820”). Level 1 inputs represent quoted prices in active markets for identical assets or liabilities.
Short-term investments
Short-term investments
The Company had short term investments, primarily consisting of time deposits with original maturities between three months and one year, which are valued based on Level 1 measurements in the fair value hierarchy, totaling approximately $62.4 million at September 30, 2024 compared to $32.7 million at December 31, 2023.
Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Estimates
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Product Warranties
Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.3
ACQUISITIONS AND DIVESTITURES (Tables)
 9 Months Ended
Sep. 30, 2024
Mergers, Acquisitions and Dispositions [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date:
Dollars in thousandsEstimated Fair ValueEstimated Useful Life
Current assets:
Cash$— 
Trade accounts receivable, net 23,716 
Inventories, net20,294 
Prepaid expenses273 
Other current assets476 
Total current assets$44,759 
Property, plant and equipment, net7,716 
Right of use asset - operating leases989 
Intangible assets, net
Completed technology202,000 12 years
Trademarks/brand names3,000 5 years
All other17,000 4 years
Goodwill61,396 
Deferred tax assets6,863 
Total assets acquired$343,723 
Current liabilities:
Accounts payable, trade3,989 
Contract liabilities3,984 
Accrued compensation1,037 
Accrued expenses and other current liabilities2,278 
Current portion of lease liability - operating leases365 
Total current liabilities$11,653 
Lease liability - operating leases624 
Deferred tax liabilities53,635 
Total liabilities assumed65,912 
Net assets acquired$277,811 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset$(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period$7,828 
Contract asset, September 30, 2024
$7,828 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability$(6,616)
Contract liability, acquired with Acclarent$3,984 
Contract liability, net of revenue recognized on contracts during the period$4,447 
Foreign currency translation$21 
Contract liability, September 30, 2024
$18,088 
Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Neurosurgery$175,956 $209,229 $583,726 $607,902 
Instruments54,238 49,920 153,148 152,523 
ENT(1)
40,588 9,056 92,103 26,946 
Total Codman Specialty Surgical270,782 268,205 828,977 787,371 
Wound Reconstruction and Care80,460 88,071 249,032 280,129 
Private Label29,592 26,145 89,872 77,034 
Total Tissue Technologies110,052 114,216 338,904 357,163 
Total revenue$380,834 $382,421 $1,167,881 $1,144,534 
(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.3
INVENTORIES (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
Inventories, net consisted of the following:
Dollars in thousandsSeptember 30, 2024December 31, 2023
Finished goods$219,347 $196,402 
Work in process85,493 74,035 
Raw materials132,090 119,171 
Total inventories, net$436,930 $389,608 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2024 were as follows:
Dollars in thousandsCodman Specialty
Surgical		Tissue TechnologiesTotal
Goodwill at December 31, 2023$666,937 $388,525 $1,055,462 
Acclarent Acquisition 61,396 — 61,396 
Foreign currency translation(210)(113)(323)
Goodwill at September 30, 2024
$728,123 $388,412 $1,116,535 
Schedule of Finite-Lived Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 September 30, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology17 years$1,427,186 $(509,825)$917,361 
Customer relationships12 years168,396 (138,022)30,374 
Trademarks/brand names27 years101,896 (41,833)60,063 
Codman tradenameIndefinite174,118 — 174,118 
Supplier relationships30 years30,211 (18,882)11,329 
All other6 years23,154 (6,851)16,303 
$1,924,961 $(715,413)$1,209,548 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
Schedule of Indefinite-Lived Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 September 30, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology17 years$1,427,186 $(509,825)$917,361 
Customer relationships12 years168,396 (138,022)30,374 
Trademarks/brand names27 years101,896 (41,833)60,063 
Codman tradenameIndefinite174,118 — 174,118 
Supplier relationships30 years30,211 (18,882)11,329 
All other6 years23,154 (6,851)16,303 
$1,924,961 $(715,413)$1,209,548 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Maximum Leverage Ratios
The Company’s maximum Consolidated Total Leverage Ratio (as defined in the March 2023 Amendment) in the financial covenants is outlined below. Concurrent with the Durepair acquisition (see Note 2. Acquisitions and Divestitures), in accordance with the terms of the March 2023 Amendment, the Company elected to increase the maximum Consolidated Total Leverage Ratio to 5.00 from the fiscal quarter ending December 31, 2024 through the fiscal quarter ending September 30, 2025.
Fiscal Quarter EndingMaximum Consolidated Total Leverage Ratio
March 31, 2023 through September 30, 2024
4.50 to 1.00
December 31, 2024 through September 30, 2025
5.00 to 1.00
December 31, 2025 through June 30, 2026
4.25 to 1.00
September 30, 2026 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Schedule of Contractual Repayments of Long-Term Debt
Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:
As of September 30, 2024
Principal Repayment
Dollars in thousands
Remainder of 2024
$4,844 
2025
33,906 
2026
38,750 
2027
53,281 
2028634,531 
$765,312 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments
The Company held the following interest rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month Term SOFR Loan— 150,000 December 13, 2017July 1, 2019June 28, 20242.423 %— 2,105 
1-month Term SOFR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %1,246 4,978 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %525 1,349 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %515 1,312 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %501 1,346 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %1,425 3,015 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %1,616 3,052 
1-month Term SOFR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %22,809 22,965 
1-month Term SOFR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,159 5,263 
Basis Swap (1)
—— March 31, 2023March 24, 2023December 31, 2027N/A(1,949)0(1,829)
$1,325,000 $1,475,000 $31,847 $43,556 
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time
The Company held the following cross-currency rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay CHFDecember 21, 2020December 22, 20253.00%CHF333,887 351,137 (30,892)(38,324)
Receive U.S.$3.98%$374,817 394,183 
Pay CHFSeptember 22, 2023September 23, 20242.40%CHF— 28,500 — (2,348)
Receive U.S.$6.27%$— 31,457 
Total$(30,892)$(40,672)
The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2024 and December 31, 2023, respectively (dollar amounts in thousands):
September 30, 2024December 31, 2023September 30, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 2,106 2,475 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,211 288,210 (48,153)(48,047)
Receive U.S.$1.94%$300,000 300,000 
Pay CHFNovember 17, 2023December 17, 2029—%CHF66,525 66,525 (5,248)(4,037)
Receive U.S.$2.54%$75,000 75,000 
Pay CHFMay 6, 2024December 18, 2030—%CHF68,483 — (6,071)— 
Receive U.S.$2.74%$75,000 — 
Total(57,366)(49,609)
Schedule of Fair Value and Presentation of Derivatives
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:
Fair Value as of
Location on Balance Sheet (1):
September 30, 2024December 31, 2023
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap
$7,335 $14,675 
Cross-currency swap708 537 
Foreign currency forward contracts292 — 
Net Investment Hedges
Cross-currency swap5,764 2,938 
Other assets
Cash Flow Hedges
Interest rate swap26,461 30,710 
Net Investment Hedges
Cross-currency swap— 1,470 
Total derivatives designated as hedges — Assets$40,560 $50,330 
Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap$265 $579 
Cross-currency swap— 4,813 
Foreign currency forward contracts— — 
Net Investment Hedges
Cross-currency swap2,120 2,903 
Other liabilities
Cash Flow Hedges
Interest rate swap1,684 1,250 
Cross-currency swap31,600 36,396 
Net Investment Hedges
Cross-currency swap61,010 51,114 
Total derivatives designated as hedges — Liabilities$96,679 $97,055 
(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2024 and 2023:
Dollars in thousandsBalance in AOCI
Beginning of
Quarter		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Three Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap$53,116 $(17,133)$4,135 $31,848 Interest expense
Cross-currency swap(16,867)(16,625)(22,089)(11,403)Other income, net
Foreign Currency Forward Contract(430)474 (119)163 Cost of Sales
Net Investment Hedges
Cross-currency swap(29,466)(21,051)2,739 (53,256)Interest income
$6,353 $(54,335)$(15,334)$(32,648)
Three Months Ended September 30, 2023
Cash Flow Hedges
Interest rate swap$56,901 $15,317 $4,964 $67,254 Interest expense
Cross-currency swap(18,925)13,796 15,347 (20,476)Other income, net
Foreign Currency Forward Contract$(123)$98 $87 $(112)
Net Investment Hedges
Cross-currency swap(21,239)6,051 1,772 (16,960)Interest income
$16,614 $35,262 $22,170 $29,706 
Dollars in thousandsBalance in AOCI
Beginning of
Year		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Nine Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap$43,556 $2,678 $14,386 $31,848 Interest expense
Cross-currency swap(15,763)13,505 9,145 (11,403)Other income (expense), net
Foreign currency forward contract— (159)(322)163 Cost of sales
Net Investment Hedges
Cross-currency swap(45,498)(364)7,394 (53,256)Interest income
$(17,705)$15,660 $30,603 $(32,648)
Nine Months Ended September 30, 2023
Cash Flow Hedges
Interest rate swap$56,712 $23,477 $12,935 $67,254 Interest expense
Cross-currency swap(20,271)3,114 3,319 (20,476)Other income (expense), net
Foreign currency forward contract— $333 $445 (112)
Net Investment Hedges
Cross-currency swap(6,914)(4,066)5,980 (16,960)Interest income
$29,527 $22,858 $22,679 $29,706 
Derivatives Not Designated as Hedging Instruments The following table summarizes the gains on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsThree Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Foreign currency swaps10 135 385 778 
Total$10 $135 $385 $778 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES AND RELATED PARTY LEASES (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Supplemental Balance Sheet Information
Supplemental balance sheet information related to operating leases were as follows:
Dollars in thousands, except lease term and discount rateSeptember 30, 2024
December 31, 2023
ROU assets$146,342 $156,184 
Current lease liabilities15,039 15,284 
Non-current lease liabilities167,808 166,849 
Total lease liabilities$182,847 $182,133 
Weighted average remaining lease term (in years):
Leased facilities16.2 years16.3 years
Leased vehicles2.2 years1.9 years
Weighted average discount rate:
Leased facilities5.6 %5.9 %
Leased vehicles2.6 %2.7 %
Supplemental Cash Flow Information
Supplemental cash flow information related to leases for the nine months ended September 30, 2024 and 2023 were as follows:
Dollars in thousandsSeptember 30, 2024
September 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$18,255 $14,778 
ROU assets obtained in exchange for lease liabilities, net of modifications:
Operating leases$1,575 $19,540 
Schedule of Operating Lease Maturities
Future minimum lease payments under operating leases at September 30, 2024 were as follows:
Dollars in thousandsRelated PartiesThird PartiesTotal
Remainder of 2024
$74 $6,057 $6,131 
2025296 23,016 23,312 
2026296 21,317 21,613 
2027296 19,425 19,721 
2028296 17,163 17,459 
2029246 16,306 16,552 
Thereafter— 165,343 165,343 
Total minimum lease payments$1,504 $268,627 $270,131 
Less: Imputed interest87,284 
Total lease liabilities182,847 
Less: Current lease liabilities15,039 
Long-term lease liabilities167,808 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES (Tables)
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate
The following table provides a summary of the Company’s effective tax rate:
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Reported tax rate47.5 %(4.8)%35.3 %8.2 %
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.3
NET INCOME PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Basic and Diluted Net Income (Loss) Per Share
Basic and diluted net income per share was as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 Dollars in thousands, except per share amounts2024202320242023
Basic net (loss) income per share:
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Weighted average common shares outstanding76,448 79,690 77,196 80,842 
Basic net (loss) income per common share$(0.14)$0.24 $(0.34)$0.59 
Diluted net (loss) income per share:
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Weighted average common shares outstanding — Basic76,448 79,690 77,196 80,842 
Effect of dilutive securities:
Stock options and restricted stock— 121 — 270 
Weighted average common shares for diluted earnings per share76,448 79,811 77,196 81,112 
Diluted net (loss) income per common share$(0.14)$0.24 $(0.34)$0.59 
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.3
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Comprehensive Income (Loss)
Comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Net (loss) income$(10,695)$19,497 $(26,379)$47,907 
Foreign currency translation adjustment5,386 (9,541)(2,558)(16,378)
Change in unrealized loss/(gain) on derivatives, net of tax(11,044)6,790 (6,714)7,858 
Pension liability adjustment, net of tax(470)(334)(475)— 
Comprehensive (loss) income, net$(16,823)$16,412 $(36,126)$39,387 
Schedule of Changes in Accumulated Other Comprehensive Loss by Component
Changes in accumulated other comprehensive (loss) income by component between December 31, 2023 and September 30, 2024 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at January 1, 2024
$21,489 $2,712 $(39,307)$(15,106)
Other comprehensive gain (loss)11,632 (475)3,129 14,286 
Less: Amounts reclassified from accumulated other comprehensive income, net18,346 — 5,688 24,034 
Net current-period other comprehensive gain (loss)(6,714)(475)(2,559)(9,748)
Balance at September 30, 2024
$14,775 $2,237 $(41,866)$(24,854)
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Net Sales and Profit by Segments Net sales and profit by each reportable segment for the three and nine months ended September 30, 2024 and 2023 are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Segment Net Sales
Codman Specialty Surgical$270,782 $268,205 $828,977 $787,371 
Tissue Technologies
110,052 114,216 338,904 357,163 
Total revenues$380,834 $382,421 $1,167,881 $1,144,534 
Segment Profit
Codman Specialty Surgical$100,538 $105,170 $368,171 $332,444 
Tissue Technologies
28,482 31,789 96,33592,132 
Segment profit129,020 136,959 464,506 424,576 
Amortization(3,760)(3,208)(17,575)(9,342)
Corporate and other(133,410)(107,158)(454,147)(339,755)
Operating income$(8,150)$26,593 $(7,216)$75,479 
Total revenue by major geographic area consisted of the following:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
United States$290,192 $269,838 $856,646 $817,622 
Europe34,368 41,524 116,653 120,040 
Asia Pacific37,052 48,777 132,548 146,956 
Rest of World19,222 22,282 62,034 59,916 
Total Revenues$380,834 $382,421 $1,167,881 $1,144,534 
Schedule of Geographic Revenue by Area Net sales and profit by each reportable segment for the three and nine months ended September 30, 2024 and 2023 are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
Segment Net Sales
Codman Specialty Surgical$270,782 $268,205 $828,977 $787,371 
Tissue Technologies
110,052 114,216 338,904 357,163 
Total revenues$380,834 $382,421 $1,167,881 $1,144,534 
Segment Profit
Codman Specialty Surgical$100,538 $105,170 $368,171 $332,444 
Tissue Technologies
28,482 31,789 96,33592,132 
Segment profit129,020 136,959 464,506 424,576 
Amortization(3,760)(3,208)(17,575)(9,342)
Corporate and other(133,410)(107,158)(454,147)(339,755)
Operating income$(8,150)$26,593 $(7,216)$75,479 
Total revenue by major geographic area consisted of the following:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2024202320242023
United States$290,192 $269,838 $856,646 $817,622 
Europe34,368 41,524 116,653 120,040 
Asia Pacific37,052 48,777 132,548 146,956 
Rest of World19,222 22,282 62,034 59,916 
Total Revenues$380,834 $382,421 $1,167,881 $1,144,534 
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES (Tables)
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2024 and September 30, 2023 is as follows (in thousands):
Nine Months Ended September 30, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Payment(12,400)
Change in fair value of contingent consideration liabilities (3,019)Research and development137 — 3,100 Selling, general and administrative
Balance as of September 30, 202412,736 2,694 300 59,400 
Short-Term $8,320 $— $— $19,600 Accrued expenses and other current liabilities
Long-Term4,416 2,694 300 39,800 Other liabilities
Total12,736 2,694 300 59,400 
Nine Months Ended September 30, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,600 
Change in fair value of contingent consideration liabilities1,991 Research and development1,887 (2,200)6,600 Selling, general and administrative
Balance as of September 30, 2023
$14,886 $2,117 $1,500 $64,200 
Short-Term $4,373 $— $503 $13,000 Accrued expenses and other current liabilities
Long-Term10,513 2,117 997 51,200 Other liabilities
Total14,886 2,117 1,500 64,200 
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and cash equivalents $ 215,157 $ 276,402
Short-term investments $ 62,441 $ 32,694
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.3
ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 9 Months Ended
Oct. 02, 2026
Oct. 02, 2025
Oct. 02, 2024
Apr. 01, 2024
Sep. 30, 2024
Sep. 30, 2024
Durepair Regeneration Matrix | Forecast            
Business Acquisition [Line Items]            
Payments for asset acquisitions $ 20.0 $ 15.0        
Durepair Regeneration Matrix | Subsequent Event            
Business Acquisition [Line Items]            
Upfront payment     $ 45.0      
Payments for asset acquisitions     $ 10.0      
Acclarent Inc.            
Business Acquisition [Line Items]            
Purchase price of business combination       $ 282.0    
Final working capital adjustment         $ 4.2  
Revenue of acquiree since acquisition date           $ 62.3
Estimated Useful Life       11 years    
Intangible asset acquired, discount rate (percent)       12.20%    
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.3
ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Apr. 01, 2024
Sep. 30, 2024
Dec. 31, 2023
Current assets:      
Goodwill   $ 1,116,535 $ 1,055,462
Acclarent Inc.      
Current assets:      
Cash $ 0    
Trade accounts receivable, net 23,716    
Inventories, net 20,294    
Prepaid expenses 273    
Other current assets 476    
Total current assets 44,759    
Property, plant and equipment, net 7,716    
Right of use asset - operating leases $ 989    
Estimated useful life 11 years    
Goodwill $ 61,396    
Deferred tax assets 6,863    
Total assets acquired 343,723    
Current liabilities:      
Accounts payable, trade 3,989    
Contract liabilities 3,984    
Accrued compensation 1,037    
Accrued expenses and other current liabilities 2,278    
Current portion of lease liability - operating leases 365    
Total current liabilities 11,653    
Lease liability - operating leases 624    
Deferred tax liabilities 53,635    
Total liabilities assumed 65,912    
Net assets acquired $ 277,811    
Intangible asset acquired, discount rate (percent) 12.20%    
Acclarent Inc. | Completed technology      
Current assets:      
Intangible assets, net $ 202,000    
Estimated useful life 12 years    
Acclarent Inc. | Trademarks and Trade Names      
Current assets:      
Intangible assets, net $ 3,000    
Estimated useful life 5 years    
Acclarent Inc. | Other Intangible Assets      
Current assets:      
Intangible assets, net $ 17,000    
Estimated useful life 4 years    
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]    
Number of days from shipment to issue a credit 90 days  
Short-term portion of contract liability $ 9,990 $ 8,540
Long-term portion of contract liability $ 8,100  
Product warranty period (up to) 2 years  
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Contract Asset  
Contract asset, beginning of period $ 9,233
Transferred to trade receivable from contract asset included in beginning of the year contract asset (9,233)
Contract asset, net of transferred to trade receivables on contracts during the period 7,828
Contract asset, end of Period 7,828
Contract Liability  
Contract liability, beginning of period 16,252
Recognition of revenue included in beginning of year contract liability (6,616)
Contract liability, acquired with Acclarent 3,984
Contract liability, net of revenue recognized on contracts during the period 4,447
Foreign currency translation 21
Contract liability, end of period $ 18,088
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Sep. 30, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Expected performance obligation, percentage 55.00%
Performance obligations expected to be satisfied, expected timing 12 months
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total Revenues $ 380,834 $ 382,421 $ 1,167,881 $ 1,144,534
Codman Specialty Surgical        
Disaggregation of Revenue [Line Items]        
Total Revenues 270,782 268,205 828,977 787,371
Codman Specialty Surgical | Neurosurgery        
Disaggregation of Revenue [Line Items]        
Total Revenues 175,956 209,229 583,726 607,902
Codman Specialty Surgical | Instruments        
Disaggregation of Revenue [Line Items]        
Total Revenues 54,238 49,920 153,148 152,523
Codman Specialty Surgical | ENT        
Disaggregation of Revenue [Line Items]        
Total Revenues 40,588 9,056 92,103 26,946
Tissue Technologies        
Disaggregation of Revenue [Line Items]        
Total Revenues 110,052 114,216 338,904 357,163
Tissue Technologies | Wound Reconstruction and Care        
Disaggregation of Revenue [Line Items]        
Total Revenues 80,460 88,071 249,032 280,129
Tissue Technologies | Private Label        
Disaggregation of Revenue [Line Items]        
Total Revenues $ 29,592 $ 26,145 $ 89,872 $ 77,034
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.3
INVENTORIES - Schedule of Net Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 219,347 $ 196,402
Work in process 85,493 74,035
Raw materials 132,090 119,171
Inventories, net $ 436,930 $ 389,608
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Goodwill [Roll Forward]  
Goodwill at beginning of period $ 1,055,462
Foreign currency translation (323)
Goodwill at end of period 1,116,535
Acclarent Inc.  
Goodwill [Roll Forward]  
Acclarent Acquisition 61,396
Codman Specialty Surgical  
Goodwill [Roll Forward]  
Goodwill at beginning of period 666,937
Foreign currency translation (210)
Goodwill at end of period 728,123
Codman Specialty Surgical | Acclarent Inc.  
Goodwill [Roll Forward]  
Acclarent Acquisition 61,396
Tissue Technologies  
Goodwill [Roll Forward]  
Goodwill at beginning of period 388,525
Foreign currency translation (113)
Goodwill at end of period 388,412
Tissue Technologies | Acclarent Inc.  
Goodwill [Roll Forward]  
Acclarent Acquisition $ 0
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,924,961 $ 1,729,837
Accumulated Amortization (715,413) (662,004)
Net 1,209,548 1,067,833
Codman tradename    
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost 174,118 174,531
Net $ 174,118 $ 174,531
Completed technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 17 years 18 years
Cost $ 1,427,186 $ 1,226,128
Accumulated Amortization (509,825) (448,519)
Net $ 917,361 $ 777,609
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 12 years 12 years
Cost $ 168,396 $ 193,895
Accumulated Amortization (138,022) (152,160)
Net $ 30,374 $ 41,735
Trademarks/brand names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 27 years 28 years
Cost $ 101,896 $ 98,892
Accumulated Amortization (41,833) (38,754)
Net $ 60,063 $ 60,138
Supplier relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 30 years 30 years
Cost $ 30,211 $ 30,211
Accumulated Amortization (18,882) (18,148)
Net $ 11,329 $ 12,063
All other    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 6 years 11 years
Cost $ 23,154 $ 6,180
Accumulated Amortization (6,851) (4,423)
Net $ 16,303 $ 1,757
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Goodwill [Line Items]            
Amortization $ 25,600,000   $ 20,900,000 $ 78,700,000 $ 62,100,000  
Non-cash impairment charges       12,173,000 0  
Expected annual amortization expense, remainder of 2024 25,600,000     25,600,000    
Expected annual amortization expense, in 2025 102,400,000     102,400,000    
Expected annual amortization expense, in 2026 102,200,000     102,200,000    
Expected annual amortization expense, in 2027 101,200,000     101,200,000    
Expected annual amortization expense, in 2028 97,600,000     97,600,000    
Expected annual amortization expense, in 2029 92,400,000     92,400,000    
Expected annual amortization expense, thereafter 511,800,000     511,800,000    
Intangible assets, net 1,209,548,000     1,209,548,000   $ 1,067,833,000
Customer Relationships            
Goodwill [Line Items]            
Non-cash impairment charges   $ 7,100,000   7,100,000    
Completed technology            
Goodwill [Line Items]            
Cost, amortization 21,800,000   $ 17,700,000 61,100,000 $ 52,800,000  
Completed technology | Completed Technology, Surgimend            
Goodwill [Line Items]            
Intangible assets, net 34,600,000     34,600,000    
Completed technology | Completed Technology, PriMatrix            
Goodwill [Line Items]            
Intangible assets, net $ 25,500,000     25,500,000    
Codman tradename            
Goodwill [Line Items]            
Impairment of indefinite-lived intangible assets       $ 0    
Tissue Technologies            
Goodwill [Line Items]            
Fair value in excess of carrying amount, percent 21.20%     21.20%    
Reporting unit, fair value increase (decrease), percent (0.045)          
Neurosurgery            
Goodwill [Line Items]            
Fair value in excess of carrying amount, percent 11.70%     11.70%    
Impairment of goodwill       $ 0    
Reporting unit, fair value increase (decrease), percent (0.038)          
Instruments            
Goodwill [Line Items]            
Fair value in excess of carrying amount, percent 22.10%     22.10%    
Impairment of goodwill       $ 0    
Reporting unit, fair value increase (decrease), percent (0.035)          
Measurement Input, Long-Term Revenue Growth Rate | Valuation Technique, Discounted Cash Flow            
Goodwill [Line Items]            
Reporting unit, measurement input increase (decrease) (0.50)          
Measurement Input, Long-Term Revenue Growth Rate | Valuation Technique, Discounted Cash Flow | Tissue Technologies            
Goodwill [Line Items]            
Reporting unit, measurement input 0.025          
Measurement Input, Long-Term Revenue Growth Rate | Valuation Technique, Discounted Cash Flow | Neurosurgery            
Goodwill [Line Items]            
Reporting unit, measurement input 0.025          
Measurement Input, Long-Term Revenue Growth Rate | Valuation Technique, Discounted Cash Flow | Instruments            
Goodwill [Line Items]            
Reporting unit, measurement input 0.025          
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow            
Goodwill [Line Items]            
Reporting unit, measurement input increase (decrease) 0.50          
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Codman tradename            
Goodwill [Line Items]            
Indefinite-lived intangible assets, measurement input   0.130        
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Tissue Technologies            
Goodwill [Line Items]            
Reporting unit, measurement input 0.125          
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Neurosurgery            
Goodwill [Line Items]            
Reporting unit, measurement input 0.120          
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Instruments            
Goodwill [Line Items]            
Reporting unit, measurement input 0.115          
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Narrative (Details)
 3 Months Ended 9 Months Ended
Feb. 07, 2020
USD ($)
$ / shares
Feb. 04, 2020
USD ($)
$ / shares
Mar. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 15, 2023
USD ($)
Mar. 24, 2023
USD ($)
Dec. 09, 2020
USD ($)
Debt Instrument [Line Items]                
Term loan component of senior credit facility       $ 29,063,000 $ 14,531,000      
Interest payments, remainder of fiscal year       12,300,000        
Interest payments, year one       48,100,000        
Interest payments, year two       45,600,000        
Interest payments, year three       42,600,000        
Interest payments, year four       9,400,000        
Securitization program outstanding borrowings, maximum limit       150,000,000        
Transferor's interests in transferred financial assets, issuance costs           $ 300,000    
Debt instrument, securitization facility, agreement term (in years)           3 years    
Transferor's interests in transferred financial assets, unamortized issuance costs           $ 100,000    
Secured long-term debt, securitization program       $ 72,800,000 $ 89,200,000      
Weighted average interest rate, accounts receivable securitization revolving loan facility       5.90% 6.40%      
Fair Value, Inputs, Level 2                
Debt Instrument [Line Items]                
Securitization facility, outstanding borrowings, fair value       $ 71,200,000        
Revolving Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity             $ 1,300,000,000  
Debt issuance costs capitalized       7,600,000        
Write off of debt issuance costs     $ 200,000          
Line of credit facility outstanding       $ 400,000,000.0 $ 70,000,000.0      
Standby Letters of Credit                
Debt Instrument [Line Items]                
Maximum borrowing capacity             60,000,000  
Swingline Loans                
Debt Instrument [Line Items]                
Maximum borrowing capacity             60,000,000  
Senior Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity             2,100,000,000  
Senior Credit Facility | Overnight Federal Funds                
Debt Instrument [Line Items]                
Interest rates available       0.50%        
Senior Credit Facility | Secured Overnight Financing Rate (SOFR)                
Debt Instrument [Line Items]                
Interest rate adjustment       0.10%        
Interest rates available       1.00%        
Senior Credit Facility | Minimum                
Debt Instrument [Line Items]                
Line of credit, commitment fee percentage       0.15%        
Senior Credit Facility | Minimum | Secured Overnight Financing Rate (SOFR)                
Debt Instrument [Line Items]                
Interest rates available       1.00%        
Senior Credit Facility | Maximum                
Debt Instrument [Line Items]                
Line of credit, commitment fee percentage       0.30%        
Senior Credit Facility | Maximum | Secured Overnight Financing Rate (SOFR)                
Debt Instrument [Line Items]                
Interest rates available       1.75%        
Senior Credit Facility | Revolving Credit Facility | Fair Value, Inputs, Level 2                
Debt Instrument [Line Items]                
Line of credit facility, fair value of amount outstanding       $ 395,300,000        
Senior Credit Facility | Standby Letters of Credit                
Debt Instrument [Line Items]                
Line of credit facility outstanding       0        
Letters of credit outstanding       1,700,000 1,700,000      
Term Loan Facility | Secured Debt                
Debt Instrument [Line Items]                
Maximum borrowing capacity             $ 775,000,000.0  
Line of credit facility outstanding       $ 765,300,000 $ 775,000,000.0      
Weighted average interest rate on debt       6.40% 6.80%      
Term loan component of senior credit facility       $ 29,100,000 $ 14,500,000      
Term Loan Facility | Secured Debt | Fair Value, Inputs, Level 2                
Debt Instrument [Line Items]                
Line of credit facility, fair value of amount outstanding       756,300,000        
2025 Notes | Convertible Debt                
Debt Instrument [Line Items]                
Convertible notes, maximum borrowing capacity $ 575,000,000.0     575,000,000.0        
Convertible notes, interest rate 0.50%              
Incremental financing costs capitalized $ 13,200,000              
Initial conversion rate 0.0135739              
Initial conversion price (in dollars per share) | $ / shares $ 73.67              
Maximum selling price of the company's common stock of the conversion price 130.00%              
Maximum average conversion value of notes 98.00%              
Minimum settled in cash per principal amount               $ 1,000
Redemption price, percentage   100.00%            
Warrant strike price (in dollars per share) | $ / shares   $ 113.34            
Fair value       $ 547,700,000        
2025 Notes | Convertible Debt | Call Option                
Debt Instrument [Line Items]                
Cost of call transactions   $ 104,200,000            
Proceeds from warrant transactions   $ 44,500,000            
Initial strike price (in dollars per share) | $ / shares   $ 73.67            
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Maximum Total Leverage Ratio Table (Details) - Senior Credit Facility
Mar. 24, 2023
March 31, 2023 through September 30, 2024  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.50
December 31, 2024 through September 30, 2025  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 5.00
December 31, 2025 through June 30, 2026  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.25
September 30, 2026 and the last day of each fiscal quarter thereafter  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.00
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Contractual Maturity Table (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2024 $ 4,844
2025 33,906
2026 38,750
2027 53,281
2028 634,531
Total long-term debt $ 765,312
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) - Cash Flow Hedges - Designated as Hedging Instrument - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Derivative [Line Items]    
Notional Amount $ 1,325,000 $ 1,475,000
Estimated Fair Value 31,847 43,556
Interest Rate Swap Designated December 13, 2017 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 0 150,000
Fixed Interest Rate 2.423%  
Estimated Fair Value $ 0 2,105
Interest Rate Swap Designated December 13, 2017 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 200,000 200,000
Fixed Interest Rate 2.313%  
Estimated Fair Value $ 1,246 4,978
Interest Rate Swap Designated October 10, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 75,000 75,000
Fixed Interest Rate 3.22%  
Estimated Fair Value $ 525 1,349
Interest Rate Swap Designated October 10, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 75,000 75,000
Fixed Interest Rate 3.199%  
Estimated Fair Value $ 515 1,312
Interest Rate Swap Designated October 10, 2018 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 75,000 75,000
Fixed Interest Rate 3.209%  
Estimated Fair Value $ 501 1,346
Interest Rate Swap Designated December 18, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 100,000 100,000
Fixed Interest Rate 2.885%  
Estimated Fair Value $ 1,425 3,015
Interest Rate Swap Designated December 18, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 100,000 100,000
Fixed Interest Rate 2.867%  
Estimated Fair Value $ 1,616 3,052
Interest Rate Swap Designated December 15, 2020 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 575,000 575,000
Fixed Interest Rate 1.415%  
Estimated Fair Value $ 22,809 22,965
Interest Rate Swap Designated December 15, 2020 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 125,000 125,000
Fixed Interest Rate 1.404%  
Estimated Fair Value $ 5,159 5,263
Interest Rate Swap Designated March 31, 2023    
Derivative [Line Items]    
Notional Amount 0 0
Estimated Fair Value $ (1,949) $ (1,829)
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Narrative (Details)
$ in Thousands, SFr in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2024
CHF (SFr)
Sep. 30, 2023
USD ($)
Oct. 16, 2024
CHF (SFr)
Sep. 30, 2024
CHF (SFr)
Sep. 23, 2024
CHF (SFr)
May 02, 2024
USD ($)
May 02, 2024
CHF (SFr)
Dec. 31, 2023
USD ($)
Sep. 22, 2023
USD ($)
Sep. 22, 2023
CHF (SFr)
Jun. 30, 2021
USD ($)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Derivative [Line Items]                                
Gain expected to be reclassified to earnings in the next twelve months $ 9,600   $ 9,600                          
Designated as Hedging Instrument                                
Derivative [Line Items]                                
Gain (loss) recorded in AOCI, change in fair value (54,335) $ 35,262 15,660   $ 22,858                      
Amount of Gain (Loss) Reclassified from AOCI into Earnings (15,334) 22,170 30,603   22,679                      
Cash Flow Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Current notional amount 1,325,000   1,325,000               $ 1,475,000          
Estimated Fair Value 31,847   31,847               43,556          
Cross-currency swap                                
Derivative [Line Items]                                
Gain (loss) reclassified into other income 1,100 1,500 3,700   4,400                      
Gain expected to be reclassified to earnings in the next twelve months 700   700                          
Current notional amount                             $ 471,600 SFr 420.1
Intercompany loan quarterly payments | SFr       SFr 5.8                        
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Gain (loss) reclassified into other income 23,200 15,300 5,400   3,300                      
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument | Other income, net                                
Derivative [Line Items]                                
Gain (loss) recorded in AOCI, change in fair value (16,625) 13,796 13,505   3,114                      
Amount of Gain (Loss) Reclassified from AOCI into Earnings (22,089) 15,347 9,145   3,319                      
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Gain (loss) reclassified into other income 2,700 1,800 7,400   6,000                      
Estimated Fair Value (57,366)   (57,366)               (49,609)          
Cross-currency swap | Codman                                
Derivative [Line Items]                                
Notional amount settled | SFr                         SFr 20.0      
Loss on settlement of derivative | SFr               SFr 2.3                
Cross-currency swap | Codman | Cash Flow Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Estimated Fair Value (30,892)   (30,892)               (40,672)          
Cross-currency swap | Short | Codman                                
Derivative [Line Items]                                
Notional amount terminated                       $ 48,500        
Current notional amount                       $ 31,500 SFr 28.5      
Foreign currency swaps | Not Designated as Hedging Instrument                                
Derivative [Line Items]                                
Current notional amount 4,600   4,600                     $ 7,300    
Estimated Fair Value 1,100   1,100               $ 1,200          
Foreign currency swaps | Net Investment Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Current notional amount                 $ 75,000 SFr 68.5            
Foreign currency forward contract | Cash Flow Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Current notional amount | SFr             SFr 10.4                  
Foreign currency forward contract | Cash Flow Hedges | Designated as Hedging Instrument | Subsequent Event                                
Derivative [Line Items]                                
Current notional amount | SFr           SFr 5.2                    
Foreign currency forward contract | Cash Flow Hedges | Designated as Hedging Instrument | Cost of Sales                                
Derivative [Line Items]                                
Gain (loss) recorded in AOCI, change in fair value 474 98 (159)   333                      
Amount of Gain (Loss) Reclassified from AOCI into Earnings (119) 87 (322)   445                      
Interest Rate Swap                                
Derivative [Line Items]                                
Gain expected to be reclassified to earnings in the next twelve months 7,100   7,100                          
Interest Rate Swap | Cash Flow Hedges | Designated as Hedging Instrument                                
Derivative [Line Items]                                
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax (17,100) 15,300 2,700   23,500                      
Gain (loss) reclassified into other income $ 4,100 $ 5,000 $ 14,400   $ 12,900                      
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)
SFr in Thousands, $ in Thousands
Sep. 30, 2024
USD ($)
Sep. 30, 2024
CHF (SFr)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
CHF (SFr)
Sep. 22, 2023
USD ($)
Sep. 22, 2023
CHF (SFr)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Cross-currency swap                
Derivative [Line Items]                
Aggregate Notional Amount             $ 471,600 SFr 420,100
Cross-currency swap | Short | Codman                
Derivative [Line Items]                
Aggregate Notional Amount         $ 31,500 SFr 28,500    
Cash Flow Hedges | Designated as Hedging Instrument                
Derivative [Line Items]                
Aggregate Notional Amount $ 1,325,000   $ 1,475,000          
Fair Value Asset (Liability) 31,847   43,556          
Cash Flow Hedges | Designated as Hedging Instrument | Cross-currency swap | Codman                
Derivative [Line Items]                
Fair Value Asset (Liability) (30,892)   (40,672)          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap One | Codman                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (30,892)   (38,324)          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap One | Long | Codman                
Derivative [Line Items]                
Fixed Rate 3.00% 3.00%            
Aggregate Notional Amount | SFr   SFr 333,887   SFr 351,137        
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap One | Short | Codman                
Derivative [Line Items]                
Fixed Rate 3.98% 3.98%            
Aggregate Notional Amount $ 374,817   394,183          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap Two | Codman                
Derivative [Line Items]                
Fair Value Asset (Liability) $ 0   (2,348)          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap Two | Long | Codman                
Derivative [Line Items]                
Fixed Rate 2.40% 2.40%            
Aggregate Notional Amount | SFr   SFr 0   SFr 28,500        
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap Two | Short | Codman                
Derivative [Line Items]                
Fixed Rate 6.27% 6.27%            
Aggregate Notional Amount $ 0   $ 31,457          
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)
€ in Thousands, SFr in Thousands, $ in Thousands
Sep. 30, 2024
USD ($)
Sep. 30, 2024
CHF (SFr)
Sep. 30, 2024
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
CHF (SFr)
Dec. 31, 2023
EUR (€)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Cross-currency swap                
Derivative [Line Items]                
Aggregate Notional Amount             $ 471,600 SFr 420,100
Designated as Hedging Instrument | Net Investment Hedges | Cross-currency swap                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (57,366)     $ (49,609)        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap One                
Derivative [Line Items]                
Fair Value Asset (Liability) $ 2,106     2,475        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap One | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | €     € 38,820     € 38,820    
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap One | Short                
Derivative [Line Items]                
Fixed Rate 2.19% 2.19% 2.19%          
Aggregate Notional Amount $ 45,000     45,000        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Two                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (48,153)     (48,047)        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Two | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | SFr   SFr 288,211     SFr 288,210      
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Two | Short                
Derivative [Line Items]                
Fixed Rate 1.94% 1.94% 1.94%          
Aggregate Notional Amount $ 300,000     300,000        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Three                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (5,248)     (4,037)        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Three | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | SFr   SFr 66,525     66,525      
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Three | Short                
Derivative [Line Items]                
Fixed Rate 2.54% 2.54% 2.54%          
Aggregate Notional Amount $ 75,000     75,000        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Four                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (6,071)     0        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Four | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | SFr   SFr 68,483     SFr 0      
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Four | Short                
Derivative [Line Items]                
Fixed Rate 2.74% 2.74% 2.74%          
Aggregate Notional Amount $ 75,000     $ 0        
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) - Designated as Hedging Instrument - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets $ 40,560 $ 50,330
Total derivatives designated as hedges — Liabilities 96,679 97,055
Interest rate swap | Cash Flow Hedges | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 7,335 14,675
Interest rate swap | Cash Flow Hedges | Other assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 26,461 30,710
Interest rate swap | Cash Flow Hedges | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 265 579
Interest rate swap | Cash Flow Hedges | Other liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 1,684 1,250
Cross-currency swap | Cash Flow Hedges | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 708 537
Cross-currency swap | Cash Flow Hedges | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 0 4,813
Cross-currency swap | Cash Flow Hedges | Other liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 31,600 36,396
Cross-currency swap | Net Investment Hedges | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 5,764 2,938
Cross-currency swap | Net Investment Hedges | Other assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 0 1,470
Cross-currency swap | Net Investment Hedges | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 2,120 2,903
Cross-currency swap | Net Investment Hedges | Other liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 61,010 51,114
Foreign currency forward contract | Cash Flow Hedges | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities $ 292 $ 0
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period $ 1,534,195 $ 1,683,160 $ 1,587,884 $ 1,804,403
Balance, end of period 1,521,587 1,579,221 1,521,587 1,579,221
Accumulated Other Comprehensive Loss        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period (18,726) 4,830 (15,106) 10,265
Balance, end of period (24,854) 1,745 (24,854) 1,745
Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Amount of Gain (Loss) Recognized in AOCI (54,335) 35,262 15,660 22,858
Amount of Gain (Loss) Reclassified from AOCI into Earnings (15,334) 22,170 30,603 22,679
Designated as Hedging Instrument | Accumulated Other Comprehensive Loss        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period 6,353 16,614 (17,705) 29,527
Balance, end of period (32,648) 29,706 (32,648) 29,706
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Interest expense        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period 53,116 56,901 43,556 56,712
Amount of Gain (Loss) Recognized in AOCI (17,133) 15,317 2,678 23,477
Amount of Gain (Loss) Reclassified from AOCI into Earnings 4,135 4,964 14,386 12,935
Balance, end of period 31,848 67,254 31,848 67,254
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges | Other income, net        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period (16,867) (18,925) (15,763) (20,271)
Amount of Gain (Loss) Recognized in AOCI (16,625) 13,796 13,505 3,114
Amount of Gain (Loss) Reclassified from AOCI into Earnings (22,089) 15,347 9,145 3,319
Balance, end of period (11,403) (20,476) (11,403) (20,476)
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Interest income        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period (29,466) (21,239) (45,498) (6,914)
Amount of Gain (Loss) Recognized in AOCI (21,051) 6,051 (364) (4,066)
Amount of Gain (Loss) Reclassified from AOCI into Earnings 2,739 1,772 7,394 5,980
Balance, end of period (53,256) (16,960) (53,256) (16,960)
Designated as Hedging Instrument | Foreign currency forward contract | Cash Flow Hedges | Cost of Sales        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, beginning of period (430) (123) 0 0
Amount of Gain (Loss) Recognized in AOCI 474 98 (159) 333
Amount of Gain (Loss) Reclassified from AOCI into Earnings (119) 87 (322) 445
Balance, end of period $ 163 $ (112) $ 163 $ (112)
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net $ 10 $ 135 $ 385 $ 778
Foreign currency swaps        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net $ 10 $ 135 $ 385 $ 778
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.3
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Grants in period, net of forfeitures (in shares) 243,964  
Options, weighted average grant date fair value (in dollars per share) $ 15.68  
Chief Executive Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Plan modification, expiration period (in months) 6 months  
Plan modification, compensation expense $ 1.4  
Chief Executive Officer | Forecast    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Accelerated stock based compensation expenses   $ 1.9
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total unrecognized compensation costs $ 3.5  
Weighted-average period for cost recognition 3 years  
Stock Options | Directors    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options exercisable, vesting period 1 year  
Stock Options | Employees    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 8 years  
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options exercisable, vesting period 3 years  
Total unrecognized compensation costs $ 35.4  
Weighted-average period for cost recognition 2 years  
Awards granted during the period (in shares) 737,623  
Other than options, weighted average grant date fair value (in dollars per share) $ 34.45  
Performance Stock and Restricted Stock Awards    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Requisite service periods of awards 3 years  
Performance Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards granted during the period (in shares) 263,350  
Other than options, weighted average grant date fair value (in dollars per share) $ 36.22  
Minimum | Stock Options | Directors and Certain Executive Officers    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 6 years  
Maximum | Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options exercisable, vesting period 4 years  
Maximum | Stock Options | Directors and Certain Executive Officers    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 10 years  
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.3
RETIREMENT PLANS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Retirement Benefits [Abstract]          
Net periodic benefit costs $ 0.4 $ 0.3 $ 1.3 $ 0.9  
Service cost component 0.8 $ 0.5 2.4 $ 1.6  
Estimated fair value of plan assets 43.4   $ 43.4   $ 45.7
Defer payment and taxation, base salary, percentage (up to)     75.00%    
Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to)     100.00%    
Deferred compensation plan, fair value of assets $ 6.5   $ 6.5   $ 6.1
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES AND RELATED PARTY LEASES - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
renewalOption
Sep. 30, 2023
USD ($)
Operating Leased Assets [Line Items]      
Number of renewal options (or more) | renewalOption   1  
Operating lease expense   $ 18.8 $ 17.9
Asset impairment charges $ 4.6    
Operating lease, impairment loss 1.7    
Impairment, long-lived asset, held-for-use $ 2.9    
Related Party      
Operating Leased Assets [Line Items]      
Operating lease expense   $ 0.2 $ 0.2
Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director   50.00%  
Annual rate of lease agreement   $ 0.3  
Related Party | Five Year Option Lease From November 1, 2029 Through October 31, 2034      
Operating Leased Assets [Line Items]      
Option to extend lease, years   5 years  
Period for extended lease   November 1, 2029 through October 31, 2034  
Related Party | Five Year Option Lease From November 1, 2034 Through October 31, 2039      
Operating Leased Assets [Line Items]      
Option to extend lease, years   5 years  
Period for extended lease   November 1, 2034 through October 31, 2039  
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Lessee, Lease, Description [Line Items]    
ROU assets $ 146,342 $ 156,184
Current lease liabilities 15,039 15,284
Non-current lease liabilities 167,808 166,849
Total lease liabilities $ 182,847 $ 182,133
Leased facilities    
Lessee, Lease, Description [Line Items]    
Weighted average remaining lease term (in years) 16 years 2 months 12 days 16 years 3 months 18 days
Weighted average discount rate 5.60% 5.90%
Leased vehicles    
Lessee, Lease, Description [Line Items]    
Weighted average remaining lease term (in years) 2 years 2 months 12 days 1 year 10 months 24 days
Weighted average discount rate 2.60% 2.70%
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 18,255 $ 14,778
ROU assets obtained in exchange for lease liabilities, net of modifications:    
Operating leases $ 1,575 $ 19,540
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Operating Leased Assets [Line Items]    
Remainder of 2024 $ 6,131  
2025 23,312  
2026 21,613  
2027 19,721  
2028 17,459  
2029 16,552  
Thereafter 165,343  
Total minimum lease payments 270,131  
Less: Imputed interest 87,284  
Total lease liabilities 182,847 $ 182,133
Less: Current lease liabilities 15,039 15,284
Long-term lease liabilities 167,808 $ 166,849
Related Parties    
Operating Leased Assets [Line Items]    
Remainder of 2024 74  
2025 296  
2026 296  
2027 296  
2028 296  
2029 246  
Thereafter 0  
Total minimum lease payments 1,504  
Third Parties    
Operating Leased Assets [Line Items]    
Remainder of 2024 6,057  
2025 23,016  
2026 21,317  
2027 19,425  
2028 17,163  
2029 16,306  
Thereafter 165,343  
Total minimum lease payments $ 268,627  
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.24.3
TREASURY STOCK - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2024
Sep. 30, 2024
Dec. 31, 2023
Jul. 31, 2024
May 16, 2024
Oct. 18, 2023
Aug. 15, 2023
Jul. 18, 2023
Jun. 30, 2023
Jan. 26, 2023
Class of Stock [Line Items]                    
Treasury stock (in shares)   14,454,000 12,751,000              
Treasury stock   $ 691,810 $ 647,262              
Treasury stock, average cost per share (in dollars per share)   $ 47.86 $ 50.76              
Accelerated share repurchase program, receipt (payment)         $ 50,000   $ 125,000     $ 150,000
Accelerated share repurchases, shares received at inception (in shares)         1,300,000   2,300,000     2,100,000
Accelerated share repurchases, percentage of expected total repurchased         70.00%   80.00%     80.00%
Accelerated share repurchases, additional shares received (in shares)       400,000   900,000     600,000  
2023 Share Repurchase Program                    
Class of Stock [Line Items]                    
Stock repurchase program, authorized amount               $ 225,000    
Remaining amount under share repurchase   $ 50,000                
2023 Share Repurchase Program | Subsequent Event                    
Class of Stock [Line Items]                    
Share repurchase program, excise tax $ 2,500                  
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES - Summary of Effective Tax Rate (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Reported tax rate 47.50% (4.80%) 35.30% 8.20%
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Effective income tax rate 47.50% (4.80%) 35.30% 8.20%
Income tax benefit from prior year income taxes   $ 3.3   $ 3.8
Income tax benefit from excess tax benefits from share-based payment arrangement     $ 1.9  
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.24.3
NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Basic net (loss) income per share:                
Net (loss) income $ (10,695) $ (12,402) $ (3,281) $ 19,497 $ 4,184 $ 24,226 $ (26,379) $ 47,907
Weighted average common shares outstanding - basic (in shares) 76,448     79,690     77,196 80,842
Basic net (loss) income per common share (in dollars per share) $ (0.14)     $ 0.24     $ (0.34) $ 0.59
Diluted net (loss) income per share:                
Net (loss) income $ (10,695) $ (12,402) $ (3,281) $ 19,497 $ 4,184 $ 24,226 $ (26,379) $ 47,907
Weighted average common shares outstanding - basic (in shares) 76,448     79,690     77,196 80,842
Effect of dilutive securities:                
Stock options and restricted stock (in shares) 0     121     0 270
Weighted average common shares for diluted earnings per share (in shares) 76,448     79,811     77,196 81,112
Diluted net (loss) income per common share (in dollars per share) $ (0.14)     $ 0.24     $ (0.34) $ 0.59
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.24.3
NET INCOME PER SHARE - Narrative (Details) - shares
shares in Millions
Sep. 30, 2024
Sep. 30, 2023
Earnings Per Share [Abstract]    
Shares excluded from computation as their effect would be antidilutive (in shares) 1.3 0.6
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.24.3
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Equity [Abstract]                
Net (loss) income $ (10,695) $ (12,402) $ (3,281) $ 19,497 $ 4,184 $ 24,226 $ (26,379) $ 47,907
Foreign currency translation adjustment 5,386     (9,541)     (2,558) (16,378)
Change in unrealized loss/(gain) on derivatives, net of tax (11,044)     6,790     (6,714) 7,858
Pension liability adjustment, net of tax (470)     (334)     (475) 0
Comprehensive (loss) income, net $ (16,823)     $ 16,412     $ (36,126) $ 39,387
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.24.3
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, beginning of period $ 1,534,195 $ 1,597,952 $ 1,587,884 $ 1,683,160 $ 1,674,938 $ 1,804,403 $ 1,587,884
Other comprehensive gain (loss)             14,286
Less: Amounts reclassified from accumulated other comprehensive income, net             24,034
Net current-period other comprehensive gain (loss) (6,128) (8,080) 4,460 (3,085) (2,237) (3,198) (9,748)
Balance, end of period 1,521,587 1,534,195 1,597,952 1,579,221 1,683,160 1,674,938 1,521,587
Total              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, beginning of period (18,726) (10,646) (15,106) 4,830 7,067 10,265 (15,106)
Net current-period other comprehensive gain (loss) (6,128) (8,080) 4,460 (3,085) (2,237) (3,198)  
Balance, end of period (24,854) $ (18,726) (10,646) $ 1,745 $ 4,830 $ 7,067 (24,854)
Gains and Losses on Derivatives              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, beginning of period     21,489       21,489
Other comprehensive gain (loss)             11,632
Less: Amounts reclassified from accumulated other comprehensive income, net             18,346
Net current-period other comprehensive gain (loss)             (6,714)
Balance, end of period 14,775           14,775
Defined Benefit Pension Items              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, beginning of period     2,712       2,712
Other comprehensive gain (loss)             (475)
Less: Amounts reclassified from accumulated other comprehensive income, net             0
Net current-period other comprehensive gain (loss)             (475)
Balance, end of period 2,237           2,237
Foreign Currency Items              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, beginning of period     $ (39,307)       (39,307)
Other comprehensive gain (loss)             3,129
Less: Amounts reclassified from accumulated other comprehensive income, net             5,688
Net current-period other comprehensive gain (loss)             (2,559)
Balance, end of period $ (41,866)           $ (41,866)
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.24.3
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Narrative (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI $ 24,034
Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI 18,346
Other Income | Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI 7,300
Interest income | Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI $ 16,800
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)
 9 Months Ended
Sep. 30, 2024
Segment
product
Segment Reporting Information [Line Items]  
Number of reportable segments | Segment 2
Codman Specialty Surgical  
Segment Reporting Information [Line Items]  
Number of products offered (more than) | product 40,000
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Net Sales        
Total Revenues $ 380,834 $ 382,421 $ 1,167,881 $ 1,144,534
Segment Profit        
Operating income (8,150) 26,593 (7,216) 75,479
Amortization (3,760) (3,208) (17,575) (9,342)
Operating Segments        
Segment Profit        
Operating income 129,020 136,959 464,506 424,576
Corporate and other        
Segment Profit        
Operating income (133,410) (107,158) (454,147) (339,755)
Codman Specialty Surgical        
Segment Net Sales        
Total Revenues 270,782 268,205 828,977 787,371
Codman Specialty Surgical | Operating Segments        
Segment Profit        
Operating income 100,538 105,170 368,171 332,444
Tissue Technologies        
Segment Net Sales        
Total Revenues 110,052 114,216 338,904 357,163
Tissue Technologies | Operating Segments        
Segment Profit        
Operating income $ 28,482 $ 31,789 $ 96,335 $ 92,132
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Total Revenues $ 380,834 $ 382,421 $ 1,167,881 $ 1,144,534
United States        
Segment Reporting Information [Line Items]        
Total Revenues 290,192 269,838 856,646 817,622
Europe        
Segment Reporting Information [Line Items]        
Total Revenues 34,368 41,524 116,653 120,040
Asia Pacific        
Segment Reporting Information [Line Items]        
Total Revenues 37,052 48,777 132,548 146,956
Rest of World        
Segment Reporting Information [Line Items]        
Total Revenues $ 19,222 $ 22,282 $ 62,034 $ 59,916
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) - Contingent Consideration Liability - Fair Value, Inputs, Level 3 - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Arkis    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period $ 15,755 $ 12,895
Change in fair value of contingent consideration liabilities (3,019) 1,991
Balance, End of Period 12,736 14,886
Arkis | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 8,320 4,373
Arkis | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 4,416 10,513
Derma Sciences    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 2,557 230
Change in fair value of contingent consideration liabilities 137 1,887
Balance, End of Period 2,694 2,117
Derma Sciences | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 0 0
Derma Sciences | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 2,694 2,117
ACell    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 300 3,700
Change in fair value of contingent consideration liabilities 0 (2,200)
Balance, End of Period 300 1,500
ACell | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 0 503
ACell | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 300 997
Surgical Innovation Associates, Inc.    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 68,700 57,600
Payment (12,400)  
Change in fair value of contingent consideration liabilities 3,100 6,600
Balance, End of Period 59,400 64,200
Surgical Innovation Associates, Inc. | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 19,600 13,000
Surgical Innovation Associates, Inc. | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period $ 39,800 $ 51,200
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 06, 2022
USD ($)
payment
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
liability
Sep. 30, 2023
USD ($)
Jan. 20, 2021
USD ($)
Jul. 29, 2019
USD ($)
Loss Contingencies [Line Items]              
Payment for contingent consideration       $ 11,923 $ 0    
Arkis              
Loss Contingencies [Line Items]              
Contingent consideration, estimated fair value             $ 25,500
Contingent consideration             13,100
Arkis | Development Milestones              
Loss Contingencies [Line Items]              
Contingent consideration, estimated fair value             10,000
Arkis | Commercial Sales Milestones              
Loss Contingencies [Line Items]              
Contingent consideration, estimated fair value             $ 15,500
Derma Sciences              
Loss Contingencies [Line Items]              
Number of contingent liabilities remaining | liability       1      
Contingent consideration, maximum undiscounted payment amount       $ 3,000      
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments              
Loss Contingencies [Line Items]              
Payment for contingent consideration       $ 33,300      
ACell, Inc.              
Loss Contingencies [Line Items]              
Contingent consideration           $ 23,900  
Number of contingent liabilities remaining | liability       1      
Contingent consideration, maximum undiscounted payment amount           $ 100,000  
Surgical Innovation Associates, Inc.              
Loss Contingencies [Line Items]              
Contingent consideration, maximum undiscounted payment amount $ 90,000            
Number of contingent liabilities | payment 2            
Surgical Innovation Associates, Inc. | Revenue Based Performance Milestones              
Loss Contingencies [Line Items]              
Contingent consideration, estimated fair value $ 32,600            
Payment for contingent consideration     $ 12,400        
Contingent consideration, maximum undiscounted payment amount 50,000            
Surgical Innovation Associates, Inc. | FDA Approval Of Premarket Approval              
Loss Contingencies [Line Items]              
Contingent consideration, estimated fair value 25,000            
Contingent consideration, maximum undiscounted payment amount $ 40,000            
Plainsboro, New Jersey Manufacturing Facility | Forecast              
Loss Contingencies [Line Items]              
Purchase price of business acquisition   $ 10,000          
EXCEL 91 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 92 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 93 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 95 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 508 376 1 false 125 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://integralife.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) Statements 6 false false R7.htm 9952156 - Disclosure - BASIS OF PRESENTATION Sheet http://integralife.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 7 false false R8.htm 9952157 - Disclosure - ACQUISITIONS AND DIVESTITURES Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURES ACQUISITIONS AND DIVESTITURES Notes 8 false false R9.htm 9952158 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS Notes 9 false false R10.htm 9952159 - Disclosure - INVENTORIES Sheet http://integralife.com/role/INVENTORIES INVENTORIES Notes 10 false false R11.htm 9952160 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 11 false false R12.htm 9952161 - Disclosure - DEBT Sheet http://integralife.com/role/DEBT DEBT Notes 12 false false R13.htm 9952162 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTS DERIVATIVE INSTRUMENTS Notes 13 false false R14.htm 9952163 - Disclosure - STOCK-BASED COMPENSATION Sheet http://integralife.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 14 false false R15.htm 9952164 - Disclosure - RETIREMENT PLANS Sheet http://integralife.com/role/RETIREMENTPLANS RETIREMENT PLANS Notes 15 false false R16.htm 9952165 - Disclosure - LEASES AND RELATED PARTY LEASES Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASES LEASES AND RELATED PARTY LEASES Notes 16 false false R17.htm 9952166 - Disclosure - TREASURY STOCK Sheet http://integralife.com/role/TREASURYSTOCK TREASURY STOCK Notes 17 false false R18.htm 9952167 - Disclosure - INCOME TAXES Sheet http://integralife.com/role/INCOMETAXES INCOME TAXES Notes 18 false false R19.htm 9952168 - Disclosure - NET INCOME PER SHARE Sheet http://integralife.com/role/NETINCOMEPERSHARE NET INCOME PER SHARE Notes 19 false false R20.htm 9952169 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOME ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Notes 20 false false R21.htm 9952170 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION SEGMENT AND GEOGRAPHIC INFORMATION Notes 21 false false R22.htm 9952171 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://integralife.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables ACQUISITIONS AND DIVESTITURES (Tables) Tables http://integralife.com/role/ACQUISITIONSANDDIVESTITURES 26 false false R27.htm 9954473 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Tables http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS 27 false false R28.htm 9954474 - Disclosure - INVENTORIES (Tables) Sheet http://integralife.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://integralife.com/role/INVENTORIES 28 false false R29.htm 9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 29 false false R30.htm 9954476 - Disclosure - DEBT (Tables) Sheet http://integralife.com/role/DEBTTables DEBT (Tables) Tables http://integralife.com/role/DEBT 30 false false R31.htm 9954477 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSTables DERIVATIVE INSTRUMENTS (Tables) Tables http://integralife.com/role/DERIVATIVEINSTRUMENTS 31 false false R32.htm 9954478 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables LEASES AND RELATED PARTY LEASES (Tables) Tables http://integralife.com/role/LEASESANDRELATEDPARTYLEASES 32 false false R33.htm 9954479 - Disclosure - INCOME TAXES (Tables) Sheet http://integralife.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://integralife.com/role/INCOMETAXES 33 false false R34.htm 9954480 - Disclosure - NET INCOME PER SHARE (Tables) Sheet http://integralife.com/role/NETINCOMEPERSHARETables NET INCOME PER SHARE (Tables) Tables http://integralife.com/role/NETINCOMEPERSHARE 34 false false R35.htm 9954481 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables) Tables http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOME 35 false false R36.htm 9954482 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Tables http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION 36 false false R37.htm 9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://integralife.com/role/COMMITMENTSANDCONTINGENCIES 37 false false R38.htm 9954484 - Disclosure - BASIS OF PRESENTATION - Narrative (Details) Sheet http://integralife.com/role/BASISOFPRESENTATIONNarrativeDetails BASIS OF PRESENTATION - Narrative (Details) Details 38 false false R39.htm 9954485 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails ACQUISITIONS AND DIVESTITURES - Narrative (Details) Details 39 false false R40.htm 9954486 - Disclosure - ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details) Details 40 false false R41.htm 9954487 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Details 41 false false R42.htm 9954488 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) Details 42 false false R43.htm 9954489 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) Details 43 false false R44.htm 9954490 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) Details 44 false false R45.htm 9954491 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details) Sheet http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails INVENTORIES - Schedule of Net Inventories (Details) Details 45 false false R46.htm 9954492 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 46 false false R47.htm 9954493 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) Details 47 false false R48.htm 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 48 false false R49.htm 9954495 - Disclosure - DEBT - Narrative (Details) Sheet http://integralife.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 49 false false R50.htm 9954496 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details) Sheet http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails DEBT - Maximum Total Leverage Ratio Table (Details) Details 50 false false R51.htm 9954497 - Disclosure - DEBT - Contractual Maturity Table (Details) Sheet http://integralife.com/role/DEBTContractualMaturityTableDetails DEBT - Contractual Maturity Table (Details) Details 51 false false R52.htm 9954498 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) Details 52 false false R53.htm 9954499 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails DERIVATIVE INSTRUMENTS - Narrative (Details) Details 53 false false R54.htm 9954500 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) Details 54 false false R55.htm 9954501 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) Details 55 false false R56.htm 9954502 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) Details 56 false false R57.htm 9954503 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) Details 57 false false R58.htm 9954504 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) Details 58 false false R59.htm 9954505 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 59 false false R60.htm 9954506 - Disclosure - RETIREMENT PLANS - Narrative (Details) Sheet http://integralife.com/role/RETIREMENTPLANSNarrativeDetails RETIREMENT PLANS - Narrative (Details) Details 60 false false R61.htm 9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails LEASES AND RELATED PARTY LEASES - Narrative (Details) Details 61 false false R62.htm 9954508 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Details 62 false false R63.htm 9954509 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Details 63 false false R64.htm 9954510 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) Details 64 false false R65.htm 9954511 - Disclosure - TREASURY STOCK - Narrative (Details) Sheet http://integralife.com/role/TREASURYSTOCKNarrativeDetails TREASURY STOCK - Narrative (Details) Details 65 false false R66.htm 9954512 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details) Sheet http://integralife.com/role/INCOMETAXESSummaryofEffectiveTaxRateDetails INCOME TAXES - Summary of Effective Tax Rate (Details) Details 66 false false R67.htm 9954513 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://integralife.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 67 false false R68.htm 9954514 - Disclosure - NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) Sheet http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) Details 68 false false R69.htm 9954515 - Disclosure - NET INCOME PER SHARE - Narrative (Details) Sheet http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails NET INCOME PER SHARE - Narrative (Details) Details 69 false false R70.htm 9954516 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Income (Loss) (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Income (Loss) (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables 70 false false R71.htm 9954517 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables 71 false false R72.htm 9954518 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Narrative (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Narrative (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables 72 false false R73.htm 9954519 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) Details 73 false false R74.htm 9954520 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) Details 74 false false R75.htm 9954521 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) Details 75 false false R76.htm 9954522 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Details 76 false false R77.htm 9954523 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 77 false false All Reports Book All Reports iart-20240930.htm iart-20240930.xsd iart-20240930_cal.xml iart-20240930_def.xml iart-20240930_lab.xml iart-20240930_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 98 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "iart-20240930.htm": { "nsprefix": "iart", "nsuri": "http://integralife.com/20240930", "dts": { "inline": { "local": [ "iart-20240930.htm" ] }, "schema": { "local": [ "iart-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "iart-20240930_cal.xml" ] }, "definitionLink": { "local": [ "iart-20240930_def.xml" ] }, "labelLink": { "local": [ "iart-20240930_lab.xml" ] }, "presentationLink": { "local": [ "iart-20240930_pre.xml" ] } }, "keyStandard": 316, "keyCustom": 60, "axisStandard": 38, "axisCustom": 1, "memberStandard": 62, "memberCustom": 60, "hidden": { "total": 7, "http://fasb.org/us-gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 508, "entityCount": 1, "segmentCount": 125, "elementCount": 758, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1195, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://integralife.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R3": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R4": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R6": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-49", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R7": { "role": "http://integralife.com/role/BASISOFPRESENTATION", "longName": "9952156 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURES", "longName": "9952157 - Disclosure - ACQUISITIONS AND DIVESTITURES", "shortName": "ACQUISITIONS AND DIVESTITURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS", "longName": "9952158 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://integralife.com/role/INVENTORIES", "longName": "9952159 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "9952160 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://integralife.com/role/DEBT", "longName": "9952161 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTS", "longName": "9952162 - Disclosure - DERIVATIVE INSTRUMENTS", "shortName": "DERIVATIVE INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://integralife.com/role/STOCKBASEDCOMPENSATION", "longName": "9952163 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://integralife.com/role/RETIREMENTPLANS", "longName": "9952164 - Disclosure - RETIREMENT PLANS", "shortName": "RETIREMENT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASES", "longName": "9952165 - Disclosure - LEASES AND RELATED PARTY LEASES", "shortName": "LEASES AND RELATED PARTY LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://integralife.com/role/TREASURYSTOCK", "longName": "9952166 - Disclosure - TREASURY STOCK", "shortName": "TREASURY STOCK", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://integralife.com/role/INCOMETAXES", "longName": "9952167 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://integralife.com/role/NETINCOMEPERSHARE", "longName": "9952168 - Disclosure - NET INCOME PER SHARE", "shortName": "NET INCOME PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOME", "longName": "9952169 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME", "shortName": "ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION", "longName": "9952170 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952171 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://integralife.com/role/BASISOFPRESENTATIONPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION (Policies)", "shortName": "BASIS OF PRESENTATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables", "longName": "9954472 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables)", "shortName": "ACQUISITIONS AND DIVESTITURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables", "longName": "9954473 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://integralife.com/role/INVENTORIESTables", "longName": "9954474 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://integralife.com/role/DEBTTables", "longName": "9954476 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables", "longName": "9954477 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables", "longName": "9954478 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables)", "shortName": "LEASES AND RELATED PARTY LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://integralife.com/role/INCOMETAXESTables", "longName": "9954479 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://integralife.com/role/NETINCOMEPERSHARETables", "longName": "9954480 - Disclosure - NET INCOME PER SHARE (Tables)", "shortName": "NET INCOME PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables", "longName": "9954481 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables", "longName": "9954482 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables", "longName": "9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://integralife.com/role/BASISOFPRESENTATIONNarrativeDetails", "longName": "9954484 - Disclosure - BASIS OF PRESENTATION - Narrative (Details)", "shortName": "BASIS OF PRESENTATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "longName": "9954485 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-100", "name": "iart:PaymentsForAssetAcquisitions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-100", "name": "iart:PaymentsForAssetAcquisitions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "longName": "9954486 - Disclosure - ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R41": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "longName": "9954487 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails", "longName": "9954488 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails", "longName": "9954489 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-101", "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-101", "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "longName": "9954490 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R45": { "role": "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails", "longName": "9954491 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details)", "shortName": "INVENTORIES - Schedule of Net Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "longName": "9954492 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R47": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "longName": "9954493 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://integralife.com/role/DEBTNarrativeDetails", "longName": "9954495 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:SecuredDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "iart:InterestPaymentsReminderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R50": { "role": "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "longName": "9954496 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details)", "shortName": "DEBT - Maximum Total Leverage Ratio Table (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-180", "name": "iart:DebtInstrumentCovenantMaximumLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "iart:DebtInstrumentCovenantMaximumLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://integralife.com/role/DEBTContractualMaturityTableDetails", "longName": "9954497 - Disclosure - DEBT - Contractual Maturity Table (Details)", "shortName": "DEBT - Contractual Maturity Table (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "longName": "9954498 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-227", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R53": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "longName": "9954499 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-261", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R54": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "longName": "9954500 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-237", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-241", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R55": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails", "longName": "9954501 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-237", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-268", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R56": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "longName": "9954502 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-318", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-318", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "longName": "9954503 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-38", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-341", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R58": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails", "longName": "9954504 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954505 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails", "longName": "9954506 - Disclosure - RETIREMENT PLANS - Narrative (Details)", "shortName": "RETIREMENT PLANS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails", "longName": "9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "unitRef": "renewaloption", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "unitRef": "renewaloption", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails", "longName": "9954508 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-392", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R63": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails", "longName": "9954509 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "longName": "9954510 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://integralife.com/role/TREASURYSTOCKNarrativeDetails", "longName": "9954511 - Disclosure - TREASURY STOCK - Narrative (Details)", "shortName": "TREASURY STOCK - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R66": { "role": "http://integralife.com/role/INCOMETAXESSummaryofEffectiveTaxRateDetails", "longName": "9954512 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details)", "shortName": "INCOME TAXES - Summary of Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": null }, "R67": { "role": "http://integralife.com/role/INCOMETAXESNarrativeDetails", "longName": "9954513 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R68": { "role": "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails", "longName": "9954514 - Disclosure - NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details)", "shortName": "NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R69": { "role": "http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails", "longName": "9954515 - Disclosure - NET INCOME PER SHARE - Narrative (Details)", "shortName": "NET INCOME PER SHARE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-411", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-411", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails", "longName": "9954516 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Income (Loss) (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R71": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "longName": "9954517 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-38", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R72": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "longName": "9954518 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Narrative (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-422", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R73": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "longName": "9954519 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R74": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "longName": "9954520 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-432", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R75": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails", "longName": "9954521 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-440", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } }, "R76": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "longName": "9954522 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-456", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-456", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true, "unique": true } }, "R77": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "longName": "9954523 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-496", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240930.htm", "unique": true } } }, "tag": { "iart_A2023ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "A2023ShareRepurchaseProgramMember", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Share Repurchase Program", "label": "2023 Share Repurchase Program [Member]", "documentation": "2023 Share Repurchase Program" } } }, "auth_ref": [] }, "iart_ACellIncMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "ACellIncMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ACell, Inc.", "label": "ACell, Inc. [Member]", "documentation": "ACell, Inc." } } }, "auth_ref": [] }, "iart_ACellMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "ACellMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ACell", "label": "ACell [Member]", "documentation": "ACell" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Roll Forward]", "verboseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "iart_AcceleratedShareRepurchasesAdditionalSharesReceived": { "xbrltype": "sharesItemType", "nsuri": "http://integralife.com/20240930", "localname": "AcceleratedShareRepurchasesAdditionalSharesReceived", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, additional shares received (in shares)", "label": "Accelerated Share Repurchases, Additional Shares Received", "documentation": "Accelerated Share Repurchases, Additional Shares Received" } } }, "auth_ref": [] }, "iart_AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, percentage of expected total repurchased", "label": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased", "documentation": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased" } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "crdr": "debit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchase program, receipt (payment)", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement." } } }, "auth_ref": [ "r150" ] }, "iart_AcceleratedShareRepurchasesSharesReceivedAtInception": { "xbrltype": "sharesItemType", "nsuri": "http://integralife.com/20240930", "localname": "AcceleratedShareRepurchasesSharesReceivedAtInception", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, shares received at inception (in shares)", "label": "Accelerated Share Repurchases, Shares Received at Inception", "documentation": "Accelerated Share Repurchases, Shares Received at Inception" } } }, "auth_ref": [] }, "iart_AcclarentInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "AcclarentInc.Member", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acclarent Inc.", "label": "Acclarent Inc. [Member]", "documentation": "Acclarent Inc." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, trade", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r90" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net of allowances of $7,423 and $4,879", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1051" ] }, "iart_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities [Member]", "documentation": "Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Pension Items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r6", "r7", "r16", "r30", "r117", "r1024", "r1025", "r1026" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains and Losses on Derivatives", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r243", "r251", "r252", "r562", "r837", "r1024" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r251", "r598", "r599", "r600", "r601", "r602", "r603" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r29", "r30", "r118", "r234", "r681", "r720", "r721" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r250", "r251", "r598", "r599", "r600", "r601", "r602", "r603" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "terseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r16", "r30", "r571", "r574", "r622", "r716", "r717", "r1024", "r1025", "r1026", "r1037", "r1038", "r1039", "r1041" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Items", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r16", "r30", "r115", "r116", "r251", "r252", "r599", "r600", "r601", "r602", "r603", "r1024" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r359", "r360", "r361", "r363", "r824" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life", "verboseLabel": "Estimated useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r361", "r824" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r955" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r104" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r735", "r1037", "r1038", "r1039", "r1041", "r1116", "r1187" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r968" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r968" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r968" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r968" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r12" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r55", "r56", "r496" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1001" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r927", "r937", "r947", "r979" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r930", "r940", "r950", "r982" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1002" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r968" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r975" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r931", "r941", "r951", "r975", "r983", "r987", "r995" ] }, "iart_AllOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "AllOtherMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other", "label": "All Other [Member]", "documentation": "All Other [Member]" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r993" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, allowance", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r235", "r335", "r339" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iart_AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs and expenses associated with debt refinancing", "label": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees", "documentation": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization", "negatedTerseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r12", "r358", "r365", "r852" ] }, "iart_AnnualRateOfLeaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "AnnualRateOfLeaseAgreement", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual rate of lease agreement", "label": "Annual Rate Of Lease Agreement", "documentation": "Annual rate of lease agreement." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares excluded from computation as their effect would be antidilutive (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r293" ] }, "iart_ArkisBioSciencesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "ArkisBioSciencesInc.Member", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arkis", "label": "Arkis BioSciences Inc. [Member]", "documentation": "Arkis BioSciences Inc. [Member]" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific", "label": "Asia Pacific [Member]", "documentation": "Region of Asia Pacific." } } }, "auth_ref": [ "r1013", "r1014", "r1015", "r1016", "r1189", "r1190", "r1191", "r1192" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r363", "r1108" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r879", "r1109", "r1110", "r1111" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r363", "r1108" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r12", "r42" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r162", "r174", "r230", "r260", "r297", "r304", "r322", "r326", "r336", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r560", "r563", "r596", "r676", "r762", "r845", "r846", "r890", "r918", "r1095", "r1096", "r1142" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "iart_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://integralife.com/20240930", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r224", "r239", "r260", "r336", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r560", "r563", "r596", "r890", "r1095", "r1096", "r1142" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r990" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r991" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r986" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r989" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r988" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r987" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r987" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r379", "r1152", "r1153" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r73", "r76", "r379", "r1152", "r1153" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "iart_BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioD Earnout Payments and Medihoney Earnout Payments", "label": "BioD Earnout Payments and Medihoney Earnout Payments [Member]", "documentation": "BioD Earnout Payments and Medihoney Earnout Payments [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased facilities", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r138" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r359", "r360", "r361", "r362", "r363", "r555", "r873", "r874" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r57", "r59", "r359", "r360", "r361", "r362", "r363", "r555", "r873", "r874" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r555" ] }, "iart_BusinessAcquisitionNumberOfContingentLiabilities": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessAcquisitionNumberOfContingentLiabilities", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of contingent liabilities", "label": "Business Acquisition, Number Of Contingent Liabilities", "documentation": "Business Acquisition, Number Of Contingent Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of business combination", "verboseLabel": "Purchase price of business acquisition", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r15" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration and others", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r557", "r1030" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, maximum undiscounted payment amount", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r66" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration, estimated fair value", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r65", "r153", "r556", "r582", "r583", "r584" ] }, "iart_BusinessCombinationContingentConsiderationNumberOfLiabilities": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationContingentConsiderationNumberOfLiabilities", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of contingent liabilities remaining", "label": "Business Combination, Contingent Consideration, Number Of Liabilities", "documentation": "Business Combination, Contingent Consideration, Number Of Liabilities" } } }, "auth_ref": [] }, "iart_BusinessCombinationIntangibleAssetAcquiredDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationIntangibleAssetAcquiredDiscountRate", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset acquired, discount rate (percent)", "label": "Business Combination, Intangible Asset Acquired, Discount Rate", "documentation": "Business Combination, Intangible Asset Acquired, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue of acquiree since acquisition date", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final working capital adjustment", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r62" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability", "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date." } } }, "auth_ref": [ "r60", "r61" ] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract With Customer, Liability, Current", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract With Customer, Liability, Current" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable, trade", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities" } } }, "auth_ref": [] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesEmployeeRelatedLiabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Employee-related Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Employee-related Liabilities" } } }, "auth_ref": [] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiabilityOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiabilityOperatingLeases", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of lease liability - operating leases", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability, Operating Leases", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Lease Liability, Operating Leases" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r61" ] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiabilityOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiabilityOperatingLeases", "crdr": "credit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability - operating leases", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r60", "r61" ] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetOperatingLeases", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset - operating leases", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r61" ] }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill" } } }, "auth_ref": [] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CallOptionMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Call Option", "label": "Call Option [Member]", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r801", "r802" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONNarrativeDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r226", "r829" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r37" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r133", "r258" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r133" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r70" ] }, "iart_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240930", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee [Abstract]" } } }, "auth_ref": [] }, "iart_CashFlowLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://integralife.com/20240930", "localname": "CashFlowLesseeTableTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Lessee [Table Text Block]", "documentation": "Cash Flow, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "iart_ChangeInContractWithCustomerAssetRollForward": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240930", "localname": "ChangeInContractWithCustomerAssetRollForward", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Asset", "label": "Change In Contract With Customer, Asset [Roll Forward]", "documentation": "Change In Contract With Customer, Asset [Roll Forward]" } } }, "auth_ref": [] }, "iart_ChangeInContractWithCustomerLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240930", "localname": "ChangeInContractWithCustomerLiabilityRollForward", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liability", "label": "Change In Contract With Customer, Liability [Roll Forward]", "documentation": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r966" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r1050" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r963" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r961" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r231", "r232", "r233", "r299", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r729", "r730", "r731", "r732", "r859", "r1005", "r1032" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant strike price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r439" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r967" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r967" ] }, "iart_CodmanMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CodmanMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Codman", "label": "Codman [Member]", "documentation": "Codman [Member]" } } }, "auth_ref": [] }, "iart_CodmanSpecialtySurgicalMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CodmanSpecialtySurgicalMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Codman Specialty Surgical", "verboseLabel": "Codman Specialty Surgical", "label": "Codman Specialty Surgical [Member]", "documentation": "Codman Specialty Surgical [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r140", "r383", "r384", "r812", "r1081", "r1086" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r906", "r907", "r908", "r910", "r911", "r912", "r915", "r1037", "r1038", "r1041", "r1116", "r1185", "r1187" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r103" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized shares (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r103", "r750" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued shares (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r103" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.01 par value; 240,000 authorized shares; 91,588 and 90,920 issued at September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r103", "r680", "r890" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r972" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r971" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r973" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r970" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "iart_CompletedTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CompletedTechnologyMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed technology", "label": "Completed Technology [Member]", "documentation": "Completed technology." } } }, "auth_ref": [] }, "iart_CompletedTechnologyPriMatrixMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CompletedTechnologyPriMatrixMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed Technology, PriMatrix", "label": "Completed Technology, PriMatrix [Member]", "documentation": "Completed Technology, PriMatrix" } } }, "auth_ref": [] }, "iart_CompletedTechnologySurgiMendMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CompletedTechnologySurgiMendMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed Technology, Surgimend", "label": "Completed Technology, SurgiMend [Member]", "documentation": "Completed Technology, SurgiMend" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (See Note 14)", "totalLabel": "Comprehensive (loss) income, net", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r31", "r247", "r249", "r254", "r671", "r689", "r690" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r113", "r253", "r670", "r688" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r172", "r180", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r266", "r297", "r306", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r845", "r846", "r1017", "r1018", "r1095", "r1096" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r172", "r180", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r266", "r297", "r306", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r845", "r846", "r1017", "r1018", "r1095", "r1096" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "iart_ContingentConsiderationLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "ContingentConsiderationLiabilityMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Member]", "documentation": "Contingent Consideration Liability [Member]" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Contract Assets and Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1101" ] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract asset, beginning of period", "periodEndLabel": "Contract asset, end of Period", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r442", "r444", "r463" ] }, "iart_ContractWithCustomerAssetNetOfReclassifiedToReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "ContractWithCustomerAssetNetOfReclassifiedToReceivable", "crdr": "debit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract asset, net of transferred to trade receivables on contracts during the period", "label": "Contract With Customer, Asset, Net Of Reclassified To Receivable", "documentation": "Contract With Customer, Asset, Net Of Reclassified To Receivable" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transferred to trade receivable from contract asset included in beginning of the year contract asset", "label": "Contract with Customer, Asset, Reclassified to Receivable", "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional." } } }, "auth_ref": [ "r861" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract liability, beginning of period", "periodEndLabel": "Contract liability, end of period", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r442", "r443", "r463" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "verboseLabel": "Short-term portion of contract liability", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r442", "r443", "r463" ] }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liability, acquired with Acclarent", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination." } } }, "auth_ref": [ "r860" ] }, "iart_ContractWithCustomerLiabilityIncreaseDecreaseFromForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "ContractWithCustomerLiabilityIncreaseDecreaseFromForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation", "documentation": "Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation" } } }, "auth_ref": [] }, "iart_ContractWithCustomerLiabilityNetOfRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "ContractWithCustomerLiabilityNetOfRevenueRecognized", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of revenue included in beginning of year contract liability", "label": "Contract With Customer, Liability, Net Of Revenue Recognized", "documentation": "Contract With Customer, Liability, Net Of Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term portion of contract liability", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r442", "r443", "r463" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liability, net of revenue recognized on contracts during the period", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible securities", "label": "Convertible Debt, Current", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r142", "r405", "r406", "r416", "r417", "r418", "r422", "r423", "r424", "r425", "r426", "r854", "r855", "r856", "r857", "r858" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term convertible securities", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r26" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r21", "r321", "r322", "r323", "r324", "r327", "r1046" ] }, "iart_CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill", "documentation": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r120", "r121", "r636" ] }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldAmortization", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost, amortization", "label": "Cost, Amortization", "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service." } } }, "auth_ref": [ "r1027" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r127" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r215", "r216", "r264", "r265", "r408", "r434", "r626", "r633", "r675", "r834", "r836" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r392", "r1093" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r392", "r1093", "r1094" ] }, "iart_CrossCurrencyInterestRateContractFourMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CrossCurrencyInterestRateContractFourMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap Four", "label": "Cross Currency Interest Rate Contract Four [Member]", "documentation": "Cross Currency Interest Rate Contract Four" } } }, "auth_ref": [] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency swap", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1103", "r1114" ] }, "iart_CrossCurrencyInterestRateContractOneMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CrossCurrencyInterestRateContractOneMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap One", "label": "Cross Currency Interest Rate Contract One [Member]", "documentation": "Cross Currency Interest Rate Contract One [Member]" } } }, "auth_ref": [] }, "iart_CrossCurrencyInterestRateContractThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CrossCurrencyInterestRateContractThreeMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap Three", "label": "Cross Currency Interest Rate Contract Three [Member]", "documentation": "Cross Currency Interest Rate Contract Three [Member]" } } }, "auth_ref": [] }, "iart_CrossCurrencyInterestRateContractTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "CrossCurrencyInterestRateContractTwoMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap Two", "label": "Cross Currency Interest Rate Contract Two [Member]", "documentation": "Cross Currency Interest Rate Contract Two [Member]" } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency swaps", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Customer relationships", "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r64", "r1066", "r1067", "r1068", "r1069", "r1071", "r1073", "r1076", "r1077" ] }, "iart_DebtCovenantPeriod1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtCovenantPeriod1Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 31, 2023 through September 30, 2024", "label": "Debt Covenant Period 1 [Member]", "documentation": "Debt Covenant Period 1" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriod2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtCovenantPeriod2Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 31, 2024 through September 30, 2025", "label": "Debt Covenant Period 2 [Member]", "documentation": "Debt Covenant Period 2" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriod3Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtCovenantPeriod3Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 31, 2025 through June 30, 2026", "label": "Debt Covenant Period 3 [Member]", "documentation": "Debt Covenant Period 3 [Member]" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriod4Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtCovenantPeriod4Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "September 30, 2026 and the last day of each fiscal quarter thereafter", "label": "Debt Covenant Period 4 [Member]", "documentation": "Debt Covenant Period 4" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtCovenantPeriodAxis", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "documentation": "Debt Covenant Period [Axis]" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtCovenantPeriodDomain", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Period [Domain]", "label": "Debt Covenant Period [Domain]", "documentation": "[Domain] for Debt Covenant Period [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://integralife.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r141", "r259", "r374", "r375", "r376", "r377", "r378", "r391", "r392", "r404", "r410", "r411", "r412", "r413", "r414", "r415", "r420", "r427", "r428", "r430", "r605" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r26", "r92", "r93", "r163", "r164", "r266", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r854", "r855", "r856", "r857", "r858", "r888", "r1033", "r1082", "r1083", "r1084", "r1134", "r1135" ] }, "iart_DebtInstrumentBasisSpreadAdjustmentOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtInstrumentBasisSpreadAdjustmentOnVariableRate", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate adjustment", "label": "Debt Instrument, Basis Spread Adjustment On Variable Rate", "documentation": "Debt Instrument, Basis Spread Adjustment On Variable Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rates available", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "iart_DebtInstrumentCombinationSettlementForDebtConversionMinimumSettledInCashPerPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtInstrumentCombinationSettlementForDebtConversionMinimumSettledInCashPerPrincipalAmount", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum settled in cash per principal amount", "label": "Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount", "documentation": "Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r143", "r407" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion rate", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r48", "r96", "r146", "r147", "r407" ] }, "iart_DebtInstrumentCovenantMaximumLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtInstrumentCovenantMaximumLeverageRatio", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum Consolidated Total Leverage Ratio", "label": "Debt Instrument, Covenant, Maximum Leverage Ratio", "documentation": "Debt Instrument, Covenant, Maximum Leverage Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, maximum borrowing capacity", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r405", "r605", "r606", "r855", "r856", "r888" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r418", "r595", "r855", "r856", "r1117", "r1118", "r1119", "r1120", "r1127" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r95", "r406" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r266", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r854", "r855", "r856", "r857", "r858", "r888", "r1033", "r1134", "r1135" ] }, "iart_DebtInstrumentMaximumAverageConversionValueOfNotes": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtInstrumentMaximumAverageConversionValueOfNotes", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum average conversion value of notes", "label": "Debt Instrument, Maximum Average Conversion Value Of Notes", "documentation": "Debt Instrument, Maximum Average Conversion Value Of Notes" } } }, "auth_ref": [] }, "iart_DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum selling price of the company's common stock of the conversion price", "label": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period", "documentation": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r26", "r266", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r854", "r855", "r856", "r857", "r858", "r888", "r1033", "r1082", "r1083", "r1084", "r1134", "r1135" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price, percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r170" ] }, "iart_DebtInstrumentSecuritizationFacilityAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtInstrumentSecuritizationFacilityAgreementTerm", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, securitization facility, agreement term (in years)", "label": "Debt Instrument, Securitization Facility, Agreement Term", "documentation": "Debt Instrument, Securitization Facility, Agreement Term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r26", "r48", "r51", "r87", "r145", "r147", "r266", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r854", "r855", "r856", "r857", "r858", "r888", "r1033", "r1134", "r1135" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate on debt", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "iart_DebtWeightedAverageInterestRateFromSecuritization": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "DebtWeightedAverageInterestRateFromSecuritization", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate, accounts receivable securitization revolving loan facility", "label": "Debt, Weighted Average Interest Rate, From Securitization", "documentation": "Debt, Weighted Average Interest Rate, From Securitization" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation plan, fair value of assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r1021" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental financing costs capitalized", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1134", "r1135" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs capitalized", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1098", "r1133", "r1134", "r1135" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r533", "r534" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax (benefit) provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r12", "r177", "r1035" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r533", "r534", "r677" ] }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defer payment and taxation, base salary, percentage (up to)", "label": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage", "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage" } } }, "auth_ref": [] }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to)", "label": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage", "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of plan assets", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r468", "r470", "r472", "r473", "r869", "r870", "r871" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit costs", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r478", "r487", "r871", "r872" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Service cost component", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r467", "r479", "r488", "r871", "r872" ] }, "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill", "documentation": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "verboseLabel": "Derivative, Name [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r740", "r742", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r776", "r777", "r778", "r779", "r782", "r783", "r784", "r785", "r802", "r803", "r806", "r807", "r906", "r908", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1128", "r1129" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivatives designated as hedges \u2014 Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r23", "r112", "r157", "r158", "r240", "r836" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivatives designated as hedges \u2014 Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r23", "r112", "r157", "r158", "r240", "r836" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated Fair Value", "terseLabel": "Fair Value Asset (Liability)", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r595" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Interest Rate", "verboseLabel": "Fixed Rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "verboseLabel": "Derivative, by Nature [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r74", "r77", "r79", "r159", "r740", "r742", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r776", "r777", "r778", "r779", "r782", "r783", "r784", "r785", "r802", "r803", "r806", "r807", "r836", "r906", "r908", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1128", "r1129" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r156", "r568", "r576" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r18", "r74", "r77" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r18", "r74", "r77", "r79", "r82", "r83", "r567" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r567" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r78", "r1011" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r576" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notional Amount", "terseLabel": "Current notional amount", "netLabel": "Aggregate Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1112", "r1113" ] }, "iart_DerivativeNotionalAmountSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "DerivativeNotionalAmountSettled", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount settled", "label": "Derivative, Notional Amount, Settled", "documentation": "Derivative, Notional Amount, Settled" } } }, "auth_ref": [] }, "iart_DerivativeNotionalAmountTerminated": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "DerivativeNotionalAmountTerminated", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount terminated", "label": "Derivative, Notional Amount, Terminated", "documentation": "Derivative, Notional Amount, Terminated" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r18", "r67", "r68", "r69", "r72", "r75", "r77", "r80", "r81", "r83", "r576" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "iart_DermaSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DermaSciencesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derma Sciences", "label": "Derma Sciences [Member]", "documentation": "Derma Sciences [Member]" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesAbstract", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r1019", "r1050", "r1186" ] }, "iart_DirectorsandCertainExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DirectorsandCertainExecutiveOfficersMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors and Certain Executive Officers", "label": "Directors and Certain Executive Officers [Member]", "documentation": "Directors and Certain Executive Officers [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462", "r862", "r863", "r864", "r865", "r866", "r867", "r868" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r462", "r862", "r863", "r864", "r865", "r866", "r867", "r868" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1102" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r494", "r499", "r526", "r527", "r530", "r876" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r922" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r954" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "iart_DurepairRegenerationMatrixMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "DurepairRegenerationMatrixMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Durepair Regeneration Matrix", "label": "Durepair Regeneration Matrix [Member]", "documentation": "Durepair Regeneration Matrix" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r965" ] }, "iart_ENTMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "ENTMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ENT", "label": "ENT [Member]", "documentation": "ENT" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Net (loss) income per share", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net (loss) income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r255", "r272", "r273", "r274", "r275", "r276", "r277", "r283", "r285", "r290", "r291", "r292", "r296", "r553", "r559", "r578", "r579", "r672", "r691", "r838" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net (loss) income per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net (loss) income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r255", "r272", "r273", "r274", "r275", "r276", "r277", "r285", "r290", "r291", "r292", "r296", "r553", "r559", "r578", "r579", "r672", "r691", "r838" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net (loss) income per share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET INCOME PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r282", "r293", "r294", "r295" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r597" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails", "http://integralife.com/role/INCOMETAXESSummaryofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reported tax rate", "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r536", "r878" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit from excess tax benefits from share-based payment arrangement", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1008", "r1106", "r1107" ] }, "iart_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "EmployeeMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees", "label": "Employee [Member]", "documentation": "Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r529" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period for cost recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r529" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity City", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity State", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r920" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r920" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r920" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1004" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r920" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r920" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r920" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r920" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1000" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1000" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1000" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r221", "r250", "r251", "r252", "r267", "r268", "r269", "r271", "r276", "r278", "r280", "r298", "r337", "r338", "r371", "r440", "r543", "r544", "r550", "r551", "r552", "r554", "r558", "r559", "r570", "r571", "r572", "r573", "r574", "r575", "r577", "r598", "r599", "r600", "r601", "r602", "r603", "r607", "r609", "r622", "r688", "r716", "r717", "r718", "r735", "r788" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r969" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r927", "r937", "r947", "r979" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r924", "r934", "r944", "r976" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r1013", "r1014", "r1015", "r1016", "r1189", "r1190", "r1191", "r1192" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r975" ] }, "us-gaap_ExtendedProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExtendedProductWarrantyPolicy", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Product Warranties", "label": "Extended Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability." } } }, "auth_ref": [ "r1092" ] }, "iart_FDAApprovalOfPremarketApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "FDAApprovalOfPremarketApprovalMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FDA Approval Of Premarket Approval", "label": "FDA Approval Of Premarket Approval [Member]", "documentation": "FDA Approval Of Premarket Approval" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r418", "r472", "r473", "r474", "r475", "r476", "r477", "r580", "r581", "r582", "r583", "r584", "r591", "r592", "r594", "r628", "r629", "r630", "r855", "r856", "r869", "r870", "r871", "r880", "r884" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r593" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r418", "r472", "r477", "r581", "r582", "r592", "r629", "r855", "r856", "r869", "r870", "r871", "r880" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r418", "r472", "r473", "r474", "r475", "r476", "r477", "r581", "r582", "r583", "r584", "r592", "r630", "r855", "r856", "r869", "r870", "r871", "r880", "r884" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r593" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r593" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contingent Consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r585", "r590", "r593" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration liabilities", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r586", "r593" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r588", "r593" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, Beginning of Period", "periodEndLabel": "Balance, End of Period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r585", "r593" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r418", "r472", "r473", "r474", "r475", "r476", "r477", "r580", "r581", "r582", "r583", "r584", "r591", "r592", "r594", "r628", "r629", "r630", "r855", "r856", "r869", "r870", "r871", "r880", "r884" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r73", "r75", "r82" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight Federal Funds", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1115" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r228", "r343", "r364", "r852" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1074", "r1193" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r824", "r852" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, remainder of 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1193" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r824", "r852" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r824", "r852" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r824", "r852" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r824", "r852" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r357", "r359", "r360", "r361", "r363", "r364", "r368", "r369", "r637", "r638", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r357", "r359", "r360", "r361", "r363", "r364", "r368", "r369", "r824" ] }, "iart_FiveYearOptionLeasePeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "FiveYearOptionLeasePeriodOneMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Year Option Lease From November 1, 2029 Through October 31, 2034", "label": "Five Year Option Lease Period One [Member]", "documentation": "Five-Year Option Lease Period One" } } }, "auth_ref": [] }, "iart_FiveYearOptionLeasePeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "FiveYearOptionLeasePeriodTwoMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Year Option Lease From November 1, 2034 Through October 31, 2039", "label": "Five Year Option Lease Period Two [Member]", "documentation": "Five-Year Option Lease Period Two" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contract", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r756", "r760", "r765", "r778", "r784", "r804", "r805", "r806", "r908" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r931", "r941", "r951", "r983" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r931", "r941", "r951", "r983" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r931", "r941", "r951", "r983" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r931", "r941", "r951", "r983" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r931", "r941", "r951", "r983" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r964" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) reclassified into other income", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r74" ] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r1031", "r1079", "r1080" ] }, "iart_GainLossOnSettlementOfDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "GainLossOnSettlementOfDerivative", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on settlement of derivative", "label": "Gain (Loss) On Settlement Of Derivative", "documentation": "Gain (Loss) On Settlement Of Derivative" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails": { "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill at beginning of period", "periodEndLabel": "Goodwill at end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r227", "r344", "r669", "r846", "r851", "r882", "r890", "r1055", "r1062" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acclarent Acquisition", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r348", "r851" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1053", "r1065" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r352" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r12", "r345", "r351", "r356", "r851", "r882" ] }, "iart_GoodwillImpairmentSensitivityAnalysisReportingUnitFairValueIncreaseDecreasePercent": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240930", "localname": "GoodwillImpairmentSensitivityAnalysisReportingUnitFairValueIncreaseDecreasePercent", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting unit, fair value increase (decrease), percent", "label": "Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Fair Value Increase (Decrease), Percent", "documentation": "Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Fair Value Increase (Decrease), Percent" } } }, "auth_ref": [] }, "iart_GoodwillImpairmentSensitivityAnalysisReportingUnitMeasurementInputIncreaseDecrease": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240930", "localname": "GoodwillImpairmentSensitivityAnalysisReportingUnitMeasurementInputIncreaseDecrease", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting unit, measurement input increase (decrease)", "label": "Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Measurement Input Increase (Decrease)", "documentation": "Goodwill Impairment, Sensitivity Analysis, Reporting Unit, Measurement Input Increase (Decrease)" } } }, "auth_ref": [] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r851" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r18", "r567" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r18" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash impairment charges", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r358", "r1031", "r1078" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of indefinite-lived intangible assets", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r358", "r1031", "r1075", "r1078" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, long-lived asset, held-for-use", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r12", "r42", "r139", "r881" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r119", "r168", "r173", "r673", "r686", "r840", "r845", "r1043", "r1045", "r1047", "r1048", "r1049" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r372", "r379", "r380", "r586", "r590", "r593", "r713", "r715", "r773", "r824", "r883", "r1154" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r379", "r380", "r586", "r590", "r593", "r713", "r715", "r773", "r824", "r883", "r1154" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://integralife.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r261", "r532", "r536", "r538", "r539", "r540", "r541", "r542", "r545", "r547", "r548", "r549", "r734", "r878" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "(Benefit) provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r175", "r178", "r279", "r280", "r297", "r312", "r326", "r535", "r536", "r546", "r693", "r878" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit from prior year income taxes", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r1106", "r1107" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r635", "r1030" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and restricted stock (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r286", "r287", "r288", "r292", "r498" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r357", "r362", "r367", "r852" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r357", "r362", "r367", "r852" ] }, "iart_IndefiniteLivedIntangibleAssetsMeasurementInput": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240930", "localname": "IndefiniteLivedIntangibleAssetsMeasurementInput", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets, measurement input", "label": "Indefinite-Lived Intangible Assets, Measurement Input", "documentation": "Intangible Assets, Indefinite-Lived, Measurement Input" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r931", "r941", "r951", "r975", "r983", "r987", "r995" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r993" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r923", "r999" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r923", "r999" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r923", "r999" ] }, "iart_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InstrumentsMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Instruments", "label": "Instruments [Member]", "documentation": "Instruments [Member]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r357", "r1073", "r1075" ] }, "iart_IntercompanyLoanQuarterlyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "IntercompanyLoanQuarterlyPayment", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany loan quarterly payments", "label": "Intercompany Loan, Quarterly Payment", "documentation": "Intercompany Loan, Quarterly Payment" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r22" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r308", "r1029" ] }, "us-gaap_InterestIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income [Member]", "documentation": "Primary financial statement caption in which reported facts about interest income have been included." } } }, "auth_ref": [] }, "iart_InterestPaymentsReminderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestPaymentsReminderOfFiscalYear", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, remainder of fiscal year", "label": "Interest Payments, Reminder Of Fiscal Year", "documentation": "Interest Payments, Reminder Of Fiscal Year" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestPaymentsYearFour", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year four", "label": "Interest Payments, Year Four", "documentation": "Interest Payments, Year Four" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestPaymentsYearOne", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year one", "label": "Interest Payments, Year One", "documentation": "Interest Payments, Year One" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestPaymentsYearThree", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year three", "label": "Interest Payments, Year Three", "documentation": "Interest Payments, Year Three" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year two", "label": "Interest Payments, Year Two", "documentation": "Interest Payments, Year Two" } } }, "auth_ref": [] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain expected to be reclassified to earnings in the next twelve months", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r84" ] }, "iart_InterestRateSwapDesignatedDecember132017Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedDecember132017Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 2", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 2" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember132017Tranche3Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedDecember132017Tranche3Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 3", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]", "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember152020Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedDecember152020Tranche1Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 15, 2020 Tranche 1", "label": "Interest Rate Swap Designated December 15, 2020 Tranche 1 [Member]", "documentation": "Interest Rate Swap Designated December 15, 2020 Tranche 1" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember152020Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedDecember152020Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 15, 2020 Tranche 2", "label": "Interest Rate Swap Designated December 15, 2020 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated December 15, 2020 Tranche 2" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember182018Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedDecember182018Tranche1Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 1", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]", "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember182018Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedDecember182018Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 2", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedMarch312023Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedMarch312023Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated March 31, 2023", "label": "Interest Rate Swap Designated March 31, 2023 [Member]", "documentation": "Interest Rate Swap Designated March 31, 2023" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedOctober102018Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedOctober102018Tranche1Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 1", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]", "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedOctober102018Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedOctober102018Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 2", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedOctober102018Tranche3Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "InterestRateSwapDesignatedOctober102018Tranche3Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 3", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]", "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "verboseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r826", "r913", "r914" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://integralife.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r340" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r137", "r832" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r236", "r830", "r890" ] }, "us-gaap_InventoryRawMaterialsAndPurchasedPartsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndPurchasedPartsNetOfReserves", "crdr": "debit", "calculation": { "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials and Purchased Parts, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items purchased for use as components of a finished product or pieces of machinery and equipment plus any items in their natural and unrefined state. This element may be used when the reporting entity combines raw materials and purchased parts into an aggregate amount." } } }, "auth_ref": [ "r137", "r1022" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r137", "r833" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r297", "r307", "r326", "r845", "r1028" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r692", "r725", "r726", "r727", "r728", "r794", "r795" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r621", "r1010" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r621", "r1010" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r613", "r621" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r613", "r621" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Maturities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1139" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1139" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r619" ] }, "iart_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240930", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal options (or more)", "label": "Lessee, Operating Lease, Number Of Renewal Options", "documentation": "Lessee, Operating Lease, Number Of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period for extended lease", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r614" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to extend lease, years", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1138" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES AND RELATED PARTY LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r608" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r26", "r92", "r93", "r94", "r98", "r99", "r100", "r101", "r260", "r336", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r561", "r563", "r564", "r596", "r749", "r839", "r918", "r1095", "r1142", "r1143" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r108", "r165", "r683", "r890", "r1034", "r1052", "r1130" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r94", "r225", "r260", "r336", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r561", "r563", "r564", "r596", "r890", "r1095", "r1142", "r1143" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r26", "r164", "r1150" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, fair value of amount outstanding", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "documentation": "Fair value of the amount outstanding under the credit facility." } } }, "auth_ref": [ "r595" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r91", "r97" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r26", "r164", "r417", "r431", "r855", "r856", "r888", "r1150" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r266", "r422" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r266", "r422" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r266", "r422" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1036" ] }, "iart_LongTermDebtMaturityAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "LongTermDebtMaturityAfterYearThree", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, after Year Three", "documentation": "Long-Term Debt, Maturity, after Year Three" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r26", "r1082", "r1083", "r1084" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r26", "r44", "r1082", "r1083", "r1084" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385", "r386", "r387", "r390", "r531", "r853", "r1087", "r1088" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r385", "r386", "r387", "r390", "r531", "r853", "r1087", "r1088" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r181", "r183", "r185", "r186", "r188", "r219", "r220", "r386", "r387", "r388", "r389", "r492", "r531", "r584", "r634", "r712", "r714", "r722", "r741", "r742", "r792", "r796", "r798", "r799", "r808", "r822", "r823", "r850", "r859", "r875", "r884", "r885", "r886", "r887", "r900", "r1097", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r967" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r967" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1118", "r1119", "r1120" ] }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Long-Term Revenue Growth Rate", "label": "Measurement Input, Long-Term Revenue Growth Rate [Member]", "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue." } } }, "auth_ref": [ "r1118", "r1119", "r1120" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r582", "r583", "r584", "r884" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r582", "r583", "r584", "r884" ] }, "iart_MergersAcquisitionsAndDispositionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240930", "localname": "MergersAcquisitionsAndDispositionsAbstract", "lang": { "en-us": { "role": { "label": "Mergers, Acquisitions and Dispositions [Abstract]", "documentation": "Mergers, Acquisitions and Dispositions" } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURES" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS AND DIVESTITURES", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r89", "r151" ] }, "iart_MilestonePaymentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "MilestonePaymentOneMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development Milestones", "label": "Milestone Payment One [Member]", "documentation": "Milestone Payment One [Member]" } } }, "auth_ref": [] }, "iart_MilestonePaymentTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "MilestonePaymentTwoMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Sales Milestones", "label": "Milestone Payment Two [Member]", "documentation": "Milestone Payment Two [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r181", "r183", "r185", "r186", "r188", "r219", "r220", "r386", "r387", "r388", "r389", "r492", "r531", "r584", "r634", "r712", "r714", "r722", "r741", "r742", "r792", "r796", "r798", "r799", "r808", "r822", "r823", "r850", "r859", "r875", "r884", "r885", "r886", "r900", "r1097", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r986" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r994" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r968" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r257" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r257" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r133", "r134", "r135" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "terseLabel": "Net (Loss) Income", "verboseLabel": "Net (loss) income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r122", "r135", "r169", "r223", "r245", "r248", "r252", "r260", "r270", "r272", "r273", "r274", "r275", "r276", "r279", "r280", "r289", "r336", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r553", "r559", "r579", "r596", "r687", "r770", "r786", "r787", "r916", "r1095" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r71" ] }, "iart_NeurosurgeryMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "NeurosurgeryMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neurosurgery", "label": "Neurosurgery [Member]", "documentation": "Neurosurgery [Member]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r967" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r931", "r941", "r951", "r975", "r983" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r958" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r957" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r975" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r994" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r994" ] }, "iart_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Noncash Lease Expense", "documentation": "Noncash Lease Expense" } } }, "auth_ref": [] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r841", "r849", "r1044" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive gain (loss)", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r25", "r30" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating (loss) income", "verboseLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r173", "r840", "r1043", "r1045", "r1047", "r1048", "r1049" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1137" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, impairment loss", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1136" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of lease liability - operating leases", "terseLabel": "Current lease liabilities", "netLabel": "Less: Current lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liability - operating leases", "terseLabel": "Non-current lease liabilities", "netLabel": "Long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r612", "r615" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use asset - operating leases", "terseLabel": "ROU assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r618", "r889" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r617", "r889" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r327", "r845", "r846" ] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity [Axis]", "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": [ "r45", "r85", "r86", "r161" ] }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityStrikePrice1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial strike price (in dollars per share)", "label": "Option Indexed to Issuer's Equity, Strike Price", "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares." } } }, "auth_ref": [ "r19", "r24" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r88", "r154", "r723", "r724" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r238", "r890" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r73", "r82" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r229" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension liability adjustment, net of tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r6", "r7", "r16", "r117", "r118", "r155" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r10", "r16", "r155" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r241", "r242", "r688" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized loss/(gain) on derivatives, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r242" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recorded in AOCI, change in fair value", "verboseLabel": "Amount\u00a0of Gain (Loss) Recognized\u00a0in AOCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r241", "r242", "r565", "r566", "r569" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount\u00a0of\u00a0Gain (Loss) Reclassified from AOCI into Earnings", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r242", "r244" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Net current-period other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r16", "r155", "r246", "r249", "r276" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r12", "r43", "r123" ] }, "us-gaap_OtherIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income", "label": "Other Income [Member]", "documentation": "Primary financial statement caption encompassing other revenue." } } }, "auth_ref": [ "r160" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r852", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1073", "r1075", "r1076", "r1077" ] }, "us-gaap_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other liabilities." } } }, "auth_ref": [ "r73", "r82" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r99" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-term Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r126" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r967" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r929", "r939", "r949", "r981" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r932", "r942", "r952", "r984" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r932", "r942", "r952", "r984" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r956" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for Contingent Consideration", "terseLabel": "Payment for contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r9" ] }, "iart_PaymentsForAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "PaymentsForAssetAcquisitions", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for asset acquisitions", "label": "Payments For Asset Acquisitions", "documentation": "Payments For Asset Acquisitions" } } }, "auth_ref": [] }, "iart_PaymentsForOptionIndexToIssuersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "PaymentsForOptionIndexToIssuersEquity", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of call transactions", "label": "Payments For Option Index To Issuers Equity", "documentation": "Payments For Options Indexed to Issuer's Equity" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromDerivativeInstrumentInvestingActivities", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net proceeds from swaps designated as net investment hedges", "label": "Payments for (Proceeds from) Derivative Instrument, Investing Activities", "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r131" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash taxes paid in net equity settlement", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r256" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash (paid) for business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of short term investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r129" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r130" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r966" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r966" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://integralife.com/role/RETIREMENTPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "RETIREMENT PLANS", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r466", "r469", "r471", "r477", "r480", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r871" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r958" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r975" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r968" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r957" ] }, "iart_PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240930", "localname": "PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director", "label": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director", "documentation": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Stock", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "iart_PerformanceStockAndRestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "PerformanceStockAndRestrictedStockAwardsMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Stock and Restricted Stock Awards", "label": "Performance Stock And Restricted Stock Awards [Member]", "documentation": "Performance Stock And Restricted Stock Awards [Member]" } } }, "auth_ref": [] }, "iart_PlainsboroNewJerseyManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "PlainsboroNewJerseyManufacturingFacilityMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plainsboro, New Jersey Manufacturing Facility", "label": "Plainsboro, New Jersey Manufacturing Facility [Member]", "documentation": "Plainsboro, New Jersey Manufacturing Facility" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r959" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1003" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r958" ] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r102", "r432" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized shares (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r102", "r750" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding shares (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r102", "r750", "r768", "r1187", "r1188" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock; no par value; 15,000 authorized shares; none outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r102", "r679", "r890" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r237", "r341", "r342", "r831" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "iart_PrivateLabelMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "PrivateLabelMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Label", "label": "Private Label [Member]", "documentation": "Private Label [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings of long-term indebtedness", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from warrant transactions", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of short term investments", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r32", "r129" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercised stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r8", "r20" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r217", "r329", "r636", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r827", "r862", "r899", "r900", "r901", "r904", "r905", "r1020", "r1089", "r1090", "r1102", "r1151", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r217", "r329", "r636", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r827", "r862", "r899", "r900", "r901", "r904", "r905", "r1020", "r1089", "r1090", "r1102", "r1151", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r13", "r620" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r13", "r620", "r674", "r685", "r890" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r138", "r620" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r956" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r956" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r181", "r183", "r185", "r186", "r188", "r219", "r220", "r386", "r387", "r388", "r389", "r469", "r492", "r522", "r523", "r524", "r531", "r584", "r631", "r632", "r634", "r712", "r714", "r722", "r741", "r742", "r792", "r796", "r798", "r799", "r808", "r822", "r823", "r850", "r859", "r875", "r884", "r885", "r886", "r887", "r900", "r908", "r1085", "r1097", "r1119", "r1145", "r1146", "r1147", "r1148", "r1149" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r181", "r183", "r185", "r186", "r188", "r219", "r220", "r386", "r387", "r388", "r389", "r469", "r492", "r522", "r523", "r524", "r531", "r584", "r631", "r632", "r634", "r712", "r714", "r722", "r741", "r742", "r792", "r796", "r798", "r799", "r808", "r822", "r823", "r850", "r859", "r875", "r884", "r885", "r886", "r887", "r900", "r908", "r1085", "r1097", "r1119", "r1145", "r1146", "r1147", "r1148", "r1149" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Amounts reclassified from accumulated other comprehensive income, net", "verboseLabel": "Gain (loss) reclassified from AOCI", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r25", "r30" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r924", "r934", "r944", "r976" ] }, "iart_RegenerativeSkinAndWoundMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "RegenerativeSkinAndWoundMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wound Reconstruction and Care", "label": "Regenerative Skin And Wound [Member]", "documentation": "Regenerative Skin And Wound [Member]" } } }, "auth_ref": [] }, "iart_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "RelatedPartiesMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Related Parties [Member]", "documentation": "Related Parties [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r334", "r481", "r623", "r624", "r678", "r684", "r744", "r745", "r746", "r747", "r748", "r767", "r769", "r791" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r262", "r263", "r623", "r624", "r625", "r626", "r678", "r684", "r744", "r745", "r746", "r747", "r748", "r767", "r769", "r791" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r334", "r481", "r623", "r624", "r678", "r684", "r744", "r745", "r746", "r747", "r748", "r767", "r769", "r791", "r1141" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on debt", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r132" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r355", "r356", "r851" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r355", "r356", "r851" ] }, "iart_ReportingUnitMeasurementInput": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240930", "localname": "ReportingUnitMeasurementInput", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting unit, measurement input", "label": "Reporting Unit, Measurement Input", "documentation": "Reporting Unit, Measurement Input" } } }, "auth_ref": [] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value in excess of carrying amount, percent", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r215", "r216", "r264", "r265", "r408", "r434", "r626", "r633", "r675", "r835", "r836" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1105" ] }, "iart_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "RestOfWorldMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of World", "label": "Rest Of World [Member]", "documentation": "Revenues from rest of the world." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r925", "r935", "r945", "r977" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r926", "r936", "r946", "r978" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r933", "r943", "r953", "r985" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r38" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r105", "r148", "r682", "r719", "r721", "r733", "r751", "r890" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r221", "r267", "r268", "r269", "r271", "r276", "r278", "r280", "r337", "r338", "r371", "r543", "r544", "r550", "r551", "r552", "r554", "r558", "r559", "r570", "r572", "r573", "r575", "r577", "r607", "r609", "r716", "r718", "r735", "r1187" ] }, "iart_ReturnPolicyIssueOfCreditNumberOfDaysFromShipment": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240930", "localname": "ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days from shipment to issue a credit", "label": "Return Policy, Issue Of Credit, Number Of Days From Shipment", "documentation": "Return Policy, Issue of Credit, Number of Days from Shipment" } } }, "auth_ref": [] }, "iart_RevenueBasedPerformanceMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "RevenueBasedPerformanceMilestonesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Based Performance Milestones", "label": "Revenue Based Performance Milestones [Member]", "documentation": "Revenue Based Performance Milestones" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue, net", "terseLabel": "Total Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r171", "r172", "r297", "r305", "r306", "r320", "r326", "r329", "r331", "r333", "r461", "r462", "r636" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r179", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r825" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUES FROM CONTRACTS WITH CUSTOMERS", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r179", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r465" ] }, "iart_RevenueProductWarrantyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240930", "localname": "RevenueProductWarrantyPeriod", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product warranty period (up to)", "label": "Revenue, Product Warranty Period", "documentation": "Revenue, Product Warranty Period" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations expected to be satisfied, expected timing", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r176" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r176" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected performance obligation, percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r1009" ] }, "us-gaap_RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes Collected from Customers", "label": "Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block]", "documentation": "Disclosure of accounting policy for election to exclude from measurement of transaction price tax assessed by governmental authority that are both imposed on and concurrent with specific revenue-producing transaction, and collected from customer. Includes, but is not limited to, sales, use, value-added and excise tax." } } }, "auth_ref": [ "r441" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "iart_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240930", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for lease liabilities, net of modifications:", "label": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r616", "r889" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r994" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r994" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r493", "r1012", "r1040" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r218", "r281", "r493", "r1006", "r1040" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r30", "r1131", "r1132" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." } } }, "auth_ref": [ "r359", "r360", "r361", "r363", "r824" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r57", "r59", "r555" ] }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://integralife.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Maximum Leverage Ratios", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r26", "r48", "r51", "r87", "r145", "r147", "r855", "r857", "r1036", "r1134" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r74", "r77", "r567" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value and Presentation of Derivatives", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r18", "r67", "r68", "r69", "r72", "r75", "r77", "r80", "r81" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and Diluted Net Income (Loss) Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1042" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r537", "r878", "r1106" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r852", "r1072" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r851" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r851", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r852", "r1075" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://integralife.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r28", "r109", "r110", "r111" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://integralife.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contractual Repayments of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r78", "r1011" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r152" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Net Sales and Profit by Segments", "terseLabel": "Schedule of Geographic Revenue by Area", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r495", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r46", "r47", "r48", "r49", "r50", "r51", "r144", "r145", "r147", "r148", "r231", "r232", "r233", "r299", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r729", "r730", "r731", "r732", "r859", "r1005", "r1032" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of borrowings under senior credit facility", "verboseLabel": "Term loan component of senior credit facility", "label": "Secured Debt, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r92", "r163" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term borrowings under senior credit facility", "label": "Secured Long-Term Debt, Noncurrent", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [ "r26" ] }, "iart_SecuredLongTermDebtSecuritizationProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "SecuredLongTermDebtSecuritizationProgram", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured long-term debt, securitization program", "label": "Secured Long-Term Debt, Securitization Program", "documentation": "Secured Long-Term Debt, Securitization Program" } } }, "auth_ref": [] }, "iart_SecuredLongTermDebtSecuritizationProgramNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "SecuredLongTermDebtSecuritizationProgramNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term borrowings under securitization facility", "label": "Secured Long-Term Debt, Securitization Program, Noncurrent", "documentation": "Secured Long-Term Debt, Securitization Program, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r1115" ] }, "iart_SecuritizationFacilityFairValueOfAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "SecuritizationFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securitization facility, outstanding borrowings, fair value", "label": "Securitization Facility, Fair Value Of Amount Outstanding", "documentation": "Securitization Facility, Fair Value Of Amount Outstanding" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r919" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r921" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r171", "r172", "r173", "r174", "r297", "r301", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r333", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r370", "r381", "r382", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r842", "r845", "r846", "r851", "r903", "r1151", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r182", "r184", "r187", "r189", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r331", "r332", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r737", "r738", "r739", "r793", "r797", "r800", "r809", "r811", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r828", "r863", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r902", "r908", "r1102", "r1151", "r1155", "r1156", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r174", "r297", "r300", "r301", "r302", "r303", "r304", "r316", "r318", "r319", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r333", "r841", "r843", "r844", "r845", "r847", "r848", "r849" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "iart_SegmentReportingInformationNumberOfProductsOffered": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240930", "localname": "SegmentReportingInformationNumberOfProductsOffered", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of products offered (more than)", "label": "Segment Reporting Information, Number Of Products Offered", "documentation": "Number of products sold by a segment" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Net Sales", "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationProfitLossAbstract", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Profit", "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r124" ] }, "iart_SeniorCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "SeniorCreditFacilityMember", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Credit Facility", "label": "Senior Credit Facility [Member]", "documentation": "Senior Credit Facility." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated stock based compensation expenses", "label": "Share-Based Payment Arrangement, Accelerated Cost", "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requisite service periods of awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r876" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r876" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r514" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other than options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r514" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r495", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants in period, net of forfeitures (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1104" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r517" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan modification, compensation expense", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525" ] }, "iart_ShareBasedPaymentArrangementPlanModificationExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240930", "localname": "ShareBasedPaymentArrangementPlanModificationExpirationPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan modification, expiration period (in months)", "label": "Share-Based Payment Arrangement, Plan Modification, Expiration Period", "documentation": "Share-Based Payment Arrangement, Plan Modification, Expiration Period" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1100" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1100" ] }, "us-gaap_ShareRepurchaseProgramExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareRepurchaseProgramExciseTax", "crdr": "debit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase program, excise tax", "label": "Share Repurchase Program, Excise Tax", "documentation": "Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1099" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r877" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period, (in shares)", "periodEndLabel": "Balance, end of period (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONNarrativeDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r166", "r167", "r1023" ] }, "us-gaap_StandbyLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandbyLettersOfCreditMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standby Letters of Credit", "label": "Standby Letters of Credit [Member]", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation." } } }, "auth_ref": [ "r0", "r1091", "r1183", "r1184" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r171", "r172", "r173", "r174", "r222", "r297", "r301", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r333", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r370", "r373", "r381", "r382", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r842", "r845", "r846", "r851", "r903", "r1151", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMENarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r103", "r106", "r107", "r221", "r250", "r251", "r252", "r267", "r268", "r269", "r271", "r276", "r278", "r280", "r298", "r337", "r338", "r371", "r440", "r543", "r544", "r550", "r551", "r552", "r554", "r558", "r559", "r570", "r571", "r572", "r573", "r574", "r575", "r577", "r598", "r599", "r600", "r601", "r602", "r603", "r607", "r609", "r622", "r688", "r716", "r717", "r718", "r735", "r788" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r182", "r184", "r187", "r189", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r331", "r332", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r737", "r738", "r739", "r793", "r797", "r800", "r809", "r811", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r828", "r863", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r902", "r908", "r1102", "r1151", "r1155", "r1156", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r267", "r268", "r269", "r298", "r609", "r636", "r725", "r736", "r743", "r744", "r745", "r746", "r747", "r748", "r750", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r769", "r771", "r772", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r788", "r909" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r218", "r281", "r493", "r1006", "r1007", "r1040" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r267", "r268", "r269", "r298", "r334", "r609", "r636", "r725", "r736", "r743", "r744", "r745", "r746", "r747", "r748", "r750", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r769", "r771", "r772", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r788", "r909" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r928", "r938", "r948", "r980" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock through employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r17", "r102", "r103", "r148" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r17", "r102", "r103", "r148" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock through employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r17", "r102", "r103", "r148" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r54", "r102", "r103", "r148" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1100" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining amount under share repurchase", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Accelerated shares repurchased (shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r17", "r102", "r103", "r148", "r732", "r788", "r810" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accelerated shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r17", "r102", "r103", "r148", "r735", "r788", "r810", "r917" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSINCOMEScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r103", "r106", "r107", "r136", "r752", "r768", "r789", "r790", "r890", "r918", "r1034", "r1052", "r1130", "r1187" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r627" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r627" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r627" ] }, "iart_SupplierRelationShipsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "SupplierRelationShipsMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier relationships", "label": "Supplier Relation Ships [Member]", "documentation": "Supplier Relation Ships [Member]" } } }, "auth_ref": [] }, "iart_SurgicalInnovationAssociatesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "SurgicalInnovationAssociatesIncMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Innovation Associates, Inc.", "label": "Surgical Innovation Associates Inc [Member]", "documentation": "Surgical Innovation Associates Inc" } } }, "auth_ref": [] }, "iart_SwinglineLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "SwinglineLoanMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swingline Loans", "label": "Swingline Loan [Member]", "documentation": "Swingline Loan [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r974" ] }, "iart_TermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "TermLoanFacilityMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility", "label": "Term Loan Facility [Member]", "documentation": "Term Loan Facility [Member]" } } }, "auth_ref": [] }, "iart_ThirdPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "ThirdPartiesMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Third Parties", "label": "Third Parties [Member]", "documentation": "Third Parties [Member]" } } }, "auth_ref": [] }, "iart_TissueTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "TissueTechnologiesMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tissue Technologies", "label": "Tissue Technologies [Member]", "documentation": "Orthopedics and Tissue Technologies [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1050", "r1140" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r966" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r973" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Codman tradename", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r63", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1073", "r1075", "r1076", "r1077" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessCombinationScheduleofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks and Trade Names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r63", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1073", "r1075", "r1076", "r1077" ] }, "iart_TrademarksBrandNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "TrademarksBrandNamesMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks/brand names", "label": "Trademarks Brand Names [Member]", "documentation": "Trademarks Brand Names." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r993" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r995" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "iart_TransferorsInterestsInTransferredFinancialAssetsIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "TransferorsInterestsInTransferredFinancialAssetsIssuanceCosts", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transferor's interests in transferred financial assets, issuance costs", "label": "Transferor's Interests In Transferred Financial Assets, Issuance Costs", "documentation": "Transferor's Interests In Transferred Financial Assets, Issuance Costs" } } }, "auth_ref": [] }, "iart_TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securitization program outstanding borrowings, maximum limit", "label": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit", "documentation": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit" } } }, "auth_ref": [] }, "iart_TransferorsInterestsInTransferredFinancialAssetsUnamortizedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240930", "localname": "TransferorsInterestsInTransferredFinancialAssetsUnamortizedIssuanceCosts", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transferor's interests in transferred financial assets, unamortized issuance costs", "label": "Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs", "documentation": "Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r996" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r997" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r997" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r995" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r995" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r998" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r996" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r52" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "negatedPeriodStartLabel": "Balance, beginning of period, treasury stock (in shares)", "negatedPeriodEndLabel": "Balance, beginning of period, treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost; 14,454 shares and 12,751 shares at September\u00a030, 2024 and December\u00a031, 2023, respectively", "terseLabel": "Treasury stock", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52", "r53", "r106" ] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockTextBlock", "presentation": [ "http://integralife.com/role/TREASURYSTOCK" ], "lang": { "en-us": { "role": { "terseLabel": "TREASURY STOCK", "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r149" ] }, "iart_TwoThousandTwentyFiveSeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240930", "localname": "TwoThousandTwentyFiveSeniorConvertibleNotesMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 Notes", "label": "Two Thousand Twenty Five Senior Convertible Notes [Member]", "documentation": "Two Thousand Twenty Five Senior Convertible Notes [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r992" ] }, "us-gaap_UnusualOrInfrequentItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Axis]", "label": "Unusual or Infrequent Item, or Both [Axis]", "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r128" ] }, "us-gaap_UnusualOrInfrequentItemDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Domain]", "label": "Unusual or Infrequent Item, or Both [Domain]", "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r128" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r582", "r583", "r884", "r1120" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Technique, Discounted Cash Flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r884", "r1118", "r1119", "r1120" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r582", "r583", "r884", "r1120" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased vehicles", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r962" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average common shares for diluted earnings per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r284", "r292" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding (See Note 13):", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r283", "r292" ] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write off of debt issuance costs", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r125" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r960" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "SubTopic": "40", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "45", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505-30/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481138/505-30-25-5" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "32", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479866/606-10-32-2A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1005": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1006": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1007": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 99 0000917520-24-000108-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000917520-24-000108-xbrl.zip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�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Ȅ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end XML 100 iart-20240930_htm.xml IDEA: XBRL DOCUMENT 0000917520 2024-01-01 2024-09-30 0000917520 2024-11-01 0000917520 2024-07-01 2024-09-30 0000917520 2023-07-01 2023-09-30 0000917520 2023-01-01 2023-09-30 0000917520 2024-09-30 0000917520 2023-12-31 0000917520 2022-12-31 0000917520 2023-09-30 0000917520 us-gaap:CommonStockMember 2023-12-31 0000917520 us-gaap:TreasuryStockCommonMember 2023-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000917520 us-gaap:RetainedEarningsMember 2023-12-31 0000917520 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000917520 2024-01-01 2024-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000917520 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000917520 us-gaap:CommonStockMember 2024-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2024-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000917520 us-gaap:RetainedEarningsMember 2024-03-31 0000917520 2024-03-31 0000917520 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000917520 2024-04-01 2024-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000917520 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000917520 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000917520 us-gaap:CommonStockMember 2024-06-30 0000917520 us-gaap:TreasuryStockCommonMember 2024-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000917520 us-gaap:RetainedEarningsMember 2024-06-30 0000917520 2024-06-30 0000917520 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000917520 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000917520 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000917520 us-gaap:CommonStockMember 2024-09-30 0000917520 us-gaap:TreasuryStockCommonMember 2024-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000917520 us-gaap:RetainedEarningsMember 2024-09-30 0000917520 us-gaap:CommonStockMember 2022-12-31 0000917520 us-gaap:TreasuryStockCommonMember 2022-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000917520 us-gaap:RetainedEarningsMember 2022-12-31 0000917520 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000917520 2023-01-01 2023-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000917520 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000917520 us-gaap:CommonStockMember 2023-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2023-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000917520 us-gaap:RetainedEarningsMember 2023-03-31 0000917520 2023-03-31 0000917520 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000917520 2023-04-01 2023-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000917520 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000917520 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000917520 us-gaap:CommonStockMember 2023-06-30 0000917520 us-gaap:TreasuryStockCommonMember 2023-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000917520 us-gaap:RetainedEarningsMember 2023-06-30 0000917520 2023-06-30 0000917520 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000917520 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000917520 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000917520 us-gaap:CommonStockMember 2023-09-30 0000917520 us-gaap:TreasuryStockCommonMember 2023-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000917520 us-gaap:RetainedEarningsMember 2023-09-30 0000917520 iart:AcclarentInc.Member 2024-04-01 2024-04-01 0000917520 iart:AcclarentInc.Member 2024-09-01 2024-09-30 0000917520 iart:AcclarentInc.Member 2024-01-01 2024-09-30 0000917520 iart:AcclarentInc.Member 2024-04-01 0000917520 iart:AcclarentInc.Member iart:CompletedTechnologyMember 2024-04-01 0000917520 iart:AcclarentInc.Member iart:CompletedTechnologyMember 2024-04-01 2024-04-01 0000917520 iart:AcclarentInc.Member us-gaap:TrademarksAndTradeNamesMember 2024-04-01 0000917520 iart:AcclarentInc.Member us-gaap:TrademarksAndTradeNamesMember 2024-04-01 2024-04-01 0000917520 iart:AcclarentInc.Member us-gaap:OtherIntangibleAssetsMember 2024-04-01 0000917520 iart:AcclarentInc.Member us-gaap:OtherIntangibleAssetsMember 2024-04-01 2024-04-01 0000917520 iart:DurepairRegenerationMatrixMember us-gaap:SubsequentEventMember 2024-10-02 2024-10-02 0000917520 srt:ScenarioForecastMember iart:DurepairRegenerationMatrixMember 2025-10-02 2025-10-02 0000917520 srt:ScenarioForecastMember iart:DurepairRegenerationMatrixMember 2026-10-02 2026-10-02 0000917520 2024-10-01 2024-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2024-07-01 2024-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2023-07-01 2023-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2024-07-01 2024-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2023-07-01 2023-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-09-30 0000917520 iart:ENTMember iart:CodmanSpecialtySurgicalMember 2024-07-01 2024-09-30 0000917520 iart:ENTMember iart:CodmanSpecialtySurgicalMember 2023-07-01 2023-09-30 0000917520 iart:ENTMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-09-30 0000917520 iart:ENTMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2024-07-01 2024-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2023-07-01 2023-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2024-07-01 2024-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2023-07-01 2023-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2024-01-01 2024-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2023-01-01 2023-09-30 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2024-07-01 2024-09-30 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2023-07-01 2023-09-30 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2024-01-01 2024-09-30 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2023-01-01 2023-09-30 0000917520 iart:TissueTechnologiesMember 2024-07-01 2024-09-30 0000917520 iart:TissueTechnologiesMember 2023-07-01 2023-09-30 0000917520 iart:TissueTechnologiesMember 2024-01-01 2024-09-30 0000917520 iart:TissueTechnologiesMember 2023-01-01 2023-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2023-12-31 0000917520 iart:TissueTechnologiesMember 2023-12-31 0000917520 iart:AcclarentInc.Member iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-09-30 0000917520 iart:AcclarentInc.Member iart:TissueTechnologiesMember 2024-01-01 2024-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2024-09-30 0000917520 iart:TissueTechnologiesMember 2024-09-30 0000917520 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember iart:TissueTechnologiesMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 us-gaap:MeasurementInputDiscountRateMember iart:TissueTechnologiesMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 iart:TissueTechnologiesMember 2024-09-30 0000917520 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember iart:NeurosurgeryMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 us-gaap:MeasurementInputDiscountRateMember iart:NeurosurgeryMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 iart:NeurosurgeryMember 2024-09-30 0000917520 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember iart:InstrumentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 us-gaap:MeasurementInputDiscountRateMember iart:InstrumentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 iart:InstrumentsMember 2024-09-30 0000917520 iart:NeurosurgeryMember 2024-01-01 2024-09-30 0000917520 iart:InstrumentsMember 2024-01-01 2024-09-30 0000917520 us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-07-01 2024-09-30 0000917520 iart:TissueTechnologiesMember 2024-07-01 2024-09-30 0000917520 iart:NeurosurgeryMember 2024-07-01 2024-09-30 0000917520 iart:InstrumentsMember 2024-07-01 2024-09-30 0000917520 us-gaap:TradeNamesMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-01 2024-03-31 0000917520 us-gaap:TradeNamesMember 2024-01-01 2024-09-30 0000917520 iart:CompletedTechnologyMember 2024-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2024-09-30 0000917520 iart:TrademarksBrandNamesMember 2024-09-30 0000917520 us-gaap:TradeNamesMember 2024-09-30 0000917520 iart:SupplierRelationShipsMember 2024-09-30 0000917520 iart:AllOtherMember 2024-09-30 0000917520 iart:CompletedTechnologyMember 2023-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2023-12-31 0000917520 iart:TrademarksBrandNamesMember 2023-12-31 0000917520 us-gaap:TradeNamesMember 2023-12-31 0000917520 iart:SupplierRelationShipsMember 2023-12-31 0000917520 iart:AllOtherMember 2023-12-31 0000917520 iart:CompletedTechnologyMember 2024-07-01 2024-09-30 0000917520 iart:CompletedTechnologyMember 2024-01-01 2024-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-09-30 0000917520 iart:CompletedTechnologyMember 2023-07-01 2023-09-30 0000917520 iart:CompletedTechnologyMember 2023-01-01 2023-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-03-31 0000917520 iart:CompletedTechnologyMember iart:CompletedTechnologySurgiMendMember 2024-09-30 0000917520 iart:CompletedTechnologyMember iart:CompletedTechnologyPriMatrixMember 2024-09-30 0000917520 iart:SeniorCreditFacilityMember 2023-03-24 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2023-03-24 0000917520 us-gaap:RevolvingCreditFacilityMember 2023-03-24 0000917520 us-gaap:StandbyLettersOfCreditMember 2023-03-24 0000917520 iart:SwinglineLoanMember 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod2Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod1Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod3Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod4Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-09-30 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-09-30 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-09-30 0000917520 iart:SeniorCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2024-01-01 2024-09-30 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember 2024-01-01 2024-09-30 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember 2024-01-01 2024-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-03-31 0000917520 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2024-09-30 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2023-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember iart:SeniorCreditFacilityMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2023-12-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2024-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-07 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-07 2020-02-07 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-12-09 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-02-04 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2024-09-30 0000917520 2023-12-15 0000917520 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedMarch312023Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:InterestRateSwapDesignatedMarch312023Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0000917520 us-gaap:InterestRateSwapMember 2024-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember 2023-09-22 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2023-09-22 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember 2024-09-23 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2020-12-21 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-09-30 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-07-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-07-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2024-07-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2023-07-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2024-09-30 0000917520 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-05-02 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2024-07-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2024-01-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-07-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-01-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SubsequentEventMember 2024-10-16 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-06-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-07-01 2024-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-06-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2024-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2024-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-06-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-09-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-06-30 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-01-01 2024-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-12-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-12-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2022-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2021-06-30 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2024-09-30 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2023-12-31 0000917520 us-gaap:CurrencySwapMember 2024-07-01 2024-09-30 0000917520 us-gaap:CurrencySwapMember 2023-07-01 2023-09-30 0000917520 us-gaap:CurrencySwapMember 2024-01-01 2024-09-30 0000917520 us-gaap:CurrencySwapMember 2023-01-01 2023-09-30 0000917520 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000917520 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000917520 iart:EmployeeMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000917520 srt:MinimumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000917520 srt:MaximumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000917520 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0000917520 us-gaap:EmployeeStockOptionMember 2024-09-30 0000917520 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000917520 iart:PerformanceStockAndRestrictedStockAwardsMember 2024-01-01 2024-09-30 0000917520 us-gaap:RestrictedStockMember 2024-09-30 0000917520 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0000917520 srt:ChiefExecutiveOfficerMember 2024-01-01 2024-09-30 0000917520 srt:ScenarioForecastMember srt:ChiefExecutiveOfficerMember 2024-01-01 2024-12-31 0000917520 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0000917520 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000917520 us-gaap:BuildingMember 2024-09-30 0000917520 us-gaap:BuildingMember 2023-12-31 0000917520 us-gaap:VehiclesMember 2024-09-30 0000917520 us-gaap:VehiclesMember 2023-12-31 0000917520 iart:RelatedPartiesMember 2024-09-30 0000917520 iart:ThirdPartiesMember 2024-09-30 0000917520 iart:FiveYearOptionLeasePeriodOneMember us-gaap:RelatedPartyMember 2024-09-30 0000917520 iart:FiveYearOptionLeasePeriodOneMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000917520 iart:FiveYearOptionLeasePeriodTwoMember us-gaap:RelatedPartyMember 2024-09-30 0000917520 iart:FiveYearOptionLeasePeriodTwoMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000917520 2023-01-01 2023-12-31 0000917520 2024-05-16 0000917520 2024-07-31 0000917520 2023-08-15 0000917520 2023-10-18 0000917520 2023-01-26 0000917520 iart:A2023ShareRepurchaseProgramMember us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0000917520 iart:A2023ShareRepurchaseProgramMember 2023-07-18 0000917520 iart:A2023ShareRepurchaseProgramMember 2024-09-30 0000917520 2024-09-30 2024-09-30 0000917520 2023-09-30 2023-09-30 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-30 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-30 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000917520 us-gaap:OtherIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0000917520 us-gaap:InterestIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2024-07-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2023-07-01 2023-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2024-07-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2023-07-01 2023-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2024-01-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2023-01-01 2023-09-30 0000917520 us-gaap:OperatingSegmentsMember 2024-07-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0000917520 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-30 0000917520 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2024-07-01 2024-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0000917520 country:US 2024-07-01 2024-09-30 0000917520 country:US 2023-07-01 2023-09-30 0000917520 country:US 2024-01-01 2024-09-30 0000917520 country:US 2023-01-01 2023-09-30 0000917520 srt:EuropeMember 2024-07-01 2024-09-30 0000917520 srt:EuropeMember 2023-07-01 2023-09-30 0000917520 srt:EuropeMember 2024-01-01 2024-09-30 0000917520 srt:EuropeMember 2023-01-01 2023-09-30 0000917520 srt:AsiaPacificMember 2024-07-01 2024-09-30 0000917520 srt:AsiaPacificMember 2023-07-01 2023-09-30 0000917520 srt:AsiaPacificMember 2024-01-01 2024-09-30 0000917520 srt:AsiaPacificMember 2023-01-01 2023-09-30 0000917520 iart:RestOfWorldMember 2024-07-01 2024-09-30 0000917520 iart:RestOfWorldMember 2023-07-01 2023-09-30 0000917520 iart:RestOfWorldMember 2024-01-01 2024-09-30 0000917520 iart:RestOfWorldMember 2023-01-01 2023-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-09-30 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-09-30 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-09-30 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-09-30 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentOneMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentTwoMember 2019-07-29 0000917520 iart:DermaSciencesMember iart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember 2024-01-01 2024-09-30 0000917520 iart:DermaSciencesMember 2024-09-30 0000917520 iart:ACellIncMember 2021-01-20 0000917520 iart:ACellIncMember 2024-09-30 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-12-06 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:RevenueBasedPerformanceMilestonesMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:FDAApprovalOfPremarketApprovalMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:RevenueBasedPerformanceMilestonesMember 2024-04-01 2024-06-30 0000917520 srt:ScenarioForecastMember iart:PlainsboroNewJerseyManufacturingFacilityMember 2025-01-01 2025-03-31 shares iso4217:USD iso4217:USD shares pure iso4217:CHF iso4217:EUR iart:renewalOption iart:Segment iart:product iart:liability iart:payment false 2024 Q3 0000917520 --12-31 0.0135739 P6Y 10-Q true 2024-09-30 false 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORP DE 51-0317849 1100 Campus Road 08540 Princeton NJ 609 275-0500 Common Stock, Par Value $.01 Per Share IART NASDAQ Yes Yes Large Accelerated Filer false false false 77163524 380834000 382421000 1167881000 1144534000 180596000 164076000 534892000 486292000 27435000 26596000 84167000 79908000 177193000 161948000 538463000 493513000 3760000 3208000 17575000 9342000 388984000 355828000 1175097000 1069055000 -8150000 26593000 -7216000 75479000 5049000 4607000 15147000 12653000 19373000 13062000 51648000 37626000 2112000 471000 2939000 1705000 -20362000 18609000 -40778000 52211000 -9667000 -888000 -14399000 4304000 -10695000 19497000 -26379000 47907000 -0.14 0.24 -0.34 0.59 -0.14 0.24 -0.34 0.59 76448000 79690000 77196000 80842000 76448000 79811000 77196000 81112000 -16823000 16412000 -36126000 39387000 215157000 276402000 62441000 32694000 7423000 4879000 248298000 259327000 436930000 389608000 86326000 67362000 50370000 32643000 1099522000 1058036000 390906000 340199000 146342000 156184000 1209548000 1067833000 1116535000 1055462000 48936000 46080000 54014000 58194000 4065803000 3781988000 29063000 14531000 15039000 15284000 572442000 0 77666000 92326000 9990000 8540000 76424000 75455000 131939000 100844000 912563000 306980000 1132292000 825563000 72800000 89200000 0 570255000 167808000 166849000 68945000 35317000 189808000 199940000 2544216000 2194104000 0 0 15000000 15000000 0 0 0 0 0.01 0.01 240000000 240000000 91588000 90920000 916000 909000 1316854000 1302484000 14454000 12751000 691810000 647262000 -24854000 -15106000 920481000 946859000 1521587000 1587884000 4065803000 3781988000 -26379000 47907000 103304000 92527000 12173000 0 -13743000 2963000 17225000 14350000 4193000 4731000 -129000 2120000 -1337000 4000 -319000 8278000 -38861000 -5050000 27579000 43350000 34401000 21700000 1745000 8774000 2686000 -22141000 1822000 141000 1336000 -893000 78642000 81205000 74818000 42330000 281994000 0 48997000 0 19250000 0 0 -5381000 -386559000 -36949000 451100000 146900000 147188000 85900000 0 7578000 50000000 275000000 11923000 0 6398000 4092000 3374000 5549000 245013000 -223035000 1659000 -4150000 -61245000 -182929000 276402000 456661000 215157000 273732000 90920000 909000 12751000 -647262000 1302484000 -15106000 946859000 1587884000 -3281000 -3281000 4460000 4460000 23000 965000 965000 541000 2000 16000 840000 1470000 2312000 4000 5608000 5612000 0 91484000 915000 12735000 -646422000 1310527000 -10646000 943578000 1597952000 -12402000 -12402000 -8080000 -8080000 107000 1000 20000 -101000 -80000 7305000 7305000 1273000 34351000 16149000 50500000 91591000 916000 14008000 -680753000 1301582000 -18726000 931176000 1534195000 -10695000 -10695000 -6128000 -6128000 -3000 0 10000 -181000 -171000 4386000 4386000 446000 11067000 -11067000 0 91588000 916000 14454000 -691810000 1316854000 -24854000 920481000 1521587000 90476000 905000 6823000 -362862000 1276977000 10265000 879118000 1804403000 24226000 24226000 -3198000 -3198000 21000 1107000 1107000 316000 1000 16000 846000 -4858000 -4011000 2000 3609000 3611000 2111000 119662000 31538000 151200000 90813000 908000 8918000 -481678000 1245297000 7067000 903344000 1674938000 4184000 4184000 -2237000 -2237000 68000 1000 21000 985000 1007000 5268000 5268000 609000 32125000 -32125000 0 90881000 909000 9527000 -513782000 1283675000 4830000 907528000 1683160000 19497000 19497000 -3085000 -3085000 54000 17000 424000 441000 5457000 5457000 2296000 99012000 27237000 126249000 90935000 909000 11823000 -612777000 1262319000 1745000 927025000 1579221000 BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the September 30, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2024 are not necessarily indicative of the results to be expected for the entire year.</span></div>The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the September 30, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2024 are not necessarily indicative of the results to be expected for the entire year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, in January 2021, subsequently amended the initial guidance in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to a SOFR-indexed rate. (See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR. The Company has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents, primarily consisting of cash on-hand as well as time deposits with original maturities of three months or less and money market funds which are highly liquid and readily convertible to cash, totaling approximately $215.2 million and $276.4 million at September 30, 2024 and December 31, 2023 respectively. Time deposits with original maturities of three months or less and money market funds are valued based on Level 1 measurements in the fair value hierarchy established within FASB Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 820”). Level 1 inputs represent </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term investments</span></div>The Company had short term investments, primarily consisting of time deposits with original maturities between three months and one year, which are valued based on Level 1 measurements in the fair value hierarchy, totaling approximately $62.4 million at September 30, 2024 compared to $32.7 million at December 31, 2023. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, in January 2021, subsequently amended the initial guidance in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to a SOFR-indexed rate. (See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR. The Company has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents, primarily consisting of cash on-hand as well as time deposits with original maturities of three months or less and money market funds which are highly liquid and readily convertible to cash, totaling approximately $215.2 million and $276.4 million at September 30, 2024 and December 31, 2023 respectively. Time deposits with original maturities of three months or less and money market funds are valued based on Level 1 measurements in the fair value hierarchy established within FASB Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 820”). Level 1 inputs represent </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted prices in active markets for identical assets or liabilities.</span></div> 215200000 276400000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term investments</span></div>The Company had short term investments, primarily consisting of time deposits with original maturities between three months and one year, which are valued based on Level 1 measurements in the fair value hierarchy, totaling approximately $62.4 million at September 30, 2024 compared to $32.7 million at December 31, 2023. 62400000 32700000 ACQUISITIONS AND DIVESTITURES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Acquisition of Acclarent, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2024, the Company completed the acquisition of all of the outstanding capital stock of Acclarent, Inc. (“Acclarent”), a developer and marketer of medical devices used in ear, nose, throat (“ENT”) procedures, from Ethicon, Inc., a subsidiary of Johnson &amp; Johnson, for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. In September 2024, the Company finalized the working capital adjustment in the amount of $4.2 million, which resulted in a reduction to goodwill. This adjustment will be settled during the three months ending December 31, 2024. The addition of Acclarent’s ENT product portfolio, including sinus balloon dilation, eustachian tube balloon dilation, and surgical navigation systems technologies, and dedicated salesforce will enhance the Company’s position in the ENT specialty device market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acclarent’s results of operations have been reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition. The Company recorded revenue from Acclarent of approximately $62.3 million, in the consolidated statements of operations and comprehensive income for the nine months ended September 30, 2024. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company’s operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed at Fair Value</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Acclarent acquisition has been accounted for using the acquisition method of accounting in accordance with FASB Topic ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 805”). This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date. The Company estimated fair values at the date of acquisition for the preliminary allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed. The Company has not completed its analysis regarding the assets acquired and liabilities assumed. Therefore, the allocation to intangible assets, goodwill, and income taxes are preliminary and subject to finalization. During the measurement period ending no later than one year after the acquisition date, the Company will continue to obtain information to assist in finalizing the fair values of the net assets acquired, which may differ materially from these preliminary estimates. If any measurement period adjustment is material, the Company will record such adjustment, including any related impact on net income, in the reporting period in which the adjustment is determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">343,723</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, trade</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,653 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">277,811</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of trade accounts receivable, prepaid expenses, other current assets, accounts payable, contract liabilities, accrued compensation, accrued expenses and other current liabilities, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the intangible assets acquired was determined using the multi-period, excess earnings method of the income approach, which estimates value based on the present value of future economic benefits attributable to the intangible assets. The significant assumptions used in developing the valuation included the estimated annual net cash flows including application of forecasted revenue, the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. Preliminary assumptions may change and may result in significant changes to the final valuation. The intangible assets acquired have a weighted average useful life of 11 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used a discount rate of 12.2% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill has been allocated to the Codman Specialty Surgical segment, as shown in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Tax Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Acquisition of Durepair®</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2024, the Company completed the acquisition of the product rights for Durepair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $45.0 million. The Company made a cash payment of $10.0 million upon the closing of the acquisition and will make additional cash payments of $15.0 million upon the first anniversary of the acquisition and $20.0 million upon the second anniversary of the acquisition. </span></div>The Company will account for the acquisition of the product rights for Durepair, which consist of certain patents and trademarks, regulatory approvals, and other records, as an asset acquisition in accordance with ASC 805 because the acquisition does not include an assembled workforce and substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset and, thus, the assets are not considered a business. 282000000 4200000 --12-31 62300000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">343,723</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, trade</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,653 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">277,811</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 23716000 20294000 273000 476000 44759000 7716000 989000 202000000 P12Y 3000000 P5Y 17000000 P4Y 61396000 6863000 343723000 3989000 3984000 1037000 2278000 365000 11653000 624000 53635000 65912000 277811000 P11Y 0.122 45000000.0 10000000.0 15000000.0 20000000.0 REVENUES FROM CONTRACTS WITH CUSTOMERS <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Accounting Policies on Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Asset and Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2024:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transferred to trade receivable from contract asset included in beginning of the year contract asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, net of transferred to trade receivables on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, September 30, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of revenue included in beginning of year contract liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, acquired with Acclarent</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, net of revenue recognized on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, September 30, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,088 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, the short-term portion of the contract liability of $10.0 million and the long-term portion of $8.1 million are included in current liabilities and other liabilities, respectively, in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company is expected to recognize revenue of approximately 55% of unsatisfied (or partially unsatisfied) performance obligations as revenue within 12 months, with the remaining balance to be recognized thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Fees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected from Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregated Revenue</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2024 and 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurosurgery</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,056 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Codman Specialty Surgical</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,782 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,205 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828,977 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787,371 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Label</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Tissue Technologies</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,052 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,904 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,421 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 15. Segment and Geographic Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for details of revenues based on the location of the customer.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Accounting Policies on Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Asset and Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Fees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.</span></div> P90D <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2024:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transferred to trade receivable from contract asset included in beginning of the year contract asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, net of transferred to trade receivables on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, September 30, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of revenue included in beginning of year contract liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, acquired with Acclarent</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, net of revenue recognized on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, September 30, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,088 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 9233000 9233000 7828000 7828000 16252000 -6616000 3984000 4447000 21000 18088000 10000000.0 8100000 0.55 P12M <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div> P2Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected from Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.</span></div> <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2024 and 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurosurgery</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,056 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Codman Specialty Surgical</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,782 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,205 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828,977 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787,371 </span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Label</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Tissue Technologies</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,052 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,904 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,421 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.</span></div> 175956000 209229000 583726000 607902000 54238000 49920000 153148000 152523000 40588000 9056000 92103000 26946000 270782000 268205000 828977000 787371000 80460000 88071000 249032000 280129000 29592000 26145000 89872000 77034000 110052000 114216000 338904000 357163000 380834000 382421000 1167881000 1144534000 INVENTORIES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,930 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,930 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 219347000 196402000 85493000 74035000 132090000 119171000 436930000 389608000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:55.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Codman Specialty <br/>Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tissue Technologies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acclarent Acquisition </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at September 30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,123 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,116,535 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 350”). Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test uses a combination of both an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and EBITDA </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multiples. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins, and a discount rate for each reporting unit. Discount rates are determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and slight changes in these assumptions could have a significant impact on the concluded value. The estimates and assumptions applied represent a Level 3 measurement in the fair value hierarchy. Level 3 inputs are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For goodwill, during the third quarter of 2024, the Company elected to bypass the qualitative evaluations of its Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units and perform quantitative tests. The quantitative test for the Tissue Technologies reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was not less than its carrying amount, with 21.2% headroom. The quantitative test for the Neurosurgery reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.0% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was not less than its carrying amount, with 11.7% headroom. The quantitative test for the Instruments and ENT reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 11.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Instruments and ENT reporting unit was not less than its carrying amount, with 22.1% headroom. Based on the results of these quantitative tests, the Company recorded no impairment of goodwill for Tissue Technologies, Neurosurgery, or Instruments and ENT reporting units.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a hypothetical sensitivity analysis of the fair value for each reporting unit by increasing the discount rate by 50 basis points, decreasing the terminal growth rate by 50 basis points, and holding all other assumptions constant, which resulted in a decrease to the estimated fair value of the Tissue Technology reporting unit by 4.5%, a decrease to the estimated fair value of the Neurosurgery reporting unit by 3.8%, and a decrease to the estimated fair value of the Instruments and ENT reporting unit by 3.5%. Based on the results of the hypothetical sensitivity analyses, the Company would still not have recorded an impairment of goodwill for Tissue Technologies, Neurosurgery, or Instruments and ENT reporting units.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For intangible assets with indefinite lives, the Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test during the third quarter 2024. In performing this test, the Company utilized a discount rate of 13.0%. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,427,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(509,825)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,924,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(715,413)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448,519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662,004)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067,833 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets for the three and nine months ended September 30, 2024 was $25.6 million and $78.7 million, respectively. Of these amounts, $21.8 million and $61.1 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets for the three and nine months ended September 30, 2023 was $20.9 million and $62.1 million, respectively. Of these amounts, $17.7 million and $52.8 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold, with the remainder included in intangible amortization in the statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $25.6 million for the remainder of 2024, $102.4 million in 2025, $102.2 million in 2026, $101.2 million in 2027, $97.6 million in 2028, $92.4 million in 2029 and $511.8 million thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2024, due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform quantitative impairment testing on certain definite-lived intangible assets including completed technology and customer relationships in accordance with FASB ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span>. The Company recorded an impairment charge related to the definite-lived intangible asset associated with the customer relationships of $7.1 million in intangible asset amortization in the consolidated statement of operations. With respect to the definite-lived intangible assets associated with the completed technology of SurgiMend® and PriMatrix®, the Company determined that the carrying amount of these definite-lived intangible assets were recoverable and, therefore, the intangible assets were not deemed to be impaired. In the second quarter of 2024, the Company approved a plan to transition the commercial distribution of SurgiMend® and PriMatrix® from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts (the “Braintree facility”). The Company considered the impact to the update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility on the assumptions used in the quantitative assessment of the definite-lived intangible assets completed in the first quarter of 2024, which did not require further evaluation for impairment. The carrying values of SurgiMend® and PriMatrix® are $34.6 million and $25.5 million, respectively, as of September 30, 2024. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:55.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Codman Specialty <br/>Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tissue Technologies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acclarent Acquisition </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at September 30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,123 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,116,535 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 666937000 388525000 1055462000 61396000 0 61396000 -210000 -113000 -323000 728123000 388412000 1116535000 0.025 0.125 0.212 0.025 0.120 0.117 0.025 0.115 0.221 0 0 0.50 -0.50 -0.045 -0.038 -0.035 0.130 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,427,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(509,825)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,924,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(715,413)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448,519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662,004)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067,833 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,427,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(509,825)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,924,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(715,413)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448,519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662,004)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067,833 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> P17Y 1427186000 509825000 917361000 P12Y 168396000 138022000 30374000 P27Y 101896000 41833000 60063000 174118000 174118000 P30Y 30211000 18882000 11329000 P6Y 23154000 6851000 16303000 1924961000 715413000 1209548000 P18Y 1226128000 448519000 777609000 P12Y 193895000 152160000 41735000 P28Y 98892000 38754000 60138000 174531000 174531000 P30Y 30211000 18148000 12063000 P11Y 6180000 4423000 1757000 1729837000 662004000 1067833000 25600000 78700000 21800000 61100000 7100000 20900000 62100000 17700000 52800000 25600000 102400000 102200000 101200000 97600000 92400000 511800000 7100000 34600000 25500000 DEBT <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the Seventh Amended and Restated Senior Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of the Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The March 2023 Amendment extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775.0 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans. The terms of the Senior Credit Facility limit the amount of dividends we may pay. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s maximum Consolidated Total Leverage Ratio (as defined in the March 2023 Amendment) in the financial covenants is outlined below. Concurrent with the Durepair acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Acquisitions and Divestitures),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accordance with the terms of the March 2023 Amendment, the Company elected to increase the maximum Consolidated Total Leverage Ratio to 5.00 from the fiscal quarter ending December 31, 2024 through the fiscal quarter ending September 30, 2025. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:394.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:111.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Quarter Ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Consolidated Total Leverage Ratio</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023 through September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2024 through September 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2025 through June 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2026 and the last day of each fiscal quarter thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%), or </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The highest of: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the prime lending rate of Bank of America, N.A.; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the one-month Term SOFR plus 1.00%. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable rates are based on the Company’s Consolidated Total Leverage Ratio (defined, as of any date of determination, as the ratio of (a) Consolidated Funded Indebtedness as of such date (as defined in the Credit Agreement) less cash that is not subject to any restriction on the use or investment thereof to (b) Consolidated EBITDA (as defined by the Seventh Amended and Restated Credit Agreement (the “Credit Agreement”)), for the period of four consecutive fiscal quarters ending on such date).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility component of the Senior Credit Facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2024, the Company was in compliance with all such covenants. The Company capitalized $7.6 million in deferred financing costs in connection with the modification of the Senior Credit Facility and wrote off $0.2 million of previously capitalized financing costs during the first quarter of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024 and December 31, 2023 there wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $400.0 million and $70.0 million, respectively, ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding under the revolving credit facility component of the Senior Credit Facility. At September 30, 2024 and December 31, 2023, there was $765.3 million and $775.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.4% and 6.8%, respectively. As of September 30, 2024 and December 31, 2023 there was $29.1 million and $14.5 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the term loan and revolving portion of the Senior Credit Facility at September 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $756.3 million, and $395.3 million, respectively. The fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nputs that reflect unadjusted quoted prices for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit outstanding as of September 30, 2024 and December 31, 2023 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taled $1.7 million. There were no amounts drawn under the letters of credit outstanding as of September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Repayment</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $12.3 million for the remainder of 2024, $48.1 million in 2025, $45.6 million in 2026, $42.6 million in 2027, and $9.4 million in 2028. Interest is calculated on the term loan portion of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Credit Agreement. As the revolving credit facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any outstanding borrowings on the revolving credit facility component of the Senior Credit Facility are due on March 24, 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”) pursuant to an indenture, dated as of February 7, 2020 (the “Original Indenture”), between the Company and Citibank, N.A., as trustee. The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. In connection with this offering, the Company capitalized $13.2 million of financing fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on an initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company’s common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period specified in the Original Indenture; (3) if the Company calls the notes for optional redemption as described in the Original Indenture; or (4) if specified corporate transactions occur. As of September 30, 2024, none of these conditions existed and the 2025 Notes are classified as current convertible securities on the consolidated balance sheet, as they are due within one year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, the Company entered into the first supplemental indenture to the Original Indenture (the “First Supplemental Indenture” and, together with Original Indenture, the “Indenture”), pursuant to which the Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement (as defined in the First Supplemental Indenture) for a conversion of the 2025 Notes, the Specified Dollar Amount (as defined in the First Supplemental Indenture) that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes will have the right to require the Company to repurchase for cash all or a portion of their 2025 Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the Indenture). The Company will also be required to increase the conversion rate for holders who convert their 2025 Notes in connection with certain Fundamental Changes (as defined in the Original Indenture) occurring prior to the maturity date or following delivery by the Company of a notice of redemption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the carrying amount of the liability of the 2025 Notes w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $575.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of the 2025 Notes at September 30, 2024 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$547.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quotes. The 2025 Notes are valued based on Level 1 measurements in the fair value hierarchy. Level 1 inputs represent </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securitization Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2024, the Company was in compliance with the covenants and none of the termination events had occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December 2023 Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, three years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024 and December 31, 2023, the Company had $72.8 million and $89.2 million, respectively, of outstanding borrowings under its Securitization Facility at an interest rate of 5.9% and 6.4%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2024 was $71.2 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nputs that reflect unadjusted quoted prices for identical assets or liabilities.</span></div> 2100000000 775000000.0 1300000000 60000000 60000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s maximum Consolidated Total Leverage Ratio (as defined in the March 2023 Amendment) in the financial covenants is outlined below. Concurrent with the Durepair acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Acquisitions and Divestitures),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accordance with the terms of the March 2023 Amendment, the Company elected to increase the maximum Consolidated Total Leverage Ratio to 5.00 from the fiscal quarter ending December 31, 2024 through the fiscal quarter ending September 30, 2025. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:394.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:111.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Quarter Ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Consolidated Total Leverage Ratio</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023 through September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2024 through September 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2025 through June 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2026 and the last day of each fiscal quarter thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5.00 4.50 5.00 4.25 4.00 0.0010 0.0100 0.0175 0.0050 0.0100 0.0015 0.0030 7600000 200000 400000000.0 70000000.0 765300000 775000000.0 0.064 0.068 29100000 14500000 756300000 395300000 1700000 1700000 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Repayment</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4844000 33906000 38750000 53281000 634531000 765312000 12300000 48100000 45600000 42600000 9400000 575000000.0 0.005 0.005 13200000 73.67 1.30 0.98 1000 1 104200000 44500000 73.67 113.34 575000000.0 547700000 150000000 300000 P3Y 100000 P3Y 72800000 89200000 0.059 0.064 71200000 DERIVATIVE INSTRUMENTS <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Hedging</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following interest rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset (Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis Swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,325,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,847 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three and nine months ended September 30, 2024, the Company recorded a loss of $17.1 million and a gain of $2.7 million, respectively, in AOCI related to the change in fair value of the interest rate swaps. For the three and nine months ended September 30, 2023 the Company recorded a gain of $15.3 million and $23.5 million, respectively, in AOCI related to the change in fair value of the interest rate swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, the Company recorded gains of $4.1 million and $14.4 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. For the three and nine months ended September 30, 2023 the Company recorded gains of $5.0 million and $12.9 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2024 within the next twelve months is $7.1 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Hedging</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-Currency Rate Swaps</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2023, the Company amended the CHF denominated intercompany loan to partially settle CHF 20.0 million and extend the termination date to September 2024 and as a result, the Company terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $48.5 million. Simultaneously, the Company entered into a cross-currency swap agreement to hedge a notional amount of CHF 28.5 million equivalent to $31.5 million of this amended intercompany loan into U.S. dollars. On September 23, 2024, the Company settled this cross-currency swap designated as a cash flow hedge of an intercompany loan. Based on the closing exchange rates, the loss upon settlement was approximately $2.3 million which was offset by the gain on the settlement of the intercompany loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2020</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,892)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,324)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 22, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,348)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,892)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-currency swaps designated as cash flow hedges are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2024, the Company recorded a loss of $16.6 million and a gain of $13.5 million, respectively, in AOCI related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded gains of $13.8 million and $3.1 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 the Company recorded a loss of $23.2 million and a gain of $5.4 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans. For the three and nine months ended September 30, 2023, the Company recorded a gain of $15.3 million and $3.3 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, the Company recorded a gain of $1.1 million and $3.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded a gain of $1.5 million and $4.4 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of September 30, 2024 within the next twelve months is $0.7 million. As of September 30, 2024, the Company does not expect any gains or losses will be reclassified into earnings because the original forecasted transactions will not occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2024, the Company entered into a cross-currency swap agreement with a notional amount of CHF 68.5 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 1, 2018, May 24, 2022, and November 21, 2023, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2024 and December 31, 2023, respectively (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,106 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,475 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,153)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,047)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.94%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 17, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 17, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,248)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,037)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 6, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 18, 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,071)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,366)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2024, the Company recorded a loss of $21.1 million and $0.4 million, respectively, in AOCI related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded a gain of $6.1 million and a loss of $4.1 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, the Company recorded a gain of $2.7 million and $7.4 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2023, the Company recorded gains of $1.8 million and $6.0 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2024 within the next twelve months is $9.6 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a hedge for forecasted intercompany purchases denominated in foreign currencies through the use of forward contracts designated as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in accumulated comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first and third quarter of 2024, the Company entered into foreign currency forwards to mitigate the exchange rate risk of CHF denominated intercompany purchases. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2024 the notional amount of foreign currency forward contracts was 10.4 million CHF. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 the Company recorded a gain of $0.5 million and a loss of $0.2 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts and a loss of $0.1 million and $0.3 million, respectively, in cost of goods sold included in the consolidated statements of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023 the Company recorded a gain of $0.1 million and $0.3 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts and a gain of $0.1 million and $0.4 million, respectively, in cost of goods sold included in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2024, the Company entered into forward currency forwards with a notional amount of 5.2 million CHF to mitigate the exchange rate risk of Swiss franc denominated intercompany purchases. These contracts settle at various dates within twelve months of execution. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location on Balance Sheet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,710 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,560 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,055 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Forward Contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,353 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,335)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Forward Contract</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,262 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,660 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,603 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,858 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,706 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments not Designated Hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $4.6 million as of September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the foreign currency swaps not designated as hedges was $1.1 million and $1.2 million as of September 30, 2024 and December 31, 2023, respectively. The following table summarizes the gains on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following interest rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset (Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis Swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,325,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,847 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps as of September 30, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2020</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,892)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,324)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 22, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,348)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,892)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2024 and December 31, 2023, respectively (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,106 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,475 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,153)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,047)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.94%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 17, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 17, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,248)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,037)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 6, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 18, 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,071)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,366)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 150000000 0.02423 0 2105000 200000000 200000000 0.02313 1246000 4978000 75000000 75000000 0.03220 525000 1349000 75000000 75000000 0.03199 515000 1312000 75000000 75000000 0.03209 501000 1346000 100000000 100000000 0.02885 1425000 3015000 100000000 100000000 0.02867 1616000 3052000 575000000 575000000 0.01415 22809000 22965000 125000000 125000000 0.01404 5159000 5263000 0 0 -1949000 -1829000 1325000000 1475000000 31847000 43556000 -17100000 2700000 15300000 23500000 4100000 14400000 5000000.0 12900000 7100000 20000000.0 48500000 28500000 31500000 2300000 471600000 420100000 5800000 0.0300 333887000 351137000 -30892000 -38324000 0.0398 374817000 394183000 0.0240 0 28500000 0 -2348000 0.0627 0 31457000 -30892000 -40672000 -16600000 13500000 13800000 3100000 23200000 5400000 15300000 3300000 1100000 3700000 1500000 4400000 700000 68500000 75000000 0 38820000 38820000 2106000 2475000 0.0219 45000000 45000000 0 288211000 288210000 -48153000 -48047000 0.0194 300000000 300000000 0 66525000 66525000 -5248000 -4037000 0.0254 75000000 75000000 0 68483000 0 -6071000 0 0.0274 75000000 0 -57366000 -49609000 -21100000 -400000 6100000 -4100000 2700000 7400000 1800000 6000000.0 9600000 10400000 500000 -200000 -100000 -300000 100000 300000 100000 400000 5200000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location on Balance Sheet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,710 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,560 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,055 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.</span></div> 7335000 14675000 708000 537000 292000 0 5764000 2938000 26461000 30710000 0 1470000 40560000 50330000 265000 579000 0 4813000 0 2120000 2903000 1684000 1250000 31600000 36396000 61010000 51114000 96679000 97055000 <div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Forward Contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,353 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,335)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Forward Contract</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,262 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,660 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,603 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,858 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,706 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 53116000 -17133000 4135000 31848000 -16867000 -16625000 -22089000 -11403000 -430000 474000 -119000 163000 -29466000 -21051000 2739000 -53256000 6353000 -54335000 -15334000 -32648000 56901000 15317000 4964000 67254000 -18925000 13796000 15347000 -20476000 -123000 98000 87000 -112000 -21239000 6051000 1772000 -16960000 16614000 35262000 22170000 29706000 43556000 2678000 14386000 31848000 -15763000 13505000 9145000 -11403000 0 -159000 -322000 163000 -45498000 -364000 7394000 -53256000 -17705000 15660000 30603000 -32648000 56712000 23477000 12935000 67254000 -20271000 3114000 3319000 -20476000 0 333000 445000 -112000 -6914000 -4066000 5980000 -16960000 29527000 22858000 22679000 29706000 7300000 4600000 1100000 1200000 The following table summarizes the gains on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:<div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10000 135000 385000 778000 10000 135000 385000 778000 STOCK-BASED COMPENSATION <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from <span style="-sec-ix-hidden:f-995">six</span> to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, there were approximately $3.5 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 243,964 stock options granted during the nine months ended September 30, 2024. For the nine months ended September 30, 2024, the weighted average grant date fair value for stock options granted was $15.68 per option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Awards of Restricted Stock and Performance Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2024, there was approximately $35.4 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 737,623 restricted stock awards and 263,350 performance stock awards during the nine months ended September 30, 2024. For the nine months ended September 30, 2024, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $34.45 and $36.22 per award, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CEO Separation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, the Company announced that Mr. De Witte would retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process and entered into a letter agreement with Mr. De Witte to modify his current employment agreement and put forth the form of a post-employment consulting agreement. The Company applied modification accounting to the outstanding equity-based awards granted to Mr. De Witte as of that date, which revalued and accelerated stock-based compensation associated with equity-based awards granted to him over his expected service period to the Company. Pursuant to this letter agreement, Mr. De Witte’s unvested equity-based awards will continue to vest during his continued service period to the Company and vested stock options were modified such that they will remain exercisable until the lesser of (a) the stated term of the stock options and (b) six months following his cessation of continued service to the Company. As a result of the modifications, the Company recorded incremental stock-based compensation expense of $1.4 million during the nine months ended September 30, 2024. The Company will record a total of $1.9 million in accelerated stock-based compensation expenses for the twelve months ended December 31, 2024 that would not have been recognized if Mr. De Witte had not announced his retirement from Integra.</span></div> P4Y P1Y P8Y P10Y P3Y 3500000 P3Y 243964 15.68 P3Y 35400000 P2Y 737623 263350 34.45 36.22 P6M 1400000 1900000 RETIREMENT PLANS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany, India and Switzerland.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2024 were $0.4 million and $1.3 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.8 million and $2.4 million for the three and nine months ended September 30, 2024, respectively, are included in other income, net in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2023 were $0.3 million and $0.9 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.5 million and $1.6 million for the three and nine months ended September 30, 2023, respectively, are included in other income, net in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of plan assets were $43.4 million and $45.7 million as of September 30, 2024 and December 31, 2023, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2024 and December 31, 2023. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $6.5 million and $6.1 million as of September 30, 2024 and December 31, 2023, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.</span></div> 400000 1300000 800000 2400000 300000 900000 500000 1600000 43400000 45700000 0.75 1 6500000 6100000 LEASES AND RELATED PARTY LEASES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2024. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease expense for the nine months ended September 30, 2024 and September 30, 2023 was $18.8 million and $17.9 million, respectively, which includes $0.2 million, in related party operating lease expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands, except lease term and discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the nine months ended September 30, 2024 and 2023 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities, net of modifications:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases at September 30, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,504 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,627 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,131 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,284 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no future minimum lease payments under finance leases at September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases one of its manufacturing facilities in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Impairment Charge</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company approved a plan to transition the commercial distribution of PriMatrix® and SurgiMend® from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts and permanently cease use of the Boston facility. As a result, in the second quarter of 2024, the Company recorded a $4.6 million impairment charge, as the carrying amounts of the operating lease right-of-use asset and fixed assets related to the Boston facility exceeded their fair values based on the Company’s estimates of future discounted cash flows through the end of the lease term and the end of their remaining useful lives, respectively. The $4.6 million impairment charge was comprised of a $1.7 million impairment of an operating lease right-of-use asset and a $2.9 million write-off of fixed assets, which was recorded as a component of cost of goods sold in the condensed consolidated statements of operations.</span></div> 1 18800000 17900000 200000 200000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands, except lease term and discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 146342000 156184000 15039000 15284000 167808000 166849000 182847000 182133000 P16Y2M12D P16Y3M18D P2Y2M12D P1Y10M24D 0.056 0.059 0.026 0.027 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the nine months ended September 30, 2024 and 2023 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities, net of modifications:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18255000 14778000 1575000 19540000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases at September 30, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,504 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,627 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,131 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,284 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 74000 6057000 6131000 296000 23016000 23312000 296000 21317000 21613000 296000 19425000 19721000 296000 17163000 17459000 246000 16306000 16552000 0 165343000 165343000 1504000 268627000 270131000 87284000 182847000 15039000 167808000 0.50 300000 P5Y November 1, 2029 through October 31, 2034 P5Y November 1, 2034 through October 31, 2039 4600000 4600000 1700000 2900000 TREASURY STOCK<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, there were 14.5 million and 12.8 million shares of treasury stock outstanding with a cost of $691.8 million and $647.3 million, at a weighted average cost per share of $47.86 and $50.76, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2024, the Company entered into a $50 million accelerated share repurchase (“May 2024 ASR”) and received 1.3 million shares of common stock at inception of the May 2024 ASR, which represented approximately 70% of the expected total shares under the May 2024 ASR. On July 31, 2024, the early exercise provision was exercised by the May 2024 ASR counterparty. The Company received an additional 0.4 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the May 2024 ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the Company entered into a $125 million accelerated share repurchase (“August 2023 ASR”) and received 2.3 million shares of common stock at inception of the August 2023 ASR, which represented approximately 80% of the expected total shares under the August 2023 ASR. On October 18, 2023 the early exercise provision was exercised by the August 2023 ASR counterparty. The Company received an additional 0.9 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the August 2023 ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2023, the Company entered into a $150 million accelerated share repurchase (“January 2023 ASR”) and received 2.1 million shares of common stock at inception of the January 2023 ASR, which represented approximately 80% of the expected total shares under the January 2023 ASR. The settlement of the January 2023 ASR agreement was completed in the second quarter of 2023, where the Company received 0.6 million shares, determined using the volume-weighted average price of the Company’s common stock during the term of the January 2023 ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 (the “Inflation Act”) was signed into law. The Inflation Act implements a new excise tax of 1% on the net share repurchases made by the Company effective for share repurchases performed January 1, 2023, or after. In October 2024, the Company made an excise tax payment of $2.5 million related to the January 2023 ASR and the August 2023 ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50 million remained</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The program, which was authorized in July 2023 and expires on December 31, 2025, allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.</span></div> 14500000 12800000 691800000 647300000 47.86 50.76 50000000 1300000 0.70 400000 125000000 2300000 0.80 900000 150000000 2100000 0.80 600000 2500000 225000000 50000000 INCOME TAXES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the Company’s effective tax rate:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reported tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rates for the three months ended September 30, 2024 and 2023 were 47.5% and (4.8)%, respectively. For the three months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income realized during the third quarter. For the three months ended September 30, 2023,the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.3 million benefit related to the filing of prior year tax returns.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rates for the nine months ended September 30, 2024 and 2023 were 35.3% and 8.2%, respectively. For the nine months ended September 30, 2024, the higher tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income and a $1.9 million shortfall from stock-based compensation, as compared to the prior year. For the nine months ended September 30, 2023, the primary drivers of the lower tax rate relate to a reduction to book income in higher-taxed jurisdictions and a $3.8 million benefit related to the filing of prior year tax returns.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Act was signed into law. The Company did not experience a material impact on the Company’s effective tax rate under the Inflation Act. Further, legislation in foreign jurisdictions may be enacted, in continued response to the base erosion and profit-sharing (“BEPS”) project begun by the Organization for Economic Cooperation and Development (“OECD”). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). Several of the jurisdictions that the Company operates in have already adopted some form of the model rules, which could impact the amount of taxes that the Company pays after 2023. However, the rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. At this time, the Company is projecting an immaterial amount related to Pillar 2 tax liability for the year ending December 31, 2024. Related changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the Company’s effective tax rate:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reported tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.475 -0.048 0.353 0.082 0.475 -0.048 3300000 0.353 0.082 1900000 3800000 NET INCOME PER SHARE<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Dollars in thousands, except per share amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Basic net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net (loss) income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares for diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net (loss) income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock of approximately 1.3 million and 0.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares at September 30, 2024, and 2023, res</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pectively, were not included in the computation of diluted net (loss) income per share because their effect would have been anti-dilutive.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Dollars in thousands, except per share amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Basic net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net (loss) income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares for diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net (loss) income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -10695000 19497000 -26379000 47907000 76448000 79690000 77196000 80842000 -0.14 0.24 -0.34 0.59 -10695000 19497000 -26379000 47907000 76448000 79690000 77196000 80842000 0 121000 0 270000 76448000 79811000 77196000 81112000 -0.14 0.24 -0.34 0.59 1300000 600000 ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss/(gain) on derivatives, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension liability adjustment, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive (loss) income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,823)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,387 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive (loss) income by component between December 31, 2023 and September 30, 2024 are presented in the table below, net of tax:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts reclassified from accumulated other comprehensive income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,866)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,854)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, the Company reclassified a gain of $7.3 million and $16.8 million from accumulated other comprehensive income to other income, net and interest income, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss/(gain) on derivatives, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension liability adjustment, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive (loss) income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,823)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,387 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -10695000 19497000 -26379000 47907000 5386000 -9541000 -2558000 -16378000 -11044000 6790000 -6714000 7858000 470000 334000 475000 0 -16823000 16412000 -36126000 39387000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive (loss) income by component between December 31, 2023 and September 30, 2024 are presented in the table below, net of tax:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts reclassified from accumulated other comprehensive income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,866)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,854)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21489000 2712000 -39307000 -15106000 11632000 -475000 3129000 14286000 18346000 0 5688000 24034000 -6714000 -475000 -2559000 -9748000 14775000 2237000 -41866000 -24854000 7300000 16800000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices; and (iii) the ENT business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">The Tissue Technologies segment consists of the Wound Reconstruction and Care business, which includes offerings such as skin and wound repair products, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The Tissue Technologies segment includes the Company’s private label business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2024 and 2023 are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Net Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,782 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787,371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,834 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,421 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,335</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,020 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,959 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464,506 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,760)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,208)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,342)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454,147)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339,755)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,150)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,216)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">856,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">817,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,034 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,421 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 2 40000 Net sales and profit by each reportable segment for the three and nine months ended September 30, 2024 and 2023 are as follows:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Net Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,782 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787,371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,834 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,421 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,335</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,020 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,959 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464,506 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,760)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,208)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,342)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454,147)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339,755)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,150)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,216)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Total revenue by major geographic area consisted of the following:<div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">856,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">817,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,034 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,421 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 270782000 268205000 828977000 787371000 110052000 114216000 338904000 357163000 380834000 382421000 1167881000 1144534000 100538000 105170000 368171000 332444000 28482000 31789000 96335000 92132000 129020000 136959000 464506000 424576000 3760000 3208000 17575000 9342000 -133410000 -107158000 -454147000 -339755000 -8150000 26593000 -7216000 75479000 290192000 269838000 856646000 817622000 34368000 41524000 116653000 120040000 37052000 48777000 132548000 146956000 19222000 22282000 62034000 59916000 380834000 382421000 1167881000 1144534000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded and actual results may differ from these estimates. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra Life Sciences claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer to the contingent consideration section of this footnote for additional information on the ACell contingent considerations. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2023, a securities class action complaint, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pembroke Pines Firefighters &amp; Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to defend the matter vigorously.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, a complaint was filed against the Company in the Court of Common Pleas of Philadelphia County in Pennsylvania asserting product liability claims relating to a surgical procedure in which the Company’s CUSA® Clarity allegedly was used. The plaintiff seeks damages against the Company based upon plaintiff’s claim that the CUSA® Clarity did not function as intended. The plaintiff also asserts separate claims against the surgeon and the hospital. In the third quarter of 2024, a settlement was reached, which has since been paid by the Company’s insurance carriers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2024 and September 30, 2023 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2024 and September 30, 2023 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,736 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.571%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,886 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Arkis BioSciences Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derma Sciences, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains, which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ACell, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the contingent consideration to be $23.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Surgical Innovations Associates, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on (1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as (2) the approval by the FDA of the pre-market approval ("PMA") application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). In the second quarter of 2024, the Company paid out $12.4 million related to the 2023 performance year. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company entered into a definitive agreement to acquire a manufacturing facility in Plainsboro, New Jersey for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10 million</span> in cash at closing. The manufacturing facility is currently leased by the Company. The transaction is expected to close in the first quarter of 2025. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2024 and September 30, 2023 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,736 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.571%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,886 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 15755000 2557000 300000 68700000 12400000 -3019000 137000 0 3100000 12736000 2694000 300000 59400000 8320000 0 0 19600000 4416000 2694000 300000 39800000 12736000 2694000 300000 59400000 12895000 230000 3700000 57600000 1991000 1887000 -2200000 6600000 14886000 2117000 1500000 64200000 4373000 0 503000 13000000 10513000 2117000 997000 51200000 14886000 2117000 1500000 64200000 25500000 10000000.0 15500000 13100000 33300000 1 3000000.0 100000000 1 23900000 90000000 2 50000000 40000000 12400000 32600000 25000000 10000000 false false false false